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  SUMMARY 
   
Summary 
The maintenance of homeostasis in the immune system is a complex process. The control of 
B cell numbers occurs at many different stages in the developmental pathway, and 
numerous factors are involved. In this thesis, certain aspects of FLT3L, BAFF-R and BAFF 
on B cells were analyzed. 
In the first part (chapter 3), the effect of increased availability of FLT3L on EPLMs, which 
have been found previously to be B cell progenitors, was investigated. Upon FLT3L 
administration in mice, the number of EPLMs increased in a dose-dependent manner, but 
the number of B cells decreased. This decrease was reversible as B cell numbers recovered 
after cessation of FLT3L treatment. In vitro studies revealed, that EPLMs from FLT3L 
treated mice had a reduction of about 20-fold in B-lineage potential, while the potential for 
the T cell lineage was only slightly reduced and myeloid potential was unchanged. 
Transplantation of EPLMs from FLT3L treated mice into lymphopenic hosts showed, that 
these cells are able to give rise to B and T cells, but not to myeloid cells. From these 
experiments we concluded, that FLT3L is able to increase the number of EPLMs, and that 
these progenitor cells can reconstitute B and T cell compartments in vivo. 
In the second part (chapter 4), novel sets of monoclonal antibodies specific for mouse 
BAFF-R or human BAFF are described. Among the anti-mBAFF-R antibodies, several 
different clones that were able to block the binding of ligand to BAFF-R could be identified. 
With the anti-hBAFF antibodies, a sensitive ELISA for the detection of hBAFF in human 
sera was developed. 
In the third part (chapter 5), the role of BAFF-R signaling in the in vivo maintenance of 
mature B cells was investigated with the use of the new monoclonal anti-mBAFF-R 
antibodies. We showed that 14 days following a single injection of a monoclonal anti-
mBAFF-R antibody that prevents BAFF binding, both follicular and marginal zone B cell 
numbers were drastically reduced, whereas B-1 cells were not affected. Injection of control, 
isotype-matched but non-blocking anti-mBAFF-R monoclonal antibodies did not result in B 
cell depletion. We also showed that this depletion is neither due to antibody-dependent 
cellular cytotoxicity nor to complement-mediated lysis. Moreover, prevention of BAFF 
binding lead to a decrease in the size of the B cell follicles and to a strong impairment of T 
cell dependent humoral immune response. These results establish a central role for BAFF - 
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BAFF-R signaling in the in vivo survival and maintenance of both follicular and marginal 
zone B cell pools. 
In the fourth part (chapter 6), the precise expression of BAFF-R on murine BM B cells was 
investigated with the use of the new monoclonal anti-mBAFF-R antibodies. We found that 
expression of BAFF-R is first detectable by flow cytometry on a fraction of CD19+ CD93+ 
CD23- bone marrow (BM) B cells. This BAFF-R+ BM B cell population showed higher 
levels of surface IgM expression and decreased recombination-activating gene 2 (RAG-2) 
transcripts than BAFF-R- immature B cells. When cultured in vitro, BAFF-R+ immature B 
cells did not undergo further B cell receptor rearrangement, while BAFF-R- immature B 
cells did. However, when cultured in the presence of an anti-kappa light chain antibody, 
BAFF-R+ immature B cells could be induced to undergo receptor editing and this correlated 
with the downregulation of both surface IgM and BAFF-R expression. Addition of BAFF 
did not inhibit this induced receptor editing. We concluded, that expression of BAFF-R can 
be used as a marker to identify immature B cells, which under normal conditions no longer 
undergo BCR editing, but can still be induced to do so by BCR engagement. 
In the last part (chapter 7), serum levels of hBAFF from patients with diseases connected 
with disturbed B cell homeostasis were analyzed. We found, that in a subset of patients with 
SLE, Sjögrens syndrome or autoimmune thyroid diseases, hBAFF levels were elevated. 
Also, hBAFF levels were elevated in most patients suffering from Hodgkin or non-Hodgkin 
lymphomas. In patients with chronic hepatitis C, hBAFF levels were elevated in a subgroup 
of patients. Furthermore, we found no correlation between hBAFF levels and anti-dsDNA 
autoantibody titers in SLE patients. In addition, hBAFF levels did not correlate with age or 
gender. Taken together, this analysis suggests, that hBAFF might be involved in the genesis 
and/or maintenance of autoimmune and chronic infectious diseases only in a subgroup of 
patients, while its role in B cell leukemias might be more pronounced. 
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1 GENERAL INTRODUCTION 
The necessity of developing a defense mechanism against life-threatening intruders is as old 
as life itself. Starting down in the phylogenetic tree with bacteria, more and more complex 
immune systems have evolved on the way up to vertebrates. Already the bacterial defense 
mechanism, the restriction modification system, fulfills one of the most important 
requirements of such a system, which is discrimination between self and non-self. The more 
complex immune systems of higher plants and invertebrates employ several mechanisms to 
recognize and eliminate pathogenic agents, including pattern recognition receptors, secreted 
antimicrobial peptides and phagocytosing cells. All these mechanisms are, among others, 
components of the so-called innate immune system, which is characterized by its fast but 
unspecific action. The innate immune system comprises highly conserved mechanisms and 
is also part of the immune system of vertebrates, where it provides the first line of defense. 
About 450 million years ago, a second, more specific immune system developed in 
vertebrates. This so-called adaptive immune system is able to react highly specificly to 
nearly all types of pathogenic molecules and microorganisms and possesses a memory 
function. The specificity of the adaptive immune system is achieved through the generation 
of numerous extremely diverse antigen receptors, the B and T cell receptors, which are 
expressed by the key players of adaptive immunity, the B and T lymphocytes, respectively. 
 
 
 
1.1 B cell development 
B cell development proceeds via several intermediate stages that can be distinguished by the 
differential expression of intracellular and cell surface markers. Several nomenclatures are 
used in different laboratories due to the usage of other sets of markers in order to delineate 
B cell developmental stages. In this work, the nomenclature established by Rolink and 
Melchers, which is based on the expression of cell surface markers and the rearrangement 
status of the immunoglobulin (Ig) genes, is used (1). 
In mice and man, two major types of B lymphocytes are distinguished, namely B-1 and B-2 
B cells. B-1 cells are less abundant than B-2 B cells and differ in many aspects from B-2 B 
cells. B-2 B cells, which is the major group of B cells both in mice and man, mature in the 
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bone marrow (BM), a primary lymphoid organ. The cells then migrate to the spleen, where 
further developmental steps take place. Mature B-2 B cells then either stay in the spleen or 
migrate to other secondary lymphoid organs like lymph nodes or mucosal-associated 
lymphoid tissues (MALT), which include among others the appendix, the tonsils and the 
Peyer’s patches. Upon encountering of antigen in the secondary lymphoid organs, mature B 
cells further develop into highly specialized effector cells. 
 
 
1.1.1 Early developmental steps in the bone marrow 
B cells derive, as all other cells of the hematopoietic system, from multipotent long-term 
hematopoietic stem cells (LT-HSCs), which reside in the BM (see fig. 1). These cells have 
self-renewing capacity and are Sca1high c-Kithigh Flt3- CD34- VCAM1+ Lin- (2-4). LT-HSCs 
develop further into short-term HSCs (ST-HSCs) and then into multipotent progenitors 
(MPPs), a heterogeneous group of Sca1high c-Kithigh Flt3low/high CD34+ VCAM1-/+ Lin- 
precursor cells (5). The gradual upregulation of Flt3 expression and downregulation of 
VCAM1 expression in ST-HSCs (Sca1high c-Kithigh Flt3-/low CD34+ VCAM1+ Lin-) and 
MPPs coincides with gradual reduction of self-renewal capacity and lineage potential (6, 7). 
A subgroup of MPPs, the lymphoid primed multipotent progenitors (LMPPs), are Sca1high c-
Kithigh Flt3high CD34+ VCAM1- Lin-. 
LMPPs can be further subdived into early lymphoid progenitors (ELPs), which are defined 
by the expression of recombination activating gene 1 (RAG-1), terminal deoxynucleotidyl 
transferase (TdT) or both (9, 10). Phenotypically, ELPs resemble LMPPs. LMPPs have no 
self-renewal capacity anymore and show a reduced lineage potential as they develop 
efficiently only into lymphoid and myeloid cells, but not into cells of the megakaryocyte-
erythrocyte lineage (11). Further progenitors along the B cell lineage path encompass the 
common lymphoid progenitor (CLP), being Sca1low c-Kitlow Flt3+ CD93+ B220- IL-7Rα+ 
and the early progenitor with lymphoid and myeloid potential (EPLM), which is Sca1low c-
Kitlow Flt3+ CD93+ B220+ IL-7Rα+ CD19- (12). EPLMs are sometimes also refered to as 
pre-pro-B cells, as both are B220+ and CD19-. 
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Figure 1: Early stages of B cell development. Hematopoietic stem cells (HSCs) develop via several 
intermediate stages into B cell lineage committed pro-B cells. Multipotent progenitors (MPPs) 
comprise VCAM1+ FLT3low and VCAM1- FLT3high cells, the latter are defined as lymphoid-primed 
multipotent progenitors (LMPPs). A subgroup of the LMPPs are early lymphoid progenitors (ELPs), 
which express RAG-1, TdT or both. Further precursor cells are the common lymphoid progenitor 
(CLP) and the early progenitor with lymphoid and myeloid potential (EPLM). Pro-B cells are the 
first cells that express CD19, a marker that defines B lineage committment. The expression of 
several surface markers and intracellular proteins is indicated with horizontal lines and the 
thickness of the lines indicates expression strenght. Factors that cause a complete or partial block at 
certain stages of B cell development are shown in pink (see chapter 1.1.5 for a description). Adapted 
from Welner et al., 2008 (8). 
 
 
The next characterized precursors are the pro-B cells, which gain expression of CD19 and 
are thus defined as Sca1low c-Kitlow Flt3+ CD93+ B220+ IL-7Rα+ CD19+ progenitor B cells 
(see fig. 2). CD19 is part of a coreceptor for the B cell receptor (BCR), which is formed at a 
later stage. Expression of CD19 is directly regulated by the transcription factor PAX5 
(paired box protein 5), which is thought to be responsible for B lineage comittment (13). In 
pro-B cells, DH to JH rearrangement of the IgH chain locus, which usually occurs on both 
alleles, is completed. Rearrangement of the immunoglobulin heavy (IgH) chain genes starts 
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already in some ELPs with joining DH to JH elements at the IgH chain locus. This DNA 
rearrangement is directed by the RAG-1 and RAG-2 proteins and the enzyme TdT catalyses 
the insertion of nucleotides at the coding joints. Pro-B cells express VpreB and λ5, which 
together form the so-called surrogate light (SL) chain. The next stage are pre-BI cells, which 
have both IgH chain genes DHJH rearranged and are phenotypically defined as c-Kitlow Flt3- 
CD93+ B220+ IL-7Rα+ CD19+. Pre-BI cells continue IgH chain rearrangement with VH to 
DHJH-rearrangement on only one allele and start to express a µH chain. Association of the 
µH chain with the SL chain results in formation of the cell surface expressed pre-BCR. Pre-
BI cells expressing a functional pre-BCR enter the cell cycle and thus become large pre-BII 
cells. Large preBII cells lose c-Kit expression and start to express CD25, which is the IL-
2Rα chain, and thus are c-Kit- Flt3- CD93high B220+ IL-7Rα+ CD19+ CD25+. Rag-1 and 
Rag-2 genes are downregulated rapidly in order to prevent further rearrangements on the H 
chain loci (14), thereby avoiding the production of cells bearing two different types of pre-
BCRs, a mechanism refered to as allelic exclusion (15). Also, the genes encoding the SL 
chain proteins, VpreB and λ5, and TdT are downregulated. After about 5-7 divisions, due to 
dilution of the long-lived SL chain proteins and the resultant decrease in pre-BCR numbers 
formed, the large pre-BII cells become resting, small pre-BII cells (16). Phenotypically, 
small pre-BII cells resemble large pre-BII cells. In small pre-BII cells, Rag-1 and Rag-2 are 
upregulated again and the cells rearrange their immunoglobulin light (IgL) chain loci. In 
contrast to the H chain locus, two different L chain loci exist, named κ and λ. Also, both L 
chain genes do not contain D elements and thus, their V-regions consist only of V and J 
elements, in this way enabling repeated V-J rearrangements on the same locus, thereby 
increasing the chance for a productive L chain gene rearrangement. In mice, rearrangement 
is initiated more often at the κL chain locus, resulting in a ratio of 10:1 for κL chain to λL 
chain expressing B cells (17). Pairing of the L chain with the µH chain forms the cell 
surface expressed BCR and cells become immature B cells, which express intermediate 
levels of B220 but have lost CD25 expression. Immature B cells are thus CD93high B220int 
CD19+ CD25- IgM+. Expression levels of IgM are extremely variable and differ from low to 
high. Low expression of surface IgM (sIgM) is a result of either impaired BCR signaling or 
due to downregulation of an autoreactive BCR (18). Only immature B cells with high 
expression of sIgM leave the bone marrow to enter the spleen (19). 
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Figure 2: Later stages of B cell development in the bone marrow. B cell lineage committed pro-B 
cells develop via several intermediate stages into immature B cells. The immature B cell stage is the 
first B cell developmental stage where the B cell receptor is expressed. The expression of several 
surface markers and intracellular proteins is indicated with horizontal lines and the thickness of the 
lines indicates expression strenght. Factors that cause a complete or partial block at certain 
developmental stages are shown in pink (see chapter 1.1.5 for a description). 
 
 
Several checkpoints exist along the B cell developmental pathway where the developing B 
cells are screened for bearing non-functional or autoreactive BCRs, being generated due to 
the random way of assembling the V, D and J Ig gene segments. The mechanisms employed 
to eliminate these cells involve both positive and negative selection methods. A first 
checkpoint exists at the pre-BI cell stage. The newly formed µH chain must be able to pair 
with the SL chain and a pre-BCR has to be expressed on the cell surface. Only cells with a 
signaling competent pre-BCR can induce cell cycling und efficiently transit to the next stage 
of development, the cycling large pre-BII cells. Cells that are not able to generate a 
functional pre-BCR are unable to enter the expansion phase. The next checkpoint is at the 
transition from the small pre-BII to the immature B cell stage, when the IgL chain genes are 
rearranged. This rearrangement has to be productive and the resulting IgL chain must be 
able to pair with the µH chain in order to form a surface expressed BCR. Cells being unable 
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to express a functional BCR can continue IgL chain gene rearrangement, a mechanism 
called receptor editing (20). Thereby, the cells have the chance to produce a new IgL chain 
protein that might be functional in combination with the µH chain already present. The 
number of possible rearrangements is limited by the survival time of the pre-BII cells. It 
could be shown that an increase in the survival time due to overexpression of the anti-
apoptotic factor Bcl-2 leads to enhanced L chain editing (21). 
The first tolerance checkpoint is at the immature B cell stage, when a new complete BCR is 
expressed for the first time. Tolerance checkpoints are intended to test BCRs for their auto-
reactivity, what is achieved by providing them with autoantigens, which in the BM are 
expressed on stromal cells. Immature B cells expressing a BCR binding with too high 
avidity to a multivalent (and hence crosslinking) self-molecule undergo receptor editing and 
might thus be able to express an innocuous BCR, resulting in positive selection. In case a 
cell can not alter its autoreactive BCR it is eliminated by apoptosis, a process refered to as 
clonal deletion. It was found that most of the newly produced immature B cells express an 
autoreactive BCR and that 25-50% of all B cells in the periphery went through receptor 
editing (22). Nonetheless, of the approximately 2 x 107 immature B cells that develop per 
day in the BM (23), only around 10-20% enter the spleen (24), meaning that 80-90% of the 
newly formed immature B cells become negatively selected at the immature B cell stage. 
 
 
1.1.2 Late developmental steps in the spleen 
Immature B cells that survived negative selection leave the bone marrow and migrate via 
the blood stream to the spleen, where they penetrate the marginal zone blood sinus to enter 
the outer region of the periarteriolar lymphoid sheath (PALS). In the spleen, immature B 
cells go through two short-lived transitional stages and finally become long-lived mature B 
cells (see fig. 3). The first developmental stage consist of transitional type 1 (T1) B cells, 
which are characterized by expressing CD19+ B220+ CD93high CD21- CD23- IgMhigh IgDlow. 
The next stage constitutes T2 B cells, which gained expression of CD21 and CD23. They 
also show a lower expression of CD93 and increased levels of IgD. Thus, T2 B cells are 
CD19+ B220+ CD93+ CD21+ CD23+ IgMhigh IgDhigh. CD21, also called complement 
receptor 2 (CR2), forms together with CD19 and CD81 the B cell co-receptor. The ligand 
for CD21 is the complement cleavage product C3d. Crosslinking of the B cell co-receptor 
by binding of CD21 to C3d coated to an antigen that is captured by the BCR, leads to 
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phosphorylation of CD19, thus initiating a signaling cascade supporting BCR signaling 
(25). CD23, the low affinity IgE receptor or FcεRII, regulates IgE production and was found 
to be an important modulator of allergic responses. Initially, CD23 is expressed as a mem-
brane bound molecule but then the majority is shed of by the metalloproteinase ADAM10 
(26). Another type of B cells, which are CD93+ and thus were considered to belong to the 
transitional types of B cells, were designated T3 B cells (CD19+ B220+ CD93+ CD21+ 
CD23+ IgMlow IgDhigh). Recent findings, however, showed that these T3 cells are not able to 
give rise to mature B cells and therefore are no precursors of mature B cells (27, 28). 
 
 
 
Figure 3: Stages of B cell development in the spleen. Immature B cells leave the bone marrow and 
enter the spleen, where they develop first into short lived transitional type B cells, T1 and T2. From 
the T2 stage, the cells develop either into mature follicular (Fol) B cells or via the marginal zone 
precursor (MZP) B cells into mature marginal zone (MZ) B cells. T2 B cells that recognize auto-
antigen are rendered anergic and are now designated anergic population 1 B cells (AnB1 cells) 
instead of T3 B cells. The expression of several surface markers and intracellular proteins is 
indicated. Factors that cause a complete or partial block at certain developmental stages are shown 
in pink (see chapter 1.1.5 for a description). 
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From the T2 stage B cells develop into one of two mature B cell stages, which are follicular 
(Fol) B cells and marginal zone (MZ) B cells. Both mature B cell types are negative for 
CD93. Fol B cells develop directly from T2 B cells and differ phenotypically from them by 
the loss of CD93 expression and by the expression levels of IgM and IgD and are CD19+ 
B220+ CD93- CD21+ CD23+ IgMlow IgDhigh. In the spleen, Fol B cells are located inside the 
splenic follicles and represent the majority of B cells. Fol B cells circulate between the 
splenic follicles, the lymph nodes and the BM until they either die or encounter antigen and 
undergo further maturation (see chapter 1.1.4). On the way to MZ B cells, T2 B cells 
develop initially into a marginal zone precursor (MZP) B cell, defined by the expression of 
CD19+ B220+ CD93- CD21high CD23high IgMhigh IgDhigh (29), and then into mature MZ B 
cells. MZ B cells are characterized by the expression of CD19+ B220+ CD93- CD21high 
CD23low IgMhigh IgDlow and are located in the outer area of the follicles, next to the marginal 
sinus and in close vicinity to the marginal zone macrophages and dendritic cells. In contrast 
to Fol B cells, MZ B cells do not migrate to other organs but have been shown to shuttle 
between the surrounding area of the marginal sinus and the Fol B cell area in the splenic 
follicles (30, 31). 
The developmental pathway of both Fol and MZ B cells is not yet clearly defined. For many 
years, the spleen was considered to be the only site where the final steps in B cell develop-
ment occur, but recent findings showed that Fol B cell maturation takes place both in the 
spleen and the BM (32, 33). In contrast, MZ B cells mature exclusively in the spleen (34). 
Also, some authors claim that MZ B cells can develop either directly from T2 progenitor B 
cells or from Fol B cells via MZP B cells (35). 
The immature transitional B cell stages represent further tolerance checkpoints. On their 
way from the BM to the spleen, newly formed immature B cells encounter a number of 
peripheral antigens that might have not have been present in the BM. Cells bearing a BCR 
reacting with a peripheral antigen are eliminated by apoptosis or anergy. Which of these 
mechanisms is applied depends on several factors, including strength of the BCR signal and 
availability of the self-antigen, the latter is directly linked to the degree of receptor occupan-
cy. A strong signal from the BCR usually leads to induction of apoptosis. Both T1 and T2 B 
cells have been shown to undergo apoptosis upon crosslinking of the BCR (24). A lower 
BCR signal in combination with a high enough occupancy of the BCR leads to induction of 
anergy, which is a state of unresponsiveness to antigen. It was shown that a constant 
occupancy of the BCR is required to maintain the anergic state (36). Anergic B cells have a 
low level of IgM expression and a short life span of about 4-5 days. The cells previously 
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identified as T3 B cells are now thought to represent anergic B cells and thus were renamed 
anergic population 1 (An1) B cells (27). 
It was shown that about 50% of the immature B cells which enter the spleen are selected 
into the mature B cell pool (24), thus the more important tolerance checkpoint is at the 
immature B cell stage, where, as mentioned above, more than 80% of the newly formed B 
cells are negatively selected. 
 
 
1.1.3 B-1 B cells 
B-1 B cells represent a second type of B cells which are primarily found in the peritoneal 
and pleural cavities but also in the spleen and parts of the intestine. Two different subsets 
can be phenotypically distinguished, namely B-1a and B-1b B cells. B-1a B cells are CD5+ 
CD19+ B220low CD23- CD11b+ IgMhigh IgDlow, whereas B-1b B cells are negative for CD5. 
Splenic B-1 cells however do not express CD11b. The developmental pathway of B-1 B 
cells is still a matter of debate. Early studies concluded that B-1 cells arise only during fetal 
life and further persist in the adult as a self-replenishing population (37, 38). Later, B-1 B 
cells were supposed to develop in the adult from the same progenitor as B-2 B cells and that 
the decision for either lineage depends on the nature of signals delivered via the BCR (39-
41). Recent findings report the existence of a B-1 restricted progenitor (B1P), being Lin- 
CD93+ CD19+ B220-/low, which is present in fetal liver and BM and adult BM (42). B1Ps are 
a heterogenous population and can be generated in vitro and in vivo from adult BM derived 
ELPs and CLPs, but not from pro-B cells or T1 B cells (43). These results argue for a 
developmental pathway similar to that observed for B-2 B cells, although other routes might 
still be possible. 
 
 
1.1.4 Antigen dependent development 
Upon encountering of antigen, mature B cells develop via several intermediate stages, into 
either antibody-secreting cells (ASCs), which are plasmablasts and plasma cells, or memory 
B cells. Plasmablasts and plasma cells differ by their cell-cycle status and the amount of 
antibody they can secrete. Plasmablast are dividing cells that secrete low amounts of 
antibody, while plasma cells are non-dividing cells that characteristically secrete high 
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amounts of soluble immunoglobulin and can be short- or long-lived. Memory B cells are 
quiescent, long-lived cells expressing high-affinity BCRs. On differentiation into plasma 
cells the characteristic B cell surface markers are gradually downregulated, thus plasma 
cells are negative for CD19, B220, surface Ig, CD21, CD23 and CD5. Plasma cells and their 
precursors, the plasmablasts, were found to express high levels of CD138 and CD93 (44). 
For murine memory B cells, so far no specific marker has been found. Memory B cells still 
express CD19, and a subset was found to have increased expression levels of CD80 and 
CD73 (45). Which of these cells are generated depends on the location of the encounter with 
antigen and the elicited immune response. Depending on the nature of the antigen, either a 
T-cell dependent (TD) or T-cell independent (TI) immune response is generated. TD anti-
gens are mainly proteins that are processed and presented on MHC class II molecules to 
CD4+ T-helper (TH) cells. TI responses are subdivided into two categories referred to as 
type 1 (TI-1) and type 2 (TI-2). TI-1 antigens are polyclonal B cell activators (mitogens) 
such as LPS or CpG, that activate B cells via Toll-like receptors (TLRs), regardless of their 
BCR specificity, whereas TI-2 antigens are highly repetitive molecules like polymeric 
proteins (e. g. flagellin) or polysaccharides that activate B cells by engagement and cross-
linking of their BCR. The three types of mature B cells, which are Fol, MZ and B-1 B cells, 
respond differently to TI and TD antigens. 
In a TD immune response, mainly Fol B cells are involved, but MZ and B-1 B cells can also 
respond. Upon encountering of antigen and stimulation by a TH cell via interaction of B cell 
expressed CD40 with TH cell expressed CD40L, Fol B cells start to proliferate. The antigen 
activated B cells can then either develop directly into ASCs within so-called extrafollicular 
regions or enter a germinal center (GC). MZ B cells responding to a TD antigen presumably 
differentiate directly into extrafollicular ASCs and do not participate in a GC reaction. For 
Fol B cells, the decision of which pathway to take seems to depend on the affinity of the 
BCR (46). B cells with a high affinity preferentially undergo an extrafollicular plasma cell 
differentiation, while cells with a weaker affinity are directed towards a GC. Within an 
extrafollicular region, activated B cells undergo rapid proliferation leading to plasmablasts 
and finally to plasma cell development. Plasma cells formed in extrafollicular regions 
express a low affinity antibody mainly of the IgM class and have a short life span of about 3 
days. GCs are specialized structures that can develop in the follicles of peripheral lymphoid 
tissues, including the spleen, lymph nodes, Peyer’s patches and/or tonsils (47). A fully 
developed GC (see fig. 4) consists of a dark zone comprised almost exclusively of densely 
packed proliferating B cells, the so-called centroblasts, and a light zone, which is made up 
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Figure 4: Schematic representation of B cell development in the germinal center. Upon antigen 
activation, B cells differentiate into centroblasts, which undergo clonal expansion in the dark zone 
of the germinal center (GC). In the centroblasts, somatic hypermutation (SHM) takes place, a 
process that induces base-pair changes into the V(D)J region of the rearranged immunoglobulin 
heavy and light chain genes. Centroblasts differentiate further into centrocytes, which are found in 
the light zone of the GC. Here, the modified antigen receptor is tested for improved binding of the 
immunizing antigen, which is presented by T cells and follicular dendritic cells (FDCs). Centrocytes 
expressing a low affinity antibody are eliminated by apoptosis. Some of the centrocytes undergo 
immunoglobulin class-switch recombination (CSR). Eventually, the selected centrocytes differentiate 
into memory or plasma cells. Adapted from Klein et al., 2008 (47). 
 
 
of non-dividing centrocytes, follicular dendritic cells (FDCs), T cells and macrophages. 
Activated Fol B cells that enter a GC develop first into centroblasts, which are characterized 
by their fast proliferation and their apoptosis-prone phenotype. In centroblasts a process 
modifying the variable region of the rearranged IgH and IgL chain genes, termed somatic 
hypermutation (SHM), takes place. SHM is initiated by the enzyme activation-induced 
cytidine deaminase (AID), which catalyzes the targeted deamination of deoxycytidine 
residues. The resulting U:G mismatch is then repaired by different error-prone DNA repair 
mechanisms, leading to a nucleotide exchange and occasionally to an amino-acid 
substitution. Centroblasts then differentiate into centrocytes and migrate to the light zone of 
the GC, where cells with a mutated BCR that have aquired a high affinity for the antigen are 
selected. Centrocytes bearing a BCR with a low affinity for the antigen die by apoptosis, 
while centrocytes with an intermediate affinity might develop back into centroblasts and 
Germinal center 
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undergo another round of SHM. In this way, high-affinity variants of the original antigen-
specific BCR are rapidly formed. The combination of introduction of mutations by SHM 
and subsequent selection of cells with a mutated BCR accounts for the so-called affinity 
maturation of antibodies. Within the positively selected centrocytes another important 
process, the so-called class-switch recombination (CSR) takes place. CSR is an irreversible 
mechanism also dependent on AID expression, by which B cells switch the class of the ex-
pressed immunoglobulin from IgM or IgD to one of the other classes, which have different 
effector functions. The determination of the resulting Ig class depends mainly on the 
combination of specific cytokines that are secreted by follicular TH cells (48). 
The further development of centrocytes seems to depend on the affinity of the mutated 
BCR. Cells with a high-affinity BCR preferentially develop via plasmablasts into plasma 
cells (49), while memory B cells are formed from centrocytes within a more broad affinity 
spectrum (50). The plasma cells formed during a GC reaction secrete high-affinity 
antibodies and have an increased life span compared to the plasma cells formed in 
extracellular foci. While some of the GC formed plasma cells stay in the organ where they 
developed, others migrate via the blood stream to the inflamed tissue or the BM. Within the 
secondary lymphoid organs and the BM, GC-derived plasma cells develop into long-lived 
plasma cells that continue with secretion of antibody, thus contributing to the establishment 
and maintenance of humoral immunity. Also, memory B cells reside in spleen, lymph nodes 
and BM. Upon re-encountering of the specific antigen, at least a subset of the previously 
formed memory B cells can rapidly develop into plasma cells which then secrete huge 
amounts of high-affinity antibodies. 
In a TI immune response, mainly MZ and B-1 B cells are involved. Generally, no GCs are 
formed and only short-lived plasma cells originating from extrafollicular regions develop. In 
contrast to Fol B cells, MZ and B-1 B cells can develop into short-lived plasma cells when 
activated via Toll-like receptors by a TI-1 antigen. Some authors claim the formation of 
memory B cells also in a TI response (51), but this subject remains controversial. Both MZ 
and B-1 B cells are thought to be a more innate-like B cell type that have a phenotype 
similar to activated Fol B cells, which is obvious from the high level of CD80 and CD86 
expression. Thus, both cell types can easily be activated and respond rapidly to antigenic 
stimuli (52). The location of MZ B cells and their functional properties facilitates early 
encounter with blood-borne antigens and a rapid response, thereby bridging the time 
interval between the immediate innate immune response and the delayed TD GC response. 
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B-1 cells can develop into ASCs without the stimulation of exogenous antigen, resulting in 
the production of natural IgM in the serum, thus providing a first line of defense. 
 
 
1.1.5 Important transcription factors and other proteins influencing 
lineage and cell fate decisions 
As outlined above, a HSC has to go through numerous intermediate stages until finally 
becoming a terminally differentiated B cell. To date, numerous transcription factors and 
other proteins, including cell surface receptors, integrins and cytokines, have been identified 
as important components, but the mechanisms selecting a HSC for the B cell lineage and 
later for a specific compartment are not yet completely resolved. 
For many years it was thought that the decision for a specific hematopoietic lineage is made 
at a very early step during differentiation, a process that was termed lineage commitment. 
Based on several factors including the expression of surface molecules and the grade of 
lineage potential, hierarchical tree models for hematopoiesis were developed. The discovery 
of new intermediate progenitors made it necessary to adjust these models during the years, 
but newer findings do not fit into these models anymore. It seems that the potential to 
differentiate into other hematopoietic lineages is irretrievably lost, if at all, then only in 
terminally differentiated cells such as plasma cells, since even mature B cells are not 
restricted to the B cell lineage. It has been shown that mature B cells are able to undergo 
dedifferentiation into uncommited precursors, which then can develop into T cells (53). 
Recently, a completely different model of hematopoiesis was presented (54). This so-called 
pairwise relationships model (fig. 5) suggests that no strict branching points exist and 
instead there is a continuum of lineage relationships. HSCs developing towards a specific 
cell fate successively loose lineage potentials, keeping the cell fate potentials that are direct-
ly adjacent in the illustration until the final step of differentiation. During differentiation 
each cell fate potential varies between being dominant, available or having been lost, 
meaning latent. The pairwise relationships model also shows that contiguous cell fates are 
regulated by the same set of transcription factors. In general, a specific transcription factor 
promotes the development towards a specific cell fate while at the same time repressing the 
potential to differentiate into another cell fate. 
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Figure 5: The pairwise relationships model of hematopoiesis. Instead of a hierarchical tree 
structure, this model depicts hematopoiesis as a continuum of lineage relationships, where no strict 
branching points exist. The known oligopotent progenitor cells are indicated by arcs. DC, dendritic 
cell; NK cell, natural killer cell. Adapted from Ceredig et al., 2009 (54). 
 
 
One of the earliest transcription factors shown to be important for differentiation into the B 
cell lineage is PU.1, which belongs to the ETS family. Expression of Pu.1 in a subset of 
MPPs directs them to the myelo-lymphoid differentiation pathway (55). Mice deficient in 
Pu.1 die during embryonic development at day 18.5 and have a reduced number of MPPs in 
the fetal liver, resulting in the absence of B cells, T cells, monocytes and granulocytes. The 
impairment of proliferation and differentiation capacities can be explained at least in part by 
a reduced expression of the cytokine receptor FLT3 and an inability to express IL-7Rα, as 
the IL-7Rα gene is thought to be regulated directly by PU.1 (56). Interestingly, the level of 
PU.1 expression seems to be crucial for the decision between the B cell and the myeloid cell 
pathway. Precursors expressing low levels of PU.1 tend to B lymphopoiesis, while high 
levels of PU.1 expression inhibit B cell development and favor the myeloid cell 
development (57). 
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The zinc-finger transcription factor IKAROS is widely expressed in all cells of the 
hematopoietic system. IKAROS exists in many isoforms which are generated by alternative 
splicing of the Ikfz1 gene. Mice expressing a mutant form of IKAROS, which is unable to 
bind to DNA, die before birth. In the embryos, B and T cells are completely absent and 
development of myeloid and erythroid cells is severely impaired. The differentiation block 
is downstream of the block observed in Pu.1-/- mice at the LMPP stage (58) and Pu.1-/- cells 
show normal levels of IKAROS (56). Ikfz1-/- progenitor cells upregulated factors important 
in myeloid cell differentiation. Enforced expression of EBF (early B-cell factor) in Ikfz1-/- 
cells can restore the B cell lineage potential, which is probably due to the ability of EBF to 
redirect the myeloid potential towards the B cell lineage (59, 60). 
Another important transcription factor essential for B cell lineage differentiation is E2A, a 
member of the basic helix-loop-helix (bHLH) protein family. Actually, two transcription 
factors, namely E12 and E47, are collectively termed E2A and are generated from a single 
gene by alternative splicing. Deficiency in the E2a gene results in a differentiation block at 
an early B cell precursor stage (61). These cells have not yet started to rearrange their IgH 
chain genes and several B cell lineage specific proteins are absent. E2A is required for the 
initiation and maintenance of the expression of another transcription factor, EBF (early B 
cell factor) and expression of EBF in E2A deficient mice rescues the observed develop-
mental block, but the obtained B cells show an impaired response to IL-7 (62). E2A is 
furthermore directly involved in the recombination of IgH and Igκ chain, accomplished 
most likely by the binding of E2A to the Eµ enhancer (63) and the intronic κ enhancer (iEκ) 
(64), respectively. Also, E2A seems to be important in secondary Igκ rearrangements during 
receptor editing (65) and in GC reactions, as it is supossed to regulate the expression of AID 
(66). 
EBF regulates the expression of several essential transcription factors, which are PAX5 
(paired box protein 5), FOXO1 (Forkhead O1) and OBF1 (Oct-binding factor 1) (67). Mice 
deficient in the gene encoding EBF show a phenotyp that is similar to the one observed in 
E2A deficient mice, with a block at the CD19- pre-pro B cell stage and the absence of IgH 
chain recombination (68). This phenotype can only partially be rescued by expression of the 
downstream transcription factor PAX5 and recently EBF has been shown to be important 
for commitment to the B cell fate independent of PAX5 (59). 
PAX5 is a paired homeodomain protein that mediates commitment to the B cell lineage (13) 
and is indispensable for maintaining the B cell fate (53, 69). This transcription factor 
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directly activates several B cell specific genes such as those encoding CD19 and Igα and 
represses the expression of genes encoding for proteins important for other lineages like M-
CSF receptor and NOTCH-1, which are specific for the myeloid and T cell lineage, 
respectively (70). Moreover, PAX5 establishes a positive feedback loop by activating the 
genes for E2A and EBF, thus promoting B cell lineage commitment. Pax5 deficient mice 
have a complete block in B cell differentiation downstream of the one seen in E2A and 
EBF1 deficient mice. The most mature B cells found in these mice are CD19- and have 
rearranged DHJH gene segment, while VH to DHJH rearrangement is severely impaired. 
These Pax5-/- B cells can differentiate in vitro and in vivo into almost all hematopoietic cell 
types, including macrophages, osteoclasts, dendritic cells (DCs), granulocytes, natural killer 
(NK) cells, T cells and erythrocytes (13, 71, 72). The importance of maintaining Pax5 
expression in order to keep B cell lineage commitment has been shown by several 
experiments. The enforced retroviral expression of the transcription factors C/EBP-α and 
C/EBP-β in differentiated B cells resulted in inhibition of PAX5 and down-regulation of its 
target genes, leading to the reprogramming of the B cells and their differentiation into 
macrophages (69). In another experiment, conditional deletion of Pax5 in mature B cells led 
to the loss of B cell specification, resulting in de-differentiation to uncommitted progenitors 
and differentiation into the T cell lineage (53). 
The transcription factor FOXO1 is like PAX5 directly regulated by EBF. FOXO1 is 
considered to be important at several steps during B cell development (73). Mice deficient 
in FOXO1 have a reduced level of IL-7Rα expression resulting in a block at the pro-B cell 
stage. Furthermore, these cells show decreased levels of RAG-1 and RAG-2 proteins 
resulting in impaired V(D)J recombination. FOXO1 was found to directly regulate the 
expression of the RAG proteins (74). Deletion of FoxO1 at later stages in B cell develop-
ment showed a complete failure of CSR, both in TD in TI-2 responses, which was assigned 
to a direct involvement of FOXO1 in the upregulation of the gene encoding AID (73). 
Interferon-regulatory factor 4 (IRF4) and IRF8 are highly related transcription factors that 
are expressed in lymphoid and myeloid lineage cells. Binding to recognition sites requires 
the interaction with other transcription factors such as PU.1 or the related SPI-B, as IRF4 
and IRF8 bind only weakly on their own. Due to redundancy, only mice deficient for both 
Irf4 and Irf8 show a block in B cell differentiation at the cycling large pre-BII cell stage. 
These cells showed upregulated expression of VpreB and λ5 and failed to downregulate the 
pre-BCR and to rearrange the IgL chain loci (75). Recently, it was shown that IRF4 and 
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IRF8 induce the expression of the transcription factors IKAROS and AIOLOS, which 
mediate the downregulation of surrogate LC expression and induce cell-cycle arrest (76). 
OBF1 is a coactivator of the transcription factors OCT1 and OCT2 and its expression is 
induced by EBF. Despite this early activation, mice deficient in OBF1 have a nearly normal 
early B cell development until the stage of BM immature B cells (77). However, in later 
developmental stages several defects have been observed. Obf1-/- mice have severely 
reduced numbers of peripheral B cells and an impaired TD immune response with a lack of 
GC formation (78). Absence of OBF1 in combination with genetic factors, meaning only on 
a C57/BL6 background, results in an almost complete loss of MZ B cells, while B-1 B cells 
are not affected (79). In contrast, development of B-1 cells is dependent on OCT-2, as cells 
from Oct2-/- mice are unable to reconstitute peritoneal B-1 cells (80). Furthermore, OCT2 
has more recently been shown to be involved in the formation of ASCs through the direct 
regulation of the expression of the IL-5R α-chain (81). Activation of this receptor by its 
ligand IL-5 resulted in increased expression of BLIMP1, a transcription factor known to be 
essential for plasma cell differentiation (see below). 
The Notch family represent a special kind of transcription factors. Upon activation of the 
receptor by ligand binding, the Notch receptor is cleaved by the proteases TACE and γ-
secretase and the so-called Notch intracellular domain (NICD) is released. NICD then 
translocates to the nucleus where it acts as a transcription factor. Engagement of either 
NOTCH1 or NOTCH2 by the ligand DELTA-LIKE1 (DLL1) has been shown to be 
necessary for MZ B cell generation (82, 83). Furthermore, engagement of NOTCH1 by 
DLL1 promotes the differentiation of activated B cells into ASCs (84). 
The transcriptional control of ASC and plasma cell generation is quite complex, as it is 
apparent from the transcription factors described so far (47, 85). Upon entry into the GC 
reaction, B cells express high levels of PAX5 and BCL6 (B cell lymphoma 6). As already 
mentioned above, PAX5 is necessary for maintaining B cell lineage commitment but also 
for the expression of AID (86) and the repression of X-box-binding protein 1 (XBP1), a 
transcription factor required for plasma cell differentiation. Despite several other functions, 
BCL6 is expressed in centroblasts and centrocytes. It was shown that BCL6 directly 
suppresses apoptotic proteins such as p53, and also the protein ATR, which is one of the 
main sensors of DNA damage, thus BCL6 expression makes the centroblasts and centro-
cytes less sensitive to genotoxic stress, caused by high proliferation rates and genomic 
remodelling within SHM and CSR. Both PAX5 and BCL6 inhibit the differentiation into 
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plasma cells, making it necessary to downregulate these proteins to achieve further differen-
tiation. BCL6 represses the expression of B-lymphocyte-induced maturation protein 1 
(BLIMP1), which was shown to be an essential regulator of plasma cell differentiation. 
Ectopic expression of BLIMP1 drives differentiation into plasma cells (87) and suppresses 
the expression of both Pax5 and Bcl6, revealling the existence of a regulatory circuit. 
BLIMP1 deficient B cells were shown to develop into cells secreting Ig, but full 
differentiation into plasma cells could not be achieved. IRF4 has been found to be essential 
for plasma cell differentiation and CSR and both BLIMP1 and IRF4, which both are 
suppossed to be upstream of XBP1, seem to be required for the development of fully 
differentiated plasma cells (88). Although much is known about the genetic regulation of 
plasma cell differentiation, a clear picture did not yet emerge and several factors remain to 
be identified. 
Despite the transcription factors, numerous cytokines have been identified that regulate B 
cell development, among which are FLT3 ligand (FLT3L), which is the ligand for Fms-like 
tyrosine kinase 3 (FLT3), interleukin 7 (IL-7) and B cell activating factor belonging to the 
TNF family (BAFF). FL acts on very early progenitors and BAFF is important in the splenic 
transitional and later developmental stages (see below). Mice deficient in IL-7 or IL-7Rα 
have a block in B cell development at the stage of pre-proB cells (89). IL-7 has been shown 
to be necessary for the maintenance of B cell potential in CLPs (90), and signaling via the 
IL-7R was found to be necessary to keep EBF levels above a certain threshold, as IL-7Rα-/- 
pre-pro B cells had undetectable levels of EBF and PAX5 expression, which resulted in 
absence or severe reduction of Igα, λ5, VpreB and RAG1/2 protein levels (89). Analysis of 
IL-7 and IL-7Rα deficient mice also revealed, that fetal and adult hematopoiesis differs 
with respect to IL-7 dependence. During fetal hematopoiesis mature B cells develop in the 
absence of IL-7. These cells have been shown to be either B-1 or MZ B cells (91), 
indicating that the development of Fol B cells depends on IL-7R signaling. 
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1.2 FLT3 and FLT3L 
1.2.1 Structure and expression pattern 
FLT3 (FMS-like tyrosine kinase), also known as FLK-2 (fetal liver kinase 2) is a receptor 
tyrosine kinase and belongs to the family of class III receptor tyrosine kinases. A subset of 
this family, characterized by an extracellular domain composed of 5 Ig-like domains and by 
a cytoplasmic domain consisting of a split tyrosine kinase motif, comprises in addition to 
FLT3 also c-KIT, M-CSFR (macrophage colony stimulating factor receptor; also known as 
FMS) and PDGFR (platelet-derived growth factor receptor). FLT3 was found to be 
expressed in a variety of tissues including BM, fetal liver, thymus, spleen, gonads, placenta 
and brain. Within the hematopoietic compartment, FLT3 expression is found on early B and 
T cell progenitors in BM and thymus and on peritoneal macrophages and monocytes (92). 
LT-HSCs from the BM have been found to be negative for FLT3 and upregulation of FLT3 
correlates with the loss of self-renewal capacity and lineage potential (see chapter 1.1.1). 
FLT3 ligand (FLT3L) is a type I transmembrane protein that exists either in a transmem-
brane, a membrane-bound or a soluble form. In mice, the most abundant isoform is the 
membrane-bound protein, which arises from alternative splicing resulting in a protein that 
terminates in a stretch of hydrophobic amino acids that serve as membrane anchor. Soluble 
FLT3L is produced by proteolycical cleavage of the transmembrane form or more rarely by 
alternative splicing. All isoforms are biologically active and can activate FLT3 signaling. 
Structurally, FLT3L is similar to stem cell factor (SCF), the ligand of c-KIT, and to M-CSF. 
In contrast to its receptor, FLT3L is ubiquitously expressed at the mRNA level, but FLT3L 
protein has only been found in stromal fibroblasts in the BM and in T cells (93). 
 
 
1.2.2 Biological function 
Mice deficient for FLT3 are viable and healthy and have an almost normal B cell 
compartment with mature B cells in normal numbers being present in peripheral blood, 
spleen and BM. B220+ B cell progenitors in the BM were diminished and more primitive 
progenitors showed in vitro a decreased potential for development into the B cell lineage. 
Moreover, competitive repopulation experiments revealed a defect at the stem cell level, as 
Flt3-/- BM cells were not able to effectively reconstitute the hematopoietic system (94). 
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Mice deficient for FLT3L are also viable and healthy but have a slightly different phenotype 
than FLT3 deficient mice, although results might not be comparable as mice were bred on 
different genetic backgrounds. In C57BL/6 Flt3L-/- mice, leukocyte cellularity was reduced 
in peripheral blood, spleen, BM and lymph nodes and the number of dendritic cells (DCs) 
and natural killer (NK) cells was severely reduced. As in mice deficient in FLT3, the 
number of B cell progenitors in the BM was significantly decreased, albeit mature B cells 
that were able to mount a TD immune response were present. Furthermore, BM-derived 
myeloid progenitors were also reduced (95). 
In vitro experiments showed that FLT3L synergistically stimulates the growth of lymphoid 
and myeloid progenitors in combination with the appropriate cytokines or interleukins, but 
that it is not efficient when used alone (96, 97). Interestingly, FLT3L has no effect on ery-
throid, mast cell or eosinophil development. Stimulation of B lymphopoiesis was observed 
when FLT3L was used in combination with IL-7, IL-3 and IL-11. Likewise, the expansion 
of CD34+ cord blood progenitors and the progenitors of granulocytes, macrophages, T cells, 
NK cells and DCs was supported when FLT3L was used in combination with SCF or TPO 
(thrombopoietin), G-CSF, M-CSF, IL-12, IL-15 and GM-CSF or IL-4, respectively (93, 98). 
In vivo studies with mice showed that administration of FLT3L results in the expansion of 
hematopoietic progenitor cells (HPCs) and stimulation of hematopoiesis, leading to 
splenomegaly, BM hyperplasia and enlargement of LNs and liver. An increase in immature 
B cell numbers is observed in BM and spleen, but the greatest effect is observed within the 
DC compartment, with extremely large numbers of functional mature DCs (99). 
Administration of FLT3L and G-CSF has a strong synergistic effect on the mobilization of 
HPCs to the blood stream and these cells are able to reconstitute lethally irradiated donors 
upon transfer. 
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1.3 BAFF and its receptors, BAFF-R, TACI and BCMA 
1.3.1 Structure and expression of BAFF 
B cell activating factor belonging to the tumor necrosis factor (TNF) family (BAFF) was 
discovered a decade ago by several different groups and thus it is also known as BLyS (B 
lymphocyte stimulator), TALL-1 (TNF- and ApoL-related leucocyte-expressed ligand 1), 
THANK (TNF homologue that activates apoptosis, NF-B, and JNK) and zTNF4 (100-104). 
BAFF is a type II transmembrane protein of the TNF ligand superfamily (TNFSF) and it is 
highly homologous to APRIL (a proliferation inducing ligand), another member of the TNF 
ligand family (105). BAFF and APRIL share about 50% similarity within the TNF 
homology domain (THD), which is a C-terminal sequence characteristic for the TNFSF. 
BAFF exists in a transmembrane and a soluble form, generated by cleavage of the 
transmembrane form by a furin-like protease. Furthermore, a shorter isoform termed 
deltaBAFF exists, which arises from alternative splicing (106). DeltaBAFF is also a trans-
membrane protein, but it lacks the furin protease recognition motif and thus can not be 
released as a soluble molecule. All forms of BAFF adopt a trimeric structure, which is 
mediated by the THD. Soluble BAFF exist as a homotrimer (107, 108), but it is reported 
that these homotrimers are able to form virus like clusters consisting of up to 60 monomers 
(109). The question of which form is prevalent is still unanswered. Furthermore, BAFF can 
also form heterotrimers with deltaBAFF or APRIL. BAFF - deltaBAFF heterotrimers exist 
only as transmembrane proteins, and the heteromultimerization is thought to inhibit the re-
lease of soluble BAFF trimers, in that way regulating the function of BAFF (110). Soluble 
BAFF - APRIL heterotrimers are biologically active and have been found in patients with 
an autoimmune disease (111). How these soluble heterotrimers are formed is unclear, as 
APRIL is only initially transcribed as a transmembrane protein, but is then processed 
already in the Golgi apparatus by a furin convertase and secreted as homotrimer (112). A 
fusion protein named TWE-PRIL, consisting of the cytoplasmic and transmembrane domain 
of TWEAK, which is another TNFSF member, and the extracellular domain of APRIL, 
exists as a membrane bound form (113). It is assumed that full-lenght BAFF and TWE-
PRIL form transmembrane heterotrimers that upon cleavage by a protease give rise to 
soluble BAFF - APRIL heterotrimers. 
BAFF is produced mainly by myeloid cells such as monocytes, macrophages and DCs, but 
it was also found in activated T cells. Moreover, activation of B cells with LPS or CpG 
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resulted in a MyD88 dependent upregulation of BAFF expression and secretion (114). In 
humans, the expression pattern is largely identical. hBAFF is produced by macrophages and 
DCs and upon activation with IFNγ or G-CSF also by neutrophils (115). Human DCs and 
monocytes were shown to upregulate hBAFF production upon stimulation with IFNα, IFNγ, 
CD40L or LPS (116). Beside the myeloid cells, several other human cell types have also 
been found to produce hBAFF upon activation, including airway (117) and salivary gland 
epithelial cells (118), fibroblast-like synoviocytes (119) and astrocytes (120). Furthermore, 
hBAFF is also produced by VCAM1 positive stromal cells from human BM (121) and by 
osteoclasts (122). Several malignant human B cell lines, such as B cell chronic lymphatic 
leukemia, multiple myeloma and Hodgkin’s lymphoma cells, also produce hBAFF (123-
125). 
 
 
1.3.2 The BAFF receptors BAFF-R, TACI and BCMA 
BAFF can bind to three receptors called BAFF receptor (BAFF-R, also known as BR3), 
transmembrane activator and CAML (calcium modulator and cyclophilin ligand) interactor 
(TACI) and B cell maturation antigen (BCMA). While BAFF-R specifically binds BAFF, 
TACI and BCMA can bind both BAFF and APRIL (fig. 6). TWE-PRIL is also thought to be 
bound by TACI and BCMA, while BAFF - APRIL heterotrimers bind to TACI (111). Both 
the transmembrane and soluble form of BAFF can bind to BAFF-R and probably also 
BCMA, while TACI has been shown to be activated only by membrane bound or 
oligomeric BAFF and APRIL, but not by the soluble trimeric form of these ligands (126). 
DeltaBAFF and its heterotrimers are unable to bind to BAFF-R or TACI (106). 
BAFF-R, TACI and BCMA belong to the TNF receptor superfamily (TNFRSF), cha-
racterized by a cysteine-rich extracellular part. This extracellular part usually contains 
several cysteine-rich domains (CRDs), which is made up of two structural modules. The 
extracellular domain of TACI consists of two CRDs, while BCMA has only one CRD in its 
extracellular domain. The CRDs of TACI and BCMA contain a specific module that is not 
commonly found in other receptors of the TNFSF. BAFF-R contains only a partial, atypical 
module and thus not a complete CRD, making it an unusual member of the TNFSF. All 
three receptors are type III transmembrane proteins that are expressed on B cells (127). In 
mice, BAFF-R is expressed on splenic B cells and a subset of CD4+ T cells, while TACI is 
highly expressed on splenic T2 and MZ B cells and at lower levels on Fol B cells, but not on 
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T1 B cells nor on resting or activated CD4+ T cells (128). BCMA is found on plasmablasts 
and plasma cells, but not on earlier developmental stages, including mature splenic B cells 
(129). 
 
 
Figure 6: BAFF and APRIL and their receptors. BAFF can bind to all three receptors, while 
APRIL only binds to TACI and BCMA. BCMA, B cell maturation antigen; TACI, transmembrane 
activator and CAML interactor; BAFF-R, BAFF receptor; APRIL, a proliferation inducing ligand; 
BAFF, B cell activating factor belonging to the TNF family. 
 
 
All BAFF receptors belong to a subgoup of the TNFRSF that trigger intracellular signaling 
events via interaction with TNF receptor associated factors (TRAFs). The six known TRAF 
molecules have a conserved C terminal domain termed TRAF domain, which enables the 
interaction with various receptors and multiple intracellular signaling molecules (130). 
BAFF-R was found to interact only with TRAF3, but none of the other TRAFs (131) and 
activates the alternative NF-κB pathway (132). In the absence of BAFF-R signaling, 
TRAF3 is distributed in the cytoplasm and interacts with NF-κB inducing kinase (NIK), 
thus inducing proteasome-mediated degradation of NIK, resulting in the inhibition of the 
NF-κB2 pathway. Upon engagement of BAFF-R, TRAF3 is recruited to the receptor and 
then degraded by TRAF2 dependent proteolysis (133), thus allowing NIK to activate the 
IκB kinase α (IKKα), which results in the processing of the NF-κB2 p100 precursor protein 
to p52 and the translocation of the p52/RelB dimer to the nucleus (134). Furthermore, 
BAFF-R signaling inhibits the nuclear translocation of the pro-apoptotic protein kinase Cδ 
(PKCδ) (135), which also seems to be mediated by TRAF3, as B cell specific deletion of 
TRAF3 results in decreased levels of nuclear PKCδ (136). It is suppossed, that interaction 
of PKCδ with a yet unknown factor inhibits its nuclear translocation, while interaction of 
TRAF3 with the unknown factor releases PKCδ from the complex, allowing PKCδ to enter 
the nucleus (130), but this hypothesis has still to be proven. BAFF-R also activates the 
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kinase AKT and the MAPK pathway with c-RAF and ERK, resulting in downregulation of 
the pro-apoptotic protein BIM (137, 138). Recently, it was shown that BAFF-R can also be 
found in the nucleus where it interacts with several proteins including histone H3, IKKβ and 
NF-κB/c-Rel, thus functioning as transcriptional regulator (139). In vitro experiments with a 
transfected cell line showed that TACI interacts with TRAF2, TRAF5 and TRAF6 (140) 
while BCMA binds TRAF1, TRAF2 and TRAF3 and activates the MAPK pathway with 
JNK and p38 and the transcription factors NF-κB and ELK-1 (141), but the signaling 
pathways activated by TACI or BCMA in a more natural situation are not yet well defined. 
 
 
1.3.3 Biological activity of BAFF and its receptors 
BAFF is an important survival and maturation factor for B cells beyond the stage of 
immature BM B cells. Mice transgenic for BAFF have enlarged spleen, lymph nodes and 
Payer’s patches, resulting from massively expanded B cell numbers. All stages beyond the 
T1 stage are affected, while elevated BAFF levels do not have any effect on progenitor B 
cell stages in the BM. The largest increase is seen in T2, MZ and splenic B220+ CD5+ B cell 
numbers, whereas Fol B cell numbers are increased to a lesser extend. BAFF transgenic 
mice exhibit also increased levels of serum immunoglobulin of all isotypes and IgG sub-
classes. Furthermore, BAFF transgenic mice develop an autoimmune disease which closely 
resembles human systemic lupus erythematosus (SLE), characterized by anti-nuclear and 
anti-dsDNA autoantibodies, circulating immune complexes and Ig deposition in the kidney, 
resulting in glomerulonephritis, kidney destruction and proteinurea (103, 142, 143). Mice 
deficient for BAFF have a severely reduced mature B cell compartment. Splenic Fol and 
MZ B cells and T2 B cells are almost completely absent, while T1 B cell numbers are only 
slightly reduced. Both B-1a and B-1b B cells from the peritoneal cavity are present in 
normal numbers. BAFF deficient mice also have extremely low serum Ig levels and the few 
mature B cells that are still present in these mice are not able to mount a normal TD or TI 
immune response (144). In vitro studies showed that BAFF prolongs the survival of BM 
immature and splenic transitional and mature B cells by prevention of apoptosis. 
Furthermore, incubation of BM immature or splenic transitional B cells resulted in 
maturation of the cells, obvious from phenotypical and functional changes (145). BAFF was 
also found to act synergistically with IL-6 to maintain BM plasma cell survival in vitro 
(129). 
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In contrast, APRIL deficient mice have normal numbers of mature B cells and show only a 
mild phenotype with impaired class switching to IgA and enlarged GCs (146), thus APRIL 
is not important for the development of mature Fol and MZ B cells, but for the antigen 
dependent developmental process. 
From the receptor knock-out mice, only mice deficient for BAFF-R show a phenotype that 
is similar to the one observed for BAFF deficient mice, thus BAFF-R was considered to be 
the main receptor responsible for the observed B cell survival and maturation effects of 
BAFF. BAFF-R-/- mice have significantly reduced numbers of splenic T2 and mature Fol 
and MZ B cells, and the numbers of peritoneal B-1, BM progenitor and splenic T1 B cells 
are unchanged. Serum Ig levels are reduced, but in contrast to BAFF deficient mice, 
immune responses to TI-II antigens and IgM responses against some TD antigens are nearly 
identical to WT mice (147). Mice deficient for BCMA have a normal mature B cell 
compartment with a normal splenic architecture. Furthermore, BM progenitor B cells and 
peritoneal B-1 cells are normal in numbers. Serum Ig levels are not changed and primary 
and secondary immune responses against TD and TI antigens proceed normally (144, 148). 
TACI deficient mice have a phenotype that closely resembles the one observed for BAFF 
transgenic mice, with enlarged lymphoid organs and increased numbers of mature B cells. 
Serum Ig levels are almost normal, only IgA levels are decreased. TD immune resonses in 
general are nearly normal, but IgM and IgG responses to a TI-II antigen are significantly 
reduced. Also, TACI-/- mice develop an SLE-like autoimmune disease (149, 150). Thus, 
TACI signaling has an inhibitory function for peripheral B cell survival. 
Both BAFF and APRIL were shown to mediate isotype switching to IgA, IgE and IgG1, in 
part in synergism with IL-4, by engagement of BAFF-R and TACI, respectively (151) and 
signaling via the APRIL - TACI axis was shown to be important for the regulation of IgA 
production (152). The expression of BAFR-R and TACI is up-regulated in response to TLR 
engagement in Fol, MZ and B-1a cells, leading to increased cell proliferation and Ig 
secretion (153, 154), thus connecting the innate with the adaptive immune system. 
BAFF signaling via BAFF-R was also shown to co-stimulate activated T cells (128) and 
thus to influence TH1-type immune responses (155). 
In the BAFF-APRIL system, several species differences have been observed comparing the 
mouse with the human system. While in the murine system TACI was found to be a nega-
tive regulator, in humans a defective TACI signaling leads to immunodeficiencies (151). 
Furthermore, murine BCMA binds APRIL with a low affinity, while human APRIL is 
bound with high affinity to human BCMA (156). 
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1.4 Aim of thesis 
B cells are an indispensable component of the adaptive immune system and the develop-
ment of mature and functional B cells is important for humoral immunity. Numerous facts 
are known about the process of differentiation of HSCs into mature B cells, including 
intermediate stages and their regulation by transcription factors, cytokines and interleukins. 
Nonetheless, certain aspects of this differentiation process are still unresolved. A better 
understanding of the underlying mechanisms might also help to develop new substances for 
the treatment of human disorders known to be associated with a dysregulated B cell 
development, including autoimmune diseases and malignant disorders such as lymphomas 
and leukemias.  
 
The discovery of EPLMs, a new type of progenitor cells with developmental potential for B 
cells, T cells and myeloid cells and expression of FLT3 (12), raised the question of how 
signaling via the FLT3 - FLT3L axis would influence the EPLM compartment and develop-
mental potential. FLT3L has long been known to affect B lymphopoiesis. Administration of 
FLT3L results in an increased number of immature B cell in BM and spleen and in vitro 
experiments showed a synergistic stimulation of B lymphopoiesis when FLT3L was used in 
combination with IL-7, IL-3 and IL-11. Mice deficient for FLT3L or FLT3 have diminished 
numbers of BM derived B cell progenitors. Due to the fact that FLT3L administration 
massively increases DC development, most studies on FLT3L and FLT3 deal with DCs. 
The analysis of EPLMs from FLT3L treated mice should give the answer to what extend 
signaling via the FLT3 - FLT3L axis influences non-myeloid cell development and especial-
ly B cell development. 
 
Although much is known about the factors that regulate B cell development in the BM, the 
factors regulating splenic B cell development remain largely unknown. BAFF has been 
found in in vitro experiments to be a survival and maturation factor for BM immature and 
splenic transitional and mature B cells and signaling via BAFF-R has been shown to 
mediate this function. BAFF-R deficient mice show a severely impaired B cell development 
starting with the T2 stage, which results in an almost complete loss of mature B cells, thus 
the analysis of an involvement of BAFF-R signaling in later stages of B cell development is 
not possible in BAFF-R-/- mice. The use of monoclonal α-mBAFF-R antibodies that are 
able to block the binding of BAFF to BAFF-R in vivo should help to analyze the role of 
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signaling via the BAFF - BAFF-R axis in development of B cells into mature Fol and MZ B 
cells and their maintenance and also in formation and maintaining memory and plasma cells 
during TD and TI immune responses. 
Furthermore, BAFF seemed to have no effect on immature B cells, although a subset of BM 
immature B cells expresses BAFF-R (157). The first stage at which BAFF seemed to be 
important was at the transition from the T1 to T2 stage in the spleen, as both BAFF and 
BAFF-R deficient mice show a block at the T1 cell stage. With the help of monoclonal 
antibodies directed against murine BAFF-R, the expression pattern of mBAFF-R should be 
analyzed in detail and the developmental stage at which BAFF-R is first expressed should 
be identified. Also, the question of why BAFF-R is expressed already on BM immature B 
cells while its function is essential not until the splenic T1 stage should be answered. 
The finding that increased expression of BAFF in mice results in the development of 
autoimmune disorders resembling SLE (142) and, in aged mice, Sjögren’s syndrome, led to 
the discovery of increased BAFF levels in humans affected with these autoimmune diseases 
(158, 159). To further elucidate the role of BAFF in human autoimmune diseases and other 
disorders associated with perturbation of B cell homeostasis, monoclonal antibodies against 
hBAFF should be made in order to develop an ELISA for hBAFF detection. With this 
ELISA, the reported observations should be confirmed and serum hBAFF levels in further 
disorders should be analyzed in order to determine an involvement of BAFF in selected 
human autoimmune, infectious and cancerous diseases. 
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2 MATERIALS AND METHODS 
2.1 General buffers and solutions 
ABI loading buffer 25 mM EDTA, pH 8.0 
 50 mg/ml blue dextran 
 in deionized formamide 
 
ACK (red blood cell lysis buffer) 0.15 M NH4Cl 
 1.0 mM KHCO3 
 0.1 mM EDTA 
 sterile filter through a 0.22 µm filter 
 
Coomassie blue staining solution 0.25 g Coomassie brilliant blue R-250 
 45 ml H2O 
 45 ml methanol 
 10 ml glacial acetic acid 
 
Coomassie destaining solution 45 ml H2O 
 45 ml methanol 
 10 ml acetic acid 
 
DNA loading buffer (6x) 0.25% bromphenol blue 
 0.25% xylene cyanol 
 1 mM EDTA 
 30% glycerol 
 
ECL stock solution A 250 mM Luminol in DMSO 
 stored at RT in the dark 
 
ECL stock solution B 90 mM p-Coumaric acid in DMSO 
 stored at RT in the dark 
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ECL stock solution C 1 M Tris/HCl, pH 8.5 
 
ECL stock solution D 35% H2O2 
 
ECL solution 1 200 µl ECL stock solution A 
 89 µl ECL stock solution B 
 2 ml ECL stock solution C 
 8 ml H2O 
 stored at 4°C 
 
ELISA blocking buffer 4% BSA 
 0.2% Tween 20 
 10 mM NaN3 
 in PBS 
 
ELISA substrate buffer for alkaline phosphatase 0.1 g MgCl2 x 6 H2O 
 10 mM NaN3 
 10% diethanolamine 
 adjust to pH 9.8 with HCl 
 fill up to 1l with ddH2O 
 
ELISA substrate stock solution (100x) 100 mg/ml Dinitrophenylphosphate 
in H2O 
 stored at -20°C 
 
FACS buffer 2% FCS 
 10 mM NaN3 
 in PBS 
 
FACS sorting buffer 2% FCS in PBS 
 sterile filter through 0.22 µm filter 
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IPTG 1 M IPTG in ddH2O 
 sterile filter through 0.22 µm filter 
 stored in aliquots at -20°C 
 use 4 µl per agar plate 
 
Lysis buffer for mouse tails 50 mM Tris/HCl, pH 8.0 
 5 mM EDTA 
 100 mM NaCl 
 0.5% SDS 
 add 20 µl Proteinase K (10 mg/ml) to 
750 µl lysis buffer directly before use 
 
PBS (10x) 1.37 M NaCl 
 27 mM KCl 
 15 mM KH2PO4 
 80 mM Na2HPO4 
 pH 7.2 
 
PBST 0.1% Tween 20 in PBS 
 
SDS-PAGE lower buffer 1 l Tris/HCl (1.5 M), pH 8.7 
 40 ml SDS (10%) 
 
SDS-PAGE reducing sample buffer (6x) 300 mM Tris/HCl, pH 6.8 
 30% glycerol 
 12% 2-Mercaptoethanol 
 12% SDS 
 0.02% bromphenolblue 
 
SDS-PAGE running buffer 0.2 M Glycine  
 25 mM TRIS 
 0.1% SDS 
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SDS-PAGE upper buffer 1 l Tris/HCl (0.5 M), pH 6.8 
 40 ml SDS (10%) 
 
Silver staining-developer solution 6 g Na2CO3 in 98 ml ddH2O 
 add 50 µl formaldehyde (37%) 
 add 2 ml Silver staining-
thiosulfate solution 
 prepare fresh before use 
 
Silver staining-fixative solution 50 ml methanol 
 12 ml glacial acetic acid 
 fill up to 100 ml with ddH2O 
 add 50 µl formaldehyde (37%) 
 prepare fresh before use 
 
Silver staining-silver nitrate solution 200 mg AgNO3 in 100 ml ddH2O 
 add 75 µl formaldehyde (37%) 
 prepare fresh before use 
 
Silver staining-stop solution 50% methanol 
 12% acetic acid 
 in ddH2O 
 prepare fresh before use 
 
Silver staining-thiosulfate solution 20 mg Na2S2O3 * 5 H2O 
 in 100 ml ddH2O 
 prepare fresh before use 
 
TAE 1 mM EDTA 
 40 mM Tris-acetate, pH 8.0 
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TBE (10x) 21.6 g Tris 
 11 g Boric acid 
 8 ml EDTA (0.5 M, pH 8.0) 
 fill up to 200 ml with dd H2O 
 
TBS 10 mM MgCl2 
 10 mM MgSO4 
 10% PEG 4000 
 5% DMSO 
 15% glycerol 
 in LB medium 
 sterile filter through 0.22 µm filter 
 
TE 1 mM EDTA 
 10 mM Tris/HCl, pH 8.0 
 
Western blot transfer buffer 0.2 M Glycine 
 25 mM TRIS 
 20% Methanol 
 
Western blot blocking buffer 5% milk powder 
 0.1% Tween 20 
 dissolve in PBS 
 
X-Gal 20 mg X-Gal in 1 ml DMF 
 store at -20°C in the dark 
 use 40 µl per agar plate 
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2.2 Bacterial media and supplements 
LB medium 10 g tryptone (BD Difco) 
 5 g yeast extract (BD Difco) 
 5 g NaCl 
 fill up to 1 l H2O and autoclave 
 
LB-Agar 15 g agar (Sigma) 
 added to 1 l LB medium and autoclave 
 
Ampicilin stock 100 mg/ml in H2O, used at 100 µg/ml 
 
Kanamycin stock 50 mg/ml in H2O, used at 50 µg/ml 
 
 
2.3 Cell culture media and supplements 
IMDM medium, SF 176.6 g IMDM powder (Gibco BRL) 
 30.24 g NaHCO3 (Fluka) 
 100 ml Penicillin/Streptomycin solution (100x) 
  (Gibco BRL) 
 100 ml MEM Non Essential Amino Acids 
(100x) (Gibco BRL) 
 10 ml Insulin (5 mg/ml) (Sigma) 
 10 ml β-Mercapthoethanol (50 mM) (Fluka) 
 30 ml Primatone RL (10%)  
 (Quest International) 
 adjust to pH 7.0 with NaOH (Fluka) 
 fill up to 10 l with fresh H2O, tridistilled 
 sterile filter through 0.22 µm filter 
 
RPMI medium Gibco BRL 
 
DMEM with Glutamax Gibco BRL 
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HAT medium 1 l SF-IMDM medium 
 20 ml FCS 
 5 ml Ciproxin 
 2 x HAT Media Supplement (50x) (Sigma) 
 10 ml IL6-supernatant 
 sterile filter through 0.22 µm filter 
 
SF-900 medium 1 x SF-900 II SFM powder for 10 l  
 (Gibco BRL) 
 3.5 g NaHCO3 
 adjust to pH 6.20 - 6.30 with NaOH 
 fill up to 10 l with fresh H2O, tridistilled 
 sterile filter through 0.22 µm filter 
 
Freezing medium 10% DMSO in FCS 
 
FCS Amimed 
 
Cellfectin Gibco BRL 
 
CuSO4 solution 500 mM CuSO4 
 sterile filtered through 0.22 µm syringe filter 
 used at 1.25 mM 
 
Cyproxin 2 mg/ml solution (Bayer AG) 
 
IL6-supernatant IL6 producing X63 cells (X63-IL6) were grown 
in 2% FCS/SF-IMDM medium for 5-7 days, 
then the suspension was sterile filtered through 
diatomaceous earth (Highflow Super Cell 
Medium, Fluka). The resulting cleared 
supernatant was kept at 4°C. 
 
Lipofectamine Reagent Invitrogen 
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Plus Reagent Invitrogen 
 
Trypsin solution Gibco BRL 
 
PEG 1500, 50%, sterile solution Boehringer Mannheim 
 
Penicillin/ Streptomycin (100x) Gibco BRL 
 
Puromycin stock 10 mg/ml in H2O 
 sterile filtered through 0.22 µm syringe filter 
 used at 5 µg/ml 
 
 
2.4 Primers 
Name Sequence (5′- 3′) Application 
hBAFF-1 GAT AAC AGG AAA TGA TCC ATT C 
amplification of hBAFF 
cDNA, 5′-UTR 
hBAFF-2r CTT AGA GGT ACA GAG AAA GG 
amplification of hBAFF 
cDNA, 3′-UTR 
hBAFF-5 GGG CCC AGG GTC CAG AAG AAA C 
soluble hBAFF cDNA, 5′-end, 
introduction of ApaI site 
hBAFF-6r GCG GCC GCT CAC AGC AGT TTC AAT GC 
soluble hBAFF cDNA, 3′-end, 
introduction of NotI site 
hBAFF-S1 CAA GTG AAT CAT CTC AGT GC 
sequencing downstream of 
pRmHa-3 promoter 
hBAFF-S2r TAT TAT CGT ATT AGG AGA AG 
sequencing upstream of 
pRmHa-3 ADH-polyA site 
mBAFF-R4 ATT AGA TCT GAA ATG GGC GCC AGG AGA CTC C 
mBAFF-R cDNA, coding 
start, introduction of BglII site 
mBAFF-R5r GAT GAA TTC CTA TTG CTC TGG GCC AGC TG 
mBAFF-R cDNA, 3′-end, 
introduction of EcoRI site 
 
Remarks: coding sequence in bold, sequence of restriction sites in italics 
Primers were obtained from Microsynth GmbH, Switzerland or from QIAGEN, Germany. 
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2.5 Plasmids 
Name Desciption Insert Reference Application 
pCR4-TOPO 
(4 kb) 
ampR, kanR, lacZ+ --- Invitrogen 
Subcloning of PCR 
products with TA-
overhang 
pCR-Blunt II-
TOPO 
(3.5 kb) 
kanR, lacZ+ --- Invitrogen 
Subcloning of PCR 
products with blunt 
ends 
phshs-puro puroR --- 
Steller et al., 
1985 (1) 
Co-transfection of 
Drosophila 
Schneider cells 
pGEM-hBAFF 
(4 kb) 
based on pGEM-T Easy 
ampR, lacZ+ 
hBAFF 
(984 bp) 
M. Rauch 
this thesis 
Storage of hBAFF 
cDNA 
pRmHa3-
HA/myc/TM 
(4.2 kb) 
based on pRmHa3  --- 
Puig et al., 
2001 
(2) 
Expression vector 
for Drosophila 
Schneider cells 
pRmHa3-HA-
hBAFF 
(4.6 kb) 
based on pRmHa3-
HA/myc/TM 
soluble hBAFF, 
aa 136-285 
(453 bp) 
M. Rauch 
this thesis 
Production of HA-
hBAFF protein in 
Drosophila SL-3 
cells 
pMIG-R1 
(6.2 kb) 
MSCV based retroviral 
vector containing the 
complete GFP coding 
sequence preceded by the 
encephalomyocarditis 
internal ribosome entry 
site 
--- 
Addgene 
#9044 
Pear et al., 
1998 (3) 
Expression vector 
for eukaryotic cell 
lines 
pMIG-mBAFF-R 
(6.7 kb) 
based on pMIG-R1 
mBAFF-R 
(528 bp) 
M. Rauch 
this thesis 
Expression of 
mBAFF-R in 
different cell lines 
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2.6 Antibodies and recombinant proteins 
2.6.1 Antibodies for FACS 
Commercial antibodies were diluted in FACS buffer and used at a final dilution of 1:200. 
 
anti-mouse CD3ε 142-2C11 BD Pharmingen 
anti-mouse CD4 RM4-5 BD Pharmingen 
anti-mouse CD5 53-7.3 BD Pharmingen 
anti-mouse CD8α 53-6.7 BD Pharmingen 
anti-mouse CD11b M1/70 BD Pharmingen 
anti-mouse CD11c HL3 BD Biosciences 
anti-mouse CD21 7G6 BD Pharmingen 
anti-mouse CD23 B3B4 BD Pharmingen 
anti-mouse CD25 α-chain 7D4 BD Pharmingen 
anti-mouse CD44 IM7 BD Biosciences 
anti-mouse CD45R (B220) RA3-6B2 BD Pharmingen 
anti-mouse CD117 (c-kit) 2B8 eBiosciences 
anti-mouse CD127 (IL-7Rα) A7R34 eBiosciences 
anti-mouse CD135 (FLT3) A2F10 eBiosciences 
anti-mouse λ1+2-LC  BD Biosciences 
anti mouse TCRβ H57 BD Biosciences 
anti-mouse TCRγ/δ GL3 BD Biosciences 
anti-mouse NK1.1 PK 136 BD Biosciences 
mouse-anti-rat IgG  Jackson ImmunoResearch Laboratories 
Streptavidin-PE used at 1:1000 BD Biosciences 
Streptavidin-PE-Cy7 used at 1:400 BD Biosciences 
Streptavidin-APC used at 1:200 Becton Dickinson 
 
 
Antibodies produced in the laboratory were individually titrated before use. 
 
anti-HA 12CA5 
anti-mouse CD19 1D3 
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anti-mouse CD90 T24 
anti-mouse CD93 PB493 
anti-mouse CD117 (c-Kit) ACK4 
anti-mouse IgM M41 
anti-mouse IgD 1.19 
anti-mouseκ-LC 187.1 
 
 
2.6.2 Antibodies and proteins used for ELISA or Western Blot 
 
anti-ratIgG-2A BD biosciences 
anti-ratIgG-2B BD biosciences 
Biotin-SP mouse anti-rat IgG Jackson ImmunoResearch 
hBAFF, soluble PeproTech 
Streptavidin-AP Amersham biosciences 
anti-ratIgG-AP Jackson ImmunoResearch 
Avidin-HRP BD biosciences 
 
 
2.7 Kits 
Big Dye 1.1 Terminator v 1.1 Cycle Sequencing Kit Applied Biosystems 
Geneclean Kit Q-Biogene 
NucleoSpin Plasmid kit Macherey-Nagel 
Pure Yield Plasmid Midiprep System Promega 
QIAEX II Gel Extraction Kit QIAGEN 
QIAfilter Plasmid Midi Kit QIAGEN 
QIAprep Spin Miniprep Kit QIAGEN 
QIAquick Gel Extraction Kit QIAGEN 
QIAquick PCR Purification Kit QIAGEN 
SuperScript First-Strand Synthesis System for RT-PCR Invitrogen 
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2.8 Cell lines 
Name Description Culture medium 
Sp2/0 
(Sp2/0-Ag14) 
mouse myeloma 
ATCC CRL-1581 
SF-IMDM, 2% FCS, 
0.5% Cyproxin 
Y3 
(Y3-Ag 1.2.3) 
rat myeloma 
ATCC CRL-1631 
SF-IMDM, 2% FCS, 
0.5% Cyproxin 
Phoenix 
amphotropic retroviral 
packaging cell line 
ATCC SD 3443 
RPMI, 10% FCS, 
50 µM β-Mercapthoethanol, 100 U/ml 
penicillin, 
100 µg/ml streptomycin, 0.5% Cyproxin 
SL-3 
Drosophila melanogaster 
ATCC CRL-1963 
SF-900, 2% FCS 
40E1 
pre-B cell 
Alt et al., 1981 (4) 
SF-IMDM, 2% FCS, 
0.5% Cyproxin 
OP9 
stroma cell line 
does not produce M-CSF 
Kodama et al., 1994 (5) 
SF-IMDM, 2% FCS, 
0.5% Cyproxin 
OP9-DL1 
OP9 expressing the Notch ligand 
Delta-like 1 (DL1) 
Schmitt et al., 2002 (6) 
SF-IMDM, 2% FCS, 
0.5% Cyproxin 
ST-2 
stroma cell line 
Hardy et al., 1987 (7) 
SF-IMDM, 2% FCS, 
0.5% Cyproxin 
 
 
2.9 Animal strains 
Name Description Source 
C57BL/6 wild type mice RCC Ltd., Füllinsdorf 
FcRγ-/- mice deficient for FcRγ-chain Taconic, Ejby, Denmark 
Bcl-2 tg 
mice transgenic for Bcl-2 gene under H2Kb 
promoter 
Dr. A. Trump, ISREC, Lausanne 
Lewis wild type rat RCC Ltd., Füllinsdorf 
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2.10 Molecular biology methods 
2.10.1 RNA isolation 
RNA from tissue or cultured cells was isolated with Tri Reagent (MRC) according to the 
manufacturer’s description, dissolved in 15 µl DEPC-treated ddH2O per 1 ml initially used 
Tri Reagent and stored at -80°C.  
 
 
2.10.2 Polymerase chain reaction (PCR) 
2.10.2.1 Analytical PCR 
For analytical purposes, PCR reactions were mixed on ice in 0.2 µl thermo PCR tubes and 
were carried out with Taq DNA polymerase. The reaction mixture was set up as follows: 
 
1-5 µl DNA template 
3 µl forward primer (5 µM) 
3 µl reverse primer (5 µM) 
1.5 µl dNTP mix (5 mM) 
2 µl PCR buffer (10x) 
0.5 µl Taq DNA polymerase 
fill up to 20µl with ddH2O 
 
The PCR reaction was performed according to the following standard program: 
 
1 cycle 94°C 45 sec (3 min for genomic DNA template) 
35 cycles 92°C 45 sec 
 Tm-3°C 30 sec 
 72°C 1 min/kb of product lenght 
1 cycle 72°C 10 min 
unlimited 10°C 
 
The melting temperature Tm of each primer was calculated based on the primer sequence. 
Therefore, each nucleotide in the primer sequence that was complementary to the target 
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DNA was counted, with A and T counting 2°C and G and C counting 4°C. The annealing 
temperature was then set 2-5°C lower than the lowest melting temperature calculated for the 
used primer pair. 
For screening of bacteria colonies after transformation, the PCR reaction mixture was set up 
as described above without DNA template. With a small tip, one colony was picked from 
the plate and the tip was dipped into the appropriate PCR tube containing the reaction 
mixture, before dipping the tip into one well of a 96-well plate containing 100 µl of 
LB/Amp medium. This plate was then kept at RT until the positive clones could be selected 
based on the result of the PCR. The content of the appropriate wells was added to 3 ml of 
LB/Amp medium in a 12 ml tube each and cultured O/N. 
 
2.10.2.2 Preparative PCR 
For preparative purposes, PCR reactions were mixed on ice in 0.2 µl thermo PCR tubes and 
carried out with Pfu DNA polymerase (Stratagene). The reaction mixture was set up as 
follows: 
 
50-200 ng DNA template 
1 µl forward primer (10µM) 
1 µl reverse primer (10 µM) 
4 µl dNTP mix (5 mM each dNTP) 
5 µl PCR buffer (10x) 
1 µl Pfu DNA polymerase (2.5 U/µl) 
fill up to 50µl with ddH2O 
 
The PCR reaction was performed according to the following program, which was suggested 
by the manufacturer: 
 
1 cycle 94°C 45 sec 
25-30 cycles 94°C 45 sec 
 Tm-5°C 45 sec 
 72°C 1.5 min/kb of product lenght 
1 cycle 72°C 10 min 
unlimited 4°C 
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For preparative amplification of demanding templates, such as GC-rich templates, Platinum 
Pfx DNA polymerase (Invitrogen) and if necessary, the corresponding PCRx Enhancer 
Solution (Invitrogen) were used, according to the manufacturer’s protocol. As the optimal 
composition of the PCR reaction mixture as well as the optimal PCR cycling conditions are 
highly dependent on the DNA template that has to be amplified, these settings had to be 
determined empirically. 
Amplification products were subsequently either cloned directly into pCR-Blunt II-TOPO 
according to the manufacturer’s protocol or purified with QIAquick PCR Purification Kit as 
recommended by the manufacturer and then subjected to restriction enzyme digestion. 
 
2.10.2.3 Sequencing PCR 
For sequencing, the PCR was carried out using a ready-to-use solution (Big Dye Terminator 
Cycle Sequencing Kit, Applied Biosystems), containing fluorescent terminator dideoxy-
nucleotides. The set-up of the reaction mixture was the following: 
 
200-500 ng plasmid DNA (3 µl mini-prep DNA) 
3.5 µl primer (1µM) 
2 µl 1/2 BD 
2 µl BD sequencing mix 
fill up to 20 µl with ddH2O 
 
The PCR reaction was performed according to the following standard program: 
 
1 cycle 96°C 1 min 
35 cycles 96°C 30 sec 
 50°C 20 sec 
 60°C 4 min 
1 cycle 60°C 5 min 
unlimited 10°C 
 
To remove free fluorescent terminator dideoxynucleotides, the PCR reaction was purified 
by DNA precipitation. Therefore, 2 µl sodium acetate (3 M, pH 4.6) and then 50 µl ethanol 
(100%, RT) were added to each tube, mixed and incubated for 20 min at RT. After 
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centrifugation at full speed in a table top centrifuge (21 000 x g) for 30 min at 20°C, the 
supernatant was removed and the pellet was washed by adding 50 µl ethanol (70%, RT) to 
each tube. Immediately after that, a further centrifugation step for 10 min at full speed and 
20°C was performed. Next, the supernatant was removed and the pellet was dried in a speed 
vac for 5 min. Pellets were then resuspended either in 40 µl ddH2O for sequencing on a 
capillary sequencer, or in 3.5 µl ABI loading buffer for sequencing on a gel sequencer. 
 
 
2.10.3 Preparation and transformation of competent bacteria 
2.10.3.1 Preparation of chemical-competent E. coli 
100 ml of pre-warmed LB medium were inoculated with 0.5 ml of a fresh overnight culture 
of E. coli DH5α or E. coli XL-2. The bacteria cells were grown at 37°C with vigorous 
shaking to early log phase, which corresponds to an OD600 of 0.3-0.6. Cells were then 
pelleted by centrifugation at 3500 x g (20 min, 4°C). The supernatant was discarded and the 
cell pellet was resuspended in 10 ml of cold and sterile TBS buffer. 100 µl aliquots of the 
bacteria suspension were shock frozen in liquid nitrogen and stored at -80°C. 
 
2.10.3.2 Preparation of electro-competent E. coli 
600 ml of pre-warmed LB medium were inoculated with 5 ml of a fresh overnight culture of 
E. coli DH10B. The bacteria culture was grown at 37°C with vigorous shaking to an OD600 
of 0.6-0.8 and the cells were then cooled down on ice for 30 min. Subsequently, the cell 
pellet was washed successively in 600 ml of ice cold and sterile ddH2O, in 300 ml of ice 
cold and sterile ddH2O and in 12 ml of ice cold and sterile 10% glycerol. Bacteria cells were 
pelleted in between the different washing steps by centrifugation at 3500 x g (20 min, 4°C). 
Finally, the pellet was resuspended in 3 ml of ice cold and sterile 10% glycerol and 50 µl 
aliquots of the bacteria suspension were shock frozen in liquid nitrogen and stored at -80°C. 
 
2.10.3.3 Transformation of chemical-competent E. coli 
An aliquot of chemical competent E. coli DH5α or E. coli XL-2 in TBS buffer was thawed 
on ice and then 1-10 µl of a ligation mix were given to 50 µl bacteria suspension. After 
incubation on ice for 15-30 min, a heat shock was performed by putting the bacteria to 42°C 
for 90 sec. Subsequently, the bacteria were cooled down on ice for 2 min. After that, 900 µl 
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LB medium without antibiotics were added and the bacteria were incubated for 40-60 min at 
37°C with shaking. Then, 50-100 µl of the transformation mixture were plated on a 
selecting agar plate, containing the appropriate antibiotic. The remaining transformation 
mixture was centrifuged at 10 000 g for 20 sec and the supernatant was discarded except for 
100 µl in which the pellet was resuspended. These 100 µl were then also plated on a 
selecting agar plate and all plates were incubated O/N at 37°C. 
 
2.10.3.4 Transformation of electro-competent E. coli 
A 50 µl aliquot of electro-competent E. coli DH10B was thawed on ice for not more than 5 
min. Then, 1-2 µl of ligation reaction was added and the mixture was transfered to a pre-
cooled 0.1 cm gap Gene Pulser cuvette (Bio-Rad), making sure that no air bubbles were 
present in the bacteria suspension. Subsequently, the cuvette was placed into the 
electroporator and pulsed with 1.8 kV, 25 µF and 200 Ω. Immediately after pulsing, 900 µl 
of cold LB medium without antibiotics were given into the cuvette and the bacteria were 
transfered to a 1.5 ml tube. After incubation for 60 min at 37°C with shaking, 50-100 µl of 
the transformation mixture were plated on an agar plate containing the appropriate 
antibiotic. The remaining transformation mixture was centrifuged at 10 000 g for 20 sec and 
the supernatant was discarded except for 100 µl in which the pellet was resuspended. These 
100 µl were then also plated on a selecting agar plate and all plates were incubated O/N at 
37°C. 
 
 
2.10.4 Agarose gel electrophoresis 
Electrophoretic separation of DNA for analytical or preparative purposes was done by using 
agarose gels of different concentrations in 1 x TAE. Before pouring, ethidium bromide (10 
µg/ml) was added to the gel resulting in a final concentration of 0.1 µg/ml. Prior to loading, 
6 x DNA loading buffer was added to each sample. Electrophoresis was performed at 3-6 
V/cm. As molecular weight marker, 5 µl of prediluted 1 kb Plus DNA ladder was used, or 
for quantification of DNA concentration 5 µl SmartLadder. 
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2.10.5 Purification of DNA from agarose gels 
To avoid DNA damage by UV light, the agarose gels were examined under less energetic 
UV light (366 nm) and the bands of interest were excised quickly. Purification was then 
performed using either QIAquick Gel Extraction Kit (Qiagen) or for larger DNA fragments 
QIAEX II Gel Extraction kit (Qiagen), in each case according to the manufacturer’s 
instruction. 
 
 
2.10.6 Restriction enzyme digestion of plasmid DNA and PCR fragments 
For analytical purposes, DNA digestion with restriction enzymes was carried out in 10-20 
µl volume according to the enzyme manufacturer’s (NEB) recommendations. Usually, the 
digestion reactions were performed for 30-60 min, unless the enzyme used required other 
conditions. 
For preparative purposes, the DNA amount needed was diluted as recommended by the 
enzyme manufacturer. Reaction conditions were set as advised, and digestions were 
performed for at least 2 h to O/N. DNA fragments where then purified by agarose gel 
electrophoresis. 
 
 
2.10.7 Ligation of DNA fragments into plasmids 
Ligations were usually performed using 50 ng plasmid DNA and 1 µl (400 U) T4 DNA 
ligase (NEB) in a volume of 20 µl. PCR products that have been directly digested with 
restriction enzymes were ligated into the plasmid using a molecular ratio between insert and 
vector of 5-10:1. DNA fragments that were cut out of plasmids were ligated into the desired 
plasmid with a molecular ratio between insert and vector of 2-4:1. The ligation was 
incubated either for 2 h at RT or O/N at 16°C. 
 
 
2.10.8 Preparation of plasmid DNA from E. coli cultures 
Plasmid DNA was prepared from fresh O/N cultures or from cultures kept at 4°C for up to 
48 h after overnight culturing. For Mini-preps, the QIAprep Spin Miniprep Kit (QIAGEN) 
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or the NucleoSpin Plasmid kit (Macherey-Nagel) were used, for preparation of larger DNA 
amounts the QIAfilter Plasmid Midi Kit (QIAGEN) or the Pure Yield Plasmid Midiprep 
System (Promega) were used. All preparations were performed according to the instructions 
of the manufacturer. 
 
 
2.10.9 Ethanol precipitation of DNA 
DNA precipitation was performed by adding 1/10 volume of 3 M Na-acetate (pH 4.8) and 2 
volumes of 100% ethanol to the DNA solution and subsequent incubation for 15-30 min at -
20°C. Next the DNA precipitate was pelleted by centrifugation (21 000 x g, 4°C, 15 min) 
and washed with ice-cold 70% ethanol. After air-drying for about 10 min, the DNA was 
dissolved in TE. To obtain sterile DNA solutions, as necessary for transfections, the 
precipitated DNA was dissolved in sterile buffer or dH2O. 
 
 
2.10.10 Sequencing 
Sequencing of plasmid DNA was performed either by capillary or gel electrophoresis. For 
using the capillary sequencer (ABI Prism Genetic Analyzer 310), the purified PCR reactions 
had to be dissolved in H2O and sequencing was performed with an injection time of 3-4 
seconds usually. Using the gel sequencer (ABI 377), the sequencing gel was prepared by 
dissolving 18 g urea and 7.5 ml Acrylamid/Bis (30%, 37.5:1) in 23 ml H2O. The gel was 
then deionized by adding a spoon of amberlite and stirring it for 20 min at RT. 200 ml of 
fresh 10x TBE was prepared and filtered through a 0.22 µm sterile filter. The gel was 
filtered through the same filter, and 6 ml of the filtered 10x TBS was added to the filtered 
gel. This mixture was then degased for 5 min and subsequently cooled on ice. The glas 
plates were freshly washed with Biorad cleaning solution and rinsed with a 9:1 isopropanol-
water mixture. Next, the glas plates were assembled with 0.2 mm spacers inbetween in the 
pouring chamber. To the ice cold gel-TBS mix, 200 µl APS (10%) and 20 µl TEMED were 
added and mixed well. Immediately afterwards, the gel was poured and then left for 2 h at 
RT to allow the gel to polymerize. Subsequently, the gel was mounted in the sequencer and 
the rest of the freshly prepared 10x TBE was diluted to obtain 1x TBE, which was used as 
running buffer. The purified PCR reactions, which were resuspended in 3.5 µl ABI loading 
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buffer, were denaturated by heating to 95°C for 3 min. The samples were then cooled down 
on ice and 1 µl of each sample was loaded on the gel. 
 
 
2.10.11 Preparation of genomic DNA from mouse tails 
700 µl lysis buffer for mouse tails were added to the mouse tail and incubated O/N at 56°C 
without shaking. The next day, 250 µl saturated NaCl were added and mixed by inverting 
the tube. After centrifugation for 10 min at full speed and RT in a table top centrifuge 
(Eppendorf), the DNA was precipitated by transfering 750 µl supernatant into a new tube 
already containing 500 µl isopropanol. The solutions were then mixed by inverting the tube 
and centrifuged for 5 min at 4°C and full speed. The supernatant was removed and the 
precipitated DNA was washed by adding 500 µl of cold 75% ethanol. After another 
centrifugation step for 5 min at 4°C and full speed, the supernatant was removed and the 
pellet was dried. To resolve the DNA, 100 µl of 1x TE buffer was added and the tube was 
incubated for 10 min at 56°C. 
When toes were used instead of tails, 350 µl of DNA lysis buffer were used and incubation 
at 56°C was reduced to 3 h. Then 125 µl saturated NaCl were added. After centrifugation, 
450 µl supernatant and 300 µl isopropanol were mixed. For washing the pellet, 350 µl of 
cold 75% ethanol were used. finally, the pellet was dissolved in 50-60 µl 1x TE buffer. 
 
 
2.11 Biochemical methods 
2.11.1 Affinity chromatography 
Affinity chromatography was used to either purify proteins provided with an HA-tag or for 
antibodies of mouse or rat origin. 
To purify proteins tagged with the hemagglutinin (HA) epitope, the monoclonal anti-HA 
antibody 12CA5 (Roche) was coupled to CNBr-activated Sepharose™ 4B, fast flow (GE 
Healthcare) according to the manufacturer’s protocol and the material was then packed into 
a column. 
For purification of HA-hBAFF protein from Drosophila SL-3 cell medium, the supernatant 
was first cleared by filtering through diatomaceous earth (Highflow Super Cell Medium, 
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Fluka) and then added to the column. Next, the column was washed with about 300 ml PBS. 
For protein elution, 0.1 M Glycin/HCl, pH 3.0 was used, and 500 µl samples were collected 
in 1.5 ml Eppendorf tubes containing 50 µl 1M Tris/HCl, pH 8.6. For each sample 
collected, OD280 was meassured and samples showing the highest OD values (usually above 
0.7) were pooled. Likewise, all other samples having an OD value above 0.2 were pooled. 
The pooled fractions were then dialysed against 1x PBS for 48 h at 4°C with changing the 
PBS 3-4 times. 
Antibodies of the IgG subtype of either mouse or rat origin were purified using ProteinG 
sepharose 4 fast flow (GE healthcare) according to the manufacturer’s protocol. 
 
 
2.11.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Glass plates were washed with a 9:1 isopropanol-H2O mixture and assebled in the pouring 
chamber of the Protean II minigel system (Bio-Rad). For two resolving gels, one the 
following mixture was prepared, depending on the size of the proteins to be separated: 
 
 10% resolving 
gel 
15% resolving gel 
H2O 7.35 ml 5.5 ml 
lower buffer 3.9 ml 3.9 ml 
Acrylamid/Bis (40%, 29:1) 3.75 ml 5.6 ml 
APS 90 µl 90 µl 
TEMED 15 µl 15 µl 
 
Immediately after preparation, the mixture was poured into the glas plate assembly, leaving 
a space of 2.5 cm to the top of the smaller glas plate. The resolving gel was then overlaid 
with 200 µl of 0.1% SDS. After polymerization, the SDS solution was removed, the 
stacking gel, prepared according to the protocol below, was poured on top of the resolving 
gel and a comb was inserted immediately. 
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 4% stacking gel 
H2O 4.5 ml 
upper buffer 1.8 ml 
Acrylamid/Bis (40%, 29:1) 0.7 ml 
APS 50 µl 
TEMED 14 µl 
 
After polymerization, the comb was removed carefully and the gel slots were washed with 
running buffer. Samples were mixed with 6 x reducing sample buffer, boiled for 5 min at 
95°C, spun down and loaded. Also, 10 µl of BenchMark Pre-Stained Protein ladder 
(Invitrogen) were loaded. The gel was run with a constant voltage of 80 V for about 2.5 h. 
 
 
2.11.3 Coomassie staining 
After electrophoresis, the resolving gel was separated from the stacking gel and stained in 
Coomassie blue staining solution for 30 min with gentle agitation. Subsequently, the gel 
was transfered to the destaining solution and incubated with gentle agitation until bands 
were visible on a clear background. If necessary, the destaining solution was replaced with 
fresh liquid. The gel was then rehydrated in 2% glycerol and dried on Whatmann 3MM 
paper in a vacuum system. 
 
 
2.11.4 Silver staining 
Silver staining is much more sensitive than Coomassie staining, thus it was used if low 
amounts of protein had to be detected. To avoid high background staining, every solution 
was made with fresh ddH2O and p. a. grade solvents. All steps were performed with a large 
excess (10 x gel volume) of incubation liquid in a freshly cleaned plastic container and with 
gentle agitation. Both unfixed or already fixed and Coomassie blue stained gels were 
stained. Unfixed gels were fixed by incubation in fixative solution for 30 min. Fixed gels 
were washed three times in 50% ethanol for 20 min and once in deionized H2O for 5-10 
min. The gels were then incubated for exactly 1 min in thiosulfate solution and then washed 
four times in deionized H2O for 20 sec. Staining of the gels was then performed by 
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incubation in silver nitrate solution for 20 min in the dark. Afterwards, gels were washed 
twice in deionized H2O for 20 sec. Then the staining of the protein bands was developed by 
incubating the gels in developer solution with continuous visual inspection until the bands 
became visible, which could take up to 10 min. To stop further staining, the gels were 
washed twice in deionized H2O for 30 sec and then incubated in stop solution for 10 min. 
Gels were then either kept in 50% methanol at 4°C or rehydrated in deionized H2O for 10 
min, soaked in 2% glycerol for 15-30 min and dried on Whatman 3MM filter paper in a 
vaccum system. 
 
 
2.11.5 Western blot 
2.11.5.1 Transfer 
To transfer proteins from a SDS-polyacrylamide gel to a Nitrocellulose membrane, the 
Trans-Blot SD Semi-Dry Electrophoretic Transfer System (BioRad) was used. Therefore, 
the resolving gel was separated from the stacking gel and soaked in transfer buffer, together 
with the membrane (Hybond C super nitrocellulose membrane, Amersham) and 2 pieces of 
filter paper (Whatmann, 3MM). These items were then assembled in a sandwich formation 
in this order: black side/anode - foamed material - filter paper - gel (inverted) - NC 
membrane - filter paper - foamed material - transparent side/cathode. To avoid air bubbles, 
the assembling was done under transfer buffer and potential air bubbles were removed 
before the cathode was fitted. The transfer was performed with a constant current of 200 
mA for 1-2 h.  
 
2.11.5.2 Immunodetection 
After the transfer, the sandwich formation was disassembled and the membrane was 
incubated in 5% milk/PBST for 1 h at RT. Then the primary antibody diluted in 5% 
milk/PBST was added and the membrane was incubated O/N at 4°C. Next, the membrane 
was washed 3 x 10 min with milk/PBST and then incubated with the secondary reagent 
Avidin-HRP diluted 1:1000 in 5% milk/PBST for 1 h at RT. Finally, the membrane was 
washed 3 x 10 min with milk/PBST and 1 x 10 min with PBST. For development, ECL 
stock solution D was diluted 1:1000 in H2O and mixed 1:1 with ECL solution 1. Of this 
mix, 2 ml were given onto the membrane and incubated for 1 min. Subsequently, excessive 
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liquid was removed with a paper towel. The membrane was then wrapped into saran wrap 
and exposed to films (Hyperfilm ECL, Amersham) for different time periods. 
 
 
2.11.6 Qualitative and quantitative ELISA 
Initially, a 96-well flat-bottom Maxisorp immuno-plate (Nunc) was coated with the 
capturing anti–body. Therefore, 50 µl of the antibody dilution (1-10 µg/ml in PBS) were 
added to each well and the plate was incubated for 1 h at RT or O/N at 4°C. Subsequently, 
the plates were washed three times with tap water containing 0.05% Tween 20 and then 50 
µl ELISA buffer were added to each well. Next, 50 µl of cell culture supernatant or protein 
dilution in ELISA buffer were added and the plate was incubated for 2-4 h at RT or O/N at 
4°C. In case a quantitative ELISA was performed also a dilution series of a standardized 
solution was applied. After the incubation, the plate was washed three times and then 50 µl 
of of the secondary antibody, diluted in ELISA buffer, was added to each well. The plate 
was incubated for 2 h at RT and washed again three times. In case the secondary antibody 
was not coupled to the enzyme alkaline phosphatase, a further incubation step with Strep-
AP or an AP-coupled antibody was performed, using 50 µl/well of AP-coupled reagent 
diluted in ELISA buffer for 30 min (when using Strep-AP) or 2 h (when using another 
antibody) at RT. Then, the plate was washed five times with tap water containing 0.05% 
Tween 20, this time with an incubation of 1 min between the single washing steps. 
Subsequently, 50 µl substrate solution were added per well and incubated at RT under 
visual inspection until the dye development was found to be optimal. The reaction was then 
stopped by adding 50 µl of 1 M NaOH per well and the plate was read at 405 nm in a 
THERMOmax microplate reader (Molecular Devices). 
 
 
2.11.7 Development of a hBAFF ELISA 
For the development of a two-step ELISA to detect hBAFF, the anti-hBAFF antibodies 
described in this thesis have been used. The best combination of these antibodies had to be 
found empirically. To determine the antibodies best suited as capture antibody, ELISA 
plates (Nunc MaxiSorb) were coated with 0.5 µg/ml or 5 µg/ml of anti-hBAFF antibody 
clones 1-35, 1-62, 2-18, 2-43, 2-44, 2-56, 2-67, 2-81, 4-62, 5-73, 6-23 and 6-46 in PBS 
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using 100 µl/well and then incubated o/n at 4°C. Subsequently, plates were washed 5 times 
in PBS with 0.5% Tween 20 and then 100 µl/well of a 1:4 dilution series of HA-hBAFF in 
ELISA buffer, ranging from about 100 ng/ml to 25 pg/ml, and ELISA buffer alone as 
negative control were applied. Plates were incubated for 2 h at RT and then washed as 
described above. To detect bound HA-hBAFF, 100 µl/well of a 1:200 dilution of anti-
HAbio antibody in ELISA buffer was used. After an incubation time of 1.5 h at RT, the 
plates were washed again as described. Then 100 µl/well of a 1:200 dilution of Strep-AP in 
ELISA buffer was applied. Plates were again incubated at RT for 1 h and washed, this time 
with incubation of the plates for 1 min between each washing step. Finally, 100 µl/well of 
substrate solution were applied and plates were incubated in the dark at RT. After 30 min 
and 60 min the plates were read in an ELISA reader at 405 nm. Antibodies selected as 
coating antibodies for further testing had to fulfill the following criteria: a) background 
value (meassured in the well incubated with ELISA buffer alone) should not exceed 0.1 OD, 
b) the concentration of HA-hBAFF that could be detected should be as low as possible 
(whereat an OD of at least twice the value for the background was considered to be 
significant detection of an antigen), c) the OD range between the highest and the lowest 
concentration detected should be wide. Based on these criteria, antibodies 1-35, 2-18, 2-43, 
2-56, 2-81, 4-62 and 5-73 were chosen as capture antibodies for further testing. 
Furthermore, only a concentration of 5 µg/ml antibody for coating turned out to be suitable. 
To determine which of the anti-hBAFF antibodies is best suited as detection antibody, plates 
were coated o/n at 4°C with the antibodies 1-35, 2-18, 2-43, 2-56, 2-81, 4-62 and 5-73 at 5 
µg/µl in PBS using 100 µl/well. Plates were washed in PBS with 0.05% Tween 20 as 
described above, then a 1:10 dilution series, ranging from 50 ng/ml to 5 pg/ml, of untagged 
hBAFF (recombinant protein, Peprotech) in ELISA buffer was applied. Plates were 
incubated for 2.5 h at RT and afterwards washed in PBS with 0.05% Tween 20. As 
detection antibodies, biotinylated anti-hBAFF antibody clones 1-35, 1-62, 2-18, 2-43, 2-44, 
2-56, 2-67, 2-81, 4-62, 5-73, 6-23 and 6-46 were applied at a concentration of about 5 µg/ml 
in ELISA buffer using 100 µl/well. Further washing in PBS with 0.05% Tween 20 and 
development was done as described before. Based on the criteria listed above, coating with 
clone 2-81 and detection with clones 4-62 or 5-73, or coating with clone 4-62 and detection 
with clone 2-81 gave the best results. These antibody combinations were used for further 
optimization of the ELISA using a different ELISA buffer (containing different amounts of 
rat serum instead of BSA). At the end, the following protocol turned out to be suitable to 
detect hBAFF down to the range of pg/ml: ELISA plates are coated with anti-hBAFF 
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antibody clone 2-81 at 5 µg/ml in cold and sterile PBS and 100 µl/well at 4°C o/n. Washing 
steps are done in 0.5x PBS, 0.05% Tween 20. Plates are washed 2x and then 3x with 
incubation at RT for 1 min inbetween. Antigen is diluted in buffer containing 1x PBS, 
0.05% Tween 20, 5% rat serum (RS-ELISA buffer) and 100 µl is added per well. As 
standard, untagged recombinant hBAFF (Peprotech) is used in a serial 1:2 dilution ranging 
from 1000 pg/ml to 62.5 pg /ml. Plates are incubated at 4°C o/n. After a washing step as 
described before, 100µl/well biotinylated anti-hBAFF antibody clone 4-62 diluted 1:200 
(about 4-5 µg/ml final concentration) in RS-ELISA buffer is applied and plateas are 
incubated for 3-4 h at RT. After another washing step, 100 µl/well Strep-AP, diluted 1:2000 
in buffer containing 1x PBS, 0.05% Tween 20, 2% rat serum, are added and plates are 
incubated for 1 h at RT. Plates are washed 5x with incubation times of 2 min inbetween 
each washing step and then developed by adding 100 µl/well substrate solution (DNPP in 
substrate buffer). Plates are incubated in the dark for 30 to 90 min and then the reaction is 
stopped by adding 100 µl/well 1M NaOH. Plates are read in an ELISA microplate reader at 
405 nm. 
For the analysis of serum samples from patients, samples were usually diluted 1:10, 1:100 
and 1:1000 in RS-ELISA buffer and applied in duplicates using 100 µl/well. The ELISA 
was then developed as described above. For calculation of hBAFF concentration, the OD 
values within the linear range of the standard curve, which were obtained from the lowest 
dilutions were used. 
 
 
2.12 Animal work 
2.12.1 BrdU labeling of mice 
Initially, mice recived an intraperitoneal injection of 1 mg BrdU in PBS and where then fed 
with drinking water containing 1 mg/ml BrdU for different periods of time. The BrdU-
containing water was protected from light by wrapping the bottle in aluminum foil and 
exchanged every 4 days. Cell suspensions were then prepared from various lymphoid 
organs and stained for intracellular BrdU as described below. 
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2.12.2 Thymus dependent and independent immunization of mice 
Mice were immunized i.p. with 100 µg NIP-OVA (Biosearch Technologies Inc., Novato, 
CA) in alum (T dependent immune response) or i.v. with 50 µg NIP-FICOLL (Biosearch 
Technologies Inc., Novato, CA) in PBS (T independent immune response). At day 14 after 
immunization, mice were bled and the serum IgG anti-NIP titer was determined by ELISA 
as previously described (8). For a recall response in the case of a T dependent immune 
response, 6 weeks after immunization mice were boosted with 10 µg NIP-OVA in PBS and 
10 days thereafter the serum IgG anti-NIP titer was determined by ELISA. 
 
 
2.12.3 Immunization of rats for hybridoma production 
Lewis rats were immunized either with 0.4-1 mg/ml purified protein in PBS, mixed 1:1 with 
CFA, or with 1-2 x 107 transfected Y3-cells mixed with CFA. 50-100 µl were injected in the 
upper side of one foot. To boost the reaction, one and two weeks after the first injection, 100 
µl of a solution containing either 10 µg purified protein in 300 µl PBS or 5-10 x 107 
transfected Y3-cells in 1 ml PBS were injected into the foot. The day after the second boost, 
the popliteal and inguinal lymph nodes of the leg in which the antigen had been injected 
were taken out and treated as described below. 
 
 
2.13 Cell culture 
2.13.1 Freezing and thawing of cells 
For freezing, the pelleted cells were resuspended in cold freezing medium at a cell density 
that was dependent on the cell line, and 1 ml aliquots were transfered to 2 ml cryotubes 
(Nunc), cooled down on ice and incubated at -80°C for at least 12 h. Subsequently, the tubes 
were transfered to their final storage place in a liquid nitrogen tank. 
For thawing, cells were unfrozen either in a 37°C water bath or at RT and transfered 
immediately to 10 ml of the appropriate medium. After centrifugation at 1200 rpm and 4°C 
for 10 min, the cell pellet was gently resuspended in the appropriate medium and transfered 
to a culture dish. 
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2.13.2 Determination of cell numbers 
Cell numbers were determined using a Neubauer counting chamber with 0.1 mm depth. An 
aliquot of the cell suspension was diluted 1:5-10 with trypan blue solution and loaded into 
the chamber. Cells in two of the outer squares, consisting of 16 small squares each, were 
counted. The cell number per ml was then calculated by multiplying the average cell 
number in an outer square with 104. 
 
 
2.13.3 Transfection and Transduction 
2.13.3.1 Transfection of Drosophila Schneider cells SL-3 
SL-3 cells were split 1:5-10 the day before transfection and plated out in a 24-well plate 
with 1 ml SF-900 medium containing 2% FCS per well. Usually, three wells per plasmid 
were prepared. The next day, 12 µg of supercoiled plasmid DNA (ethanol precipitated and 
dissolved in sterile H2O), 100 µl SF-900 medium, 1.2 µg phshs-puro and 20 µl Plus Reagent 
were mixed together in a sterile tube and incubated for 15 min at RT. After the incubation, 8 
µl Lipofectamine and 200 µl SF-900 medium were mixed, given to the plasmid-mix and 
incubated for another 15 min at RT. In the meanwhile, the SL-3 cells were carefully washed 
three times with 1 ml SF-900 medium per well and finally 300 µl SF-900 medium was 
added. Then, 100 µl/well of the DNA-Lipofectamin-mix was added, and the cells were 
incubated O/N at 25°C. The next day, the supernatant was removed and to each well 1 ml 
SF-900 medium with 2% FCS was given. After 2-3 days, the medium was changed again 
and cells were now grown in SF-900/2% FCS medium containing 5 µg/ml puromycin for 
selection. Cells were kept for 2-3 weeks in selection medium and were split during this 
period when necessary. 
 
2.13.3.2 Transfection of Phoenix cells 
The day before transfection, Phoenix cells were plated out in a 6-well plate with 5-7.5 x 105 
cells/well in 1-2 ml RPMI medium containing 10% FCS and 50 µM β-Mercapthoethanol. 
Usually, 2-3 wells per plasmid were prepared. The next day, 2 µg supercoiled plasmid DNA 
(ethanol precipitated and dissolved in sterile H2O), 100 µl SF-RPMI medium and 10 µl Plus 
Reagent per well were mixed together in a sterile tube and incubated for 15 min at RT. After 
CHAPTER 2  MATERIALS AND METHODS 
   
  67 
the incubation, 2.5 µl Lipofectamine and 100 µl SF-RPMI medium were mixed, given to the 
plasmid-mix and incubated for another 15-45 min at RT. In the meanwhile, the Phoenix 
cells were carefully washed twice times with 1.5 ml/well SF-RPMI medium and finally 1 ml 
SF-RPMI medium was added per well. Then, 200 µl DNA-Lipofectamin-mix were added 
per well, and the cells were incubated for 5-6 h at 37°C and 5% CO2. Next, the supernatant 
was removed and to each well 3 ml RPMI medium containing 10% FCS and 50 µM β-
Mercapthoethanol were given. After 20-24 h, the medium was changed again and 2 ml fresh 
RPMI medium with 10% FCS and 50 µM β-Mercapthoethanol were added. Cells were 
incubated for another 24 h and then the virus containing supernatant was taken, centrifuged 
at 10 000 rpm and 4°C for 1 min and either used directly for transduction or transfered to 
freezing vials and stored at -80°C. 
 
2.13.3.3 Transduction of eucaryotic cell lines 
For transduction of cells by spininfection, 1-5 x 105 cells in 10-20 µl were transfered to a 
sterile 1.5 ml tube and mixed with 1 ml of virus-containing Phoenix cell supernatant. Cells 
were then centrifuged for 4 h at 3300 rpm (1160 x g) and 30°C. Afterwards the supernatant 
was removed carefully. The cell pellet was eventually resuspended in 1 ml of the 
appropriate medium and transfered to a culture dish. 
 
 
2.13.4 Hybridoma production 
From the popliteal and inguinal lymph nodes of a rat immunized as described above, a cell 
suspension was prepared in 50 ml IMDM/2% FCS medium. the suspension was transfered 
to 50 ml tubes and cells were centrifuged at 1000 rpm and 4°C for 10 min. To get rid of the 
fat contained in the lymph nodes, cell pellets were resuspended in 10 ml SF-DMEM (with 
glutamax, Gibco BRL) and transfered to a fresh 50 ml tube, combining all cell suspensions. 
The tube was then filled up to 50 ml with SF-DMEM and centrifuged again. Subsequently, 
another washing step was performed. In parallel, Sp2/0 cells were harvested by 
centrifugation at 1000 rpm and 4°C for 10 min and then washed twice with SF-DMEM. 
Then Sp2/0 cells were combined with the lymph node cells, using an amount of Sp2/0 cells 
that was slightly greater than that of the lymph node cells, and centrifuged again. 
Afterwards, the supernatant was completely removed and the tube was shaken in a 37°C 
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water bath, while at the same time 1 ml of pre-warmed 50% PEG solution was added 
dropwise during 1 min to the pellet. The dissolved pellet was shaken for an additional 1 min 
in the water bath, and then 10 ml of pre-warmed alkaline SF-DMEM were added dropwise 
to the cell suspension while shaking the tube carefully. Subsequently, the cell suspension 
was centrifuged at 800 rpm and RT for 5 min. The pellet was resuspended carefully in 5000 
ml pre-warmed HAT medium and plated out into 96-well U-bottom plates adding 200 µl 
per well. Plates were then incubated at 37°C for 10-12 days until cell clusters became 
visible by the naked eye. Finally, supernatants were analyzed by FACS or ELISA, positive 
cell clusters were subcloned, re-tested and frozen. 
 
 
2.13.5 Staining of sections for fluorescence microscopy 
Organs were taken out of sacrificed mice, snap frozen in OCT compound and kept at -80°C 
until further usage. Cryostat sections of 4 µm were prepared, fixed for 10 min in aceton and 
stored at -20°C. Slides were allowed to thaw for 10 min at RT before staining and then a 
hydrophobic ring was drawn around the tissue section with a Dako Pen (DAKO) to 
minimize the amount of antibody solution needed. Sections were stained with anti-IgMFITC 
(M41) and anti-IgDBiotin (1.19) or anti-Thy1FITC (T24) and anti-IgMBiotin (M41). Therefore, 
sections were covered with antibody dilution (1:50 in FACS buffer) and incubated for 30 
min at RT in the dark. Then slides were rinsed in PBS and washed with shaking in PBS for 
15 min at RT. Biotin-labeled antibodies were visualized using streptavidin Texas red (BD 
Biosciences) at a dilution of 1:2000 in FACS-buffer for 15 min at RT. Slides were washed 
again as described and then covered with 1-2 drops of a 1:1 mixture of PBS and glycerol 
and a 24 x 45 mm cover glass (Medite). Stained sections were analyzed using an Axioskop 
Immunofluorescence (Zeis, Feldbach, CH) equipped with a Nikon digital camera. 
 
 
2.13.6 Flow cytometry 
2.13.6.1 Lysis of red blood cells 
The pelleted cells were resuspended in 1-2 ml of ACK buffer and incubated at RT for 1 min. 
To stop the lysis reaction, 10 ml of medium or FACS buffer were added. After centrifuga-
tion at 1000 rpm and 4°C for 10 min, the cells were resuspended in the appropriate medium. 
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2.13.6.2 Surface staining of cells 
For staining of cell surface antigens, usually 50-100 µl cell suspension (1-2 x 107 cells/ml) 
were mixed together with the appropriate volume of antibody dilution in a 96-well U-
bottom plate and incubated on ice for at least 30 min, covered with aluminum foil to protect 
the fluorescent dyes. To wash the cells, 100 µl of FACS buffer were added to each well and 
the plate was centrifuged at 250 x g and 4°C for 5 min. The supernatant was then poured out 
quickly and the plate was dried carefully on a paper towel. Cells were resuspended in the 
remaining supernatant by vortexing the plate. If necessary, a further staining step with a 
Streptavidin-coupled fluoreszent dye was performed, with an incubation for 15 min on ice, 
followed by another washing step. Finally, cells were resuspended in an appropriate volume 
of FACS buffer. Unless PE-Cy7 was used as fluorescent dye, 10 µg/ml propidium iodide 
(PI) were added to the FACS buffer, in order to be able to exclude dead cells. Negative and 
single stained compensation controls were always included. FACS analysis was carried out 
on a FACSCalibur (Becton Dickinson) and analyzed using the CellQuest Pro v4.0.1 
software (Becton Dickinson). Cells were gated on the lymphoid FSC/SSC gate and on PI-
negative living cells, if PI was included. 
The appropriate dilutions of the antibodies that were produced in the lab were determined 
by titration before. Commercial antibodies were mostly used at a final concentration of 
1:200. Strep-PE was used at a final concentration of 1:1000, Strep-APC at 1:200 and Strep-
PE-Cy7 at 1:400. 
 
2.13.6.3 Intracellular anti-BrdU staining 
For detecting incorporated BrdU, intracellular staining using the BrdU Flow Kit (BD 
Biosciences) was performed. Therefore, 2-3 x 106 cells were stained for surface antigens as 
described above but without addition of PI, including all control stainings. Stained cells 
were then transfered into tubes and centrifuged. The cell pellets were resuspended in 100 µl 
Cytofix/Cytoperm and incubated for 20 min on ice. For washing the cells, 1 ml of 
Permwash buffer was added and cells were pelleted by centrifugation, resuspended in 100 
µl Cytoperm Plus and incubated for 10 min on ice. Subsequently, cells were washed again 
with 1 ml of Permwash buffer and resuspended in 100 µl DNAse solution (provided in the 
kit or alternatively DNAse I, 2000 U/ml in PBS) and incubated at 37°C for 1 h. After 
another washing step with 1 ml Permwash buffer, cells were resuspended in 50 µl anti-BrdU 
antibody dilution (1:100) and incubated for 20 min at RT. Cells were then washed again in 1 
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ml Permwash buffer and analyzed on a FACSCalibur (Becton Dickinson) using the 
CellQuest Pro v4.0.1 software (Becton Dickinson). 
 
 
2.14 References 
1. Steller, H., and V. Pirrotta. 1985. A transposable P vector that confers selectable 
G418 resistance to Drosophila larvae. EMBO J. 4:167-171. 
2. Puig, O., F. Caspary, G. Rigaut, B. Rutz, E. Bouveret, E. Bragado-Nilsson, M. 
Wilm, and B. Seraphin. 2001. The tandem affinity purification (TAP) method: a 
general procedure of protein complex purification. Methods 24:218-229. 
3. Pear, W. S., J. P. Miller, L. Xu, J. C. Pui, B. Soffer, R. C. Quackenbush, A. M. 
Pendergast, R. Bronson, J. C. Aster, M. L. Scott, and D. Baltimore. 1998. Efficient 
and rapid induction of a chronic myelogenous leukemia-like myeloproliferative 
disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92:3780-
3792. 
4. Alt, F., N. Rosenberg, S. Lewis, E. Thomas, and D. Baltimore. 1981. Organization 
and reorganization of immunoglobulin genes in A-MULV-transformed cells: 
rearrangement of heavy but not light chain genes. Cell 27:381-390. 
5. Kodama, H., M. Nose, S. Niida, S. Nishikawa, and S. Nishikawa. 1994. Involvement 
of the c-kit receptor in the adhesion of hematopoietic stem cells to stromal cells. 
Exp. Hematol. 22:979-984. 
6. Schmitt, T. M., and J. C. Zuniga-Pflucker. 2002. Induction of T cell development 
from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity 17:749-756. 
7. Hardy, R. R., T. Kishimoto, and K. Hayakawa. 1987. Differentiation of B cell 
progenitors in vitro: generation of surface IgM+ B cells, including Ly-1 B cells, 
from Thy-1- asialoGM1+ cells in newborn liver. Eur. J. Immunol. 17:1769-1774. 
8. Schubart, D. B., A. Rolink, M. H. Kosco-Vilbois, F. Botteri, and P. Matthias. 1996. 
B-cell-specific coactivator OBF-1/OCA-B/Bob1 required for immune response and 
germinal centre formation. Nature 383:538-542. 
 
 
CHAPTER 3  FLT3 LIGAND AND B CELL DEVELOPMENT 
   
  71 
3 FLT3 LIGAND AND B CELL DEVELOPMENT 
 
 
3.1 Increasing Flt3L availability alters composition of a novel 
bone marrow lymphoid progenitor compartment 
 
 
Rhodri Ceredig1, Melanie Rauch2, Gina Balciunaite2 and Antonius Rolink2 
 
1 Center for Biomedicine, Developmental and Molecular Immunology, Department of 
Clinical and Biological Sciences (DKBW), University of Basel, Switzerland 
 
2 Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 645, 
Etablissement Francais du Sang Bourgogne Franche-Comté, Besançon, France 
 
 
Published in Blood 2006, 108, 1216-1222. 
 
 
FLT3 LIGAND AND B CELL DEVELOPMENT  CHAPTER 3 
   
 
72 
 
CHAPTER 3  FLT3 LIGAND AND B CELL DEVELOPMENT 
   
  73 
 
FLT3 LIGAND AND B CELL DEVELOPMENT  CHAPTER 3 
   
 
74 
 
CHAPTER 3  FLT3 LIGAND AND B CELL DEVELOPMENT 
   
  75 
 
FLT3 LIGAND AND B CELL DEVELOPMENT  CHAPTER 3 
   
 
76 
 
CHAPTER 3  FLT3 LIGAND AND B CELL DEVELOPMENT 
   
  77 
 
FLT3 LIGAND AND B CELL DEVELOPMENT  CHAPTER 3 
   
 
78 
 
 
CHAPTER 3  FLT3 LIGAND AND B CELL DEVELOPMENT 
   
  79 
3.2 Addendum 
The most important cytokines regulating early B cell development are FLT3L and IL-7. 
Mice deficient for FLT3L have reduced numbers of CLPs, but normal numbers of common 
myeloid progenitors (CMPs). Serial transplantation experiments showed that HSCs from 
Flt3L deficient mice are present in normal numbers and have no intrinsic defect, indicating 
that FLT3L does not act on HSCs (1). Therefore, the reduced number of CLPs in Flt3L 
deficient mice results from the missing survival effect of FLT3L on CLPs directly or on one 
of the immediate progenitors of CLPs. More recently it was shown that LMPPs, which are 
progenitors of CLPs, are reduced in Flt3L-/- mice and show a reduced expression of the 
genes encoding IL-7Rα and RAG-1 at the mRNA level (2). The work presented here shows 
that FLT3L also has a potent stimulatory effect on EPLMs, a B cell progenitor stage down-
stream of CLPs (3). A synergistic effect between FLT3L and IL-7 was reported a decade 
ago (4), and this effect is most obvious in mice double deficient for FLT3L and IL-7 or IL-
7Rα. Both the Flt3L x Il-7 and Flt3L x Il-7rα double deficient mice completely lack B220+ 
CD19+, B220+ IgM+ and B220+ CD5+ B cells. Furthermore, the pre-pro B cell population is 
extremely reduced, while later developmental stages are completely absent and no Pax5 
expression is detectable in BM cells (5, 6). The analysis of these double deficient mice in 
combination with mice deficient for the gene encoding the TSLP receptor showed that 
FLT3L is responsible for IL-7 independent B lymphopoiesis and not TSLP (6). This data 
strongly suggest that FLT3L has a synergistic and nonredundant role in B lymphopoiesis 
and that signaling via FLT3 is important for survival, proliferation and lineage commitment 
of several early B cell progenitor stages. 
Interestingly, increased availability of FLT3L results in reduced numbers of mature B cells. 
The reason for this observation is presumably related to the fact that repression of FLT3 
signaling by PAX5 is important for B cell lineage commitment. PAX5 directly regulates the 
expression of Flt3, leading to downregulation of Flt3 (7). Furthermore, enforced retroviral 
expression of FLT3 in HSCs reduced their ability to develop into the B cell lineage both in 
vivo and in vitro (7). Thus, it might be that intensified signaling via FLT3 through increased 
availability of FLT3L interferes with either Pax5 expression or the PAX5 mediated 
downmodulation of Flt3, leading to the observed reduction in the number of mature B cells 
and the potential to develop into the B cell lineage. Whether this assumption is correct and 
how the intensified FLT3 signaling disturbs the normal B cell developmental pathway 
remains to be elucidated. 
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4 PRODUCTION AND CHARACTERIZATION OF MONO-
CLONAL ANTIBODIES AGAINST HUMAN BAFF AND 
MURINE BAFF-R AND DEVELOPMENT OF A HUMAN 
BAFF ELISA 
4.1 Monoclonal antibodies against human BAFF 
4.1.1 Hybridoma production 
BAFF mainly exists in a soluble form generated by cleaving the membrane bound form, 
thus it was decided to use the extracellular part of the hBAFF protein (aa 136-285) as 
antigen for immunization. Cloning, production and purification of soluble hBAFF, and 
production and selection of hybridomas is described in chapter 2. Finally, 49 hybridoma 
clones producing a monoclonal anti-hBAFF antibody remained. 
 
 
4.1.2 Specification of anti-hBAFF antibody characteristics 
Most likely, within the 49 anti-hBAFF producing hybridomas obtained, several are of the 
same origin, meaning that some of the antibodies produced are identical. Instead of 
sequencing the V-regions of the Ig genes from individual anti-hBAFF hybridomas, it was 
attempted to identify independent clones by characterizing the binding properties of the 
various anti-hBAFF antibodies obtained. 
 
 
4.1.2.1 Cross-reactivity with HA-mBAFF 
The protein sequence of the secreted extracellular part of human and mouse BAFF is to 
85% identical, thus the possibility that a certain antibody possesses affinity for both human 
and mouse BAFF is very likely. To determine whether any of the anti-hBAFF antibodies 
produced could also bind to mBAFF, an ELISA with Fc-tagged mBAFF was performed. 
Of the 35 monoclonal antibodies tested, seven showed affinity to mBAFF (fig. 1). However, 
compared to the signal for hBAFF, only one antibody (clone 2-44-14) possesses pronounced 
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specificity for mBAFF, obvious from the comparable high signals observed. Clone 5-85 
gave an intermediate signal for mBAFF, and clone 6-23 seemed to react better with mBAFF 
than with hBAFF, but the signal strength for binding to mBAFF observed for these clones 
was in both cases rather low. The four other positive clones all showed a low signal, 
indicating only a marginal specificity for mBAFF (fig. 1 and tab. 1). 
 
 
Figure 1. Crossreactivity of anti-hBAFF antibodies to mBAFF. The supernatant of the indicated 
anti-hBAFF hybridoma clones was tested in an ELISA for its capacity to bind to Fc-tagged mBAFF 
(black bars) or Fc-tagged hBAFF (white bars). 
 
 
4.1.2.2 Ability to block hBAFF from binding to receptor 
Binding of an anti-hBAFF antibody to a hBAFF molecule might interfere with binding of 
this hBAFF molecule to its cellular receptor, BAFF-R. Blocking of hBAFF binding to its 
receptor by an antibody indicates that this antibody recognizes an epitope that is either 
necessary for receptor binding or in close vicinity thereto. Thus, the observation of 
interference allows to draw conclusions on the epitope recognized by a certain anti-hBAFF 
antibody. 
To determine the blocking ability of the anti-hBAFF antibodies, recombinant HA-hBAFF 
was pre-incubated with hybridoma supernatant and then used for staining splenic B cells, 
which were identified by using B220 as a marker. Among the 49 antibodies tested, the vast 
majority (about 70%) were non-blocking antibodies, giving FACS stainings which were 
almost indistinguishable from the positive control staining (fig. 2A, middle panel and upper 
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right). In contrast, the 15 antibodies classified as blocking antibodies showed an almost 
complete absence of HA-hBAFF binding, resembling the FACS staining obtained for the 
negative control (fig. 2A, lower panel and upper left). In figure 2B, an overlay of the results 
obtained for several non-blocking (left) and blocking (right) anti-hBAFF antibodies is 
shown. As expected, the curves for the non-blocking antibodies superimpose the curve 
given by the positive control staining, whereas the curves from the blocking antibodies 
superimpose the negative control staining curve. 
 
 
Figure 2. Blocking of HA-hBAFF binding to splenic B cells. Total spleen cells were stained with 
anti-B220FITC and HA-hBAFF which was pre-incubated with supernatant of different anti-hBAFF 
hybridoma cell lines. As controls, cells were stained with anti-B220FITC alone (C-) or with anti-
B220FITC and HA-hBAFF pre-incubated in medium (C+). A) FACS plots of a selection of anti-
hBAFF antibodies classified as non-blocking (middle panel) or blocking (lower panel) are shown. 
B) Overlay of several non-blocking (left) or blocking (right) hybridomas, gated on B220+ cells. 
 
 
On the basis of this result several blocking and non-blocking antibody producing 
hybridomas were chosen and the antibodies were purified in order to be able to quantify the 
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amount of antibody used. Then, HA-hBAFF was pre-incubated with different amounts of 
antibody and afterwards used to stain the human Burkitt lymphoma cell line, Raji, known to 
express large amounts of hBAFF-R on its surface (1). 
 
 
Figure 3. Concentration-dependent blocking of HA-hBAFF binding to Raji cells. A) and B) 5 µg 
or 0.5 µg of the indicated anti-hBAFF antibodies were incubated with HA-hBAFF and the resulting 
antibody-antigen complex was used to stain human Raji cells. Unstained cells and cells stained with 
HA-hBAFF were used as controls (black lines). HA-hBAFF binding was revealed using a 
biotinylated anti-HA antibody and Strep-PE. Anti-hBAFF antibodies were divided into A) non-
blocking antibodies and B) blocking antibodies. 
 
 
The extent of blocking observed was dependent on the nature of the antibody, as shown 
before, and also on the antibody amount used (fig. 3). The antibody clones categorized as 
non-blocking (fig. 3A) showed only little if any blocking at 5 µg (upper picture) and no 
blocking at 0.5 µg (lower picture). In particular, even when used at 5 µg, clone 2-44-14 did 
not at all block the binding of HA-hBAFF to Raji cells at all. In contrast, antibody clones 4-
62 and 2-56 showed an almost complete block of hBAFF binding when used at 5 µg and 
still prevented to a large extend the binding of hBAFF when used at 0.5 µg (fig. 3B, green 
and red curves). Clones 5-73 and 2-18 also blocked the binding of HA-hBAFF when used at 
5 µg and 0.5 µg, but in both cases less efficient than the aforementioned antibody clones 
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(fig. 3B). Clone 6-46, which showed an intermediate level of blocking at 5 µg, did not at all 
block the binding of hBAFF to Raji cells at all, when used at 0.5 µg (fig. 3A and B). 
To further confirm the above observation that of the four blocking antibodies clones 4-62 
and 2-56 perform better than clones 5-73 and 2-18, for each of these antibodies six different 
amounts were used for a blocking experiment as described above. As shown in figure 4, all 
of these antibody clones block the binding of hBAFF completely or at least considerably 
when used at 5 to 0.3 µg and no blocking can be observed when used at 0.03 µg or below. 
The results of this experiment confirm the above findings, that clones 4-62 and 2-56 are the 
most efficient ones for blocking hBAFF binding, followed by clones 5-73 and 2-18. 
 
 
Figure 4. Correlation between concentration and blocking ability of several blocking anti-hBAFF 
antibodies. Different amounts of the indicated antibodies, namely 5 µg (blue), 0.5 µg (orange), 0.3 
µg (green), 0.1 µg (red), 0.03 µg (light blue) and 0.01 µg (purple), were incubated with HA-hBAFF 
and the resulting complex was then used to stain human Raji cells. Binding of HA-hBAFF was 
revealed using anti-HAbio and Strep-PE. As controls, unstained cells and cells stained with HA-
hBAFF where used, which both are depicted in black. 
 
 
The combination of all results indicated that diverse anti-hBAFF antibody clones were 
obtained. For further usage eight independent clones were chosen. The characteristics of the 
selected anti-hBAFF antibodies are summarized in table 1. 
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Table 1. Monoclonal anti-hBAFF antibodies. Overview of the selected anti-hBAFF monoclonal 
antibodies and their features. 
 
 
 
4.2 Development and validation of a human BAFF ELISA 
For the detection of hBAFF in blood serum, a two-step or Sandwich ELISA had to be 
developed. As described in detail in chapter 2, from the anti-hBAFF antibodies obtained the 
antibodies best suited as capture and detection antibody were identified using an empirical 
method. Finally, antibodies 2-81 and 4-62 in combination with an ELISA buffer containing 
rat serum instead of BSA were found to work best. In order to test the functionality, 
reliability, specificity and sensitivity of the newly developed ELISA assay, several tests 
were made. 
Initially serum and plasma of hBAFF transgenic mice were analysed. Therefore, two-fold 
serial dilutions of each sample, ranging from 1:10 to 1:80, were analyzed in duplicates. For 
the standard curve, commercially available untagged hBAFF in concentrations from 2 ng/ml 
to 125 pg/ml was used. For the first analysis, only the sample values obtained for the 1:20 
dilution were taken. As shown in figure 5, hBAFF could be detected in serum and in plasma 
Clone Subclones
Blocking of 
hBAFF binding
Cross-reactivity 
with mBAFF
2-18 2-18-1 + -
2-44
2-44-6               
2-44-14
- - - +++
2-56
2-56-9               
2-56-10
+++ -
2-81
2-81-5                
2-81-8
- - -
4-62 none +++ -
5-73 none ++ +
6-23
6-23-2                
6-23-7
- +
6-46 none +/- -
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samples of all transgenic mice. No signal was detected when serum of WT mice was used 
(data not shown). 
 
 
 
 
 
 
Figure 5. hBAFF concen-
tration in serum and plasma 
of hBAFF transgenic mice. 
Serum and plasma were taken 
at the same time. From each 
sample two independently 
made dilutions of 1:20 were 
analyzed in parallel. Mean 
values and the corresponding 
standard deviations are 
given. 
 
 
These results indicate that the new ELISA is sensitive enough to detect hBAFF in the range 
of pg/ml in serum and plasma of mice. Furthermore, the new ELISA is highly specific for 
hBAFF, as it does not detect murine BAFF nor does it show any crossreactivity with other 
proteins present in serum of WT mice. Moreover, the low SD values obtained indicate that 
intra-assay variations are only marginal. The analysis of the serum and plasma samples 
showed, that in all cases the signal strength found for plasma was lower than the values for 
the corresponding serum sample, but no statistically significant difference could be ob-
served (fig. 5). Thus, plasma and serum are comparably well suited for hBAFF 
measurements. 
Next the values obtained for the different dilutions were compared. As the concentration of 
hBAFF in samples from patients may be several folds higher than in healthy individuals, it 
might be necessary to compare values obtained from different dilutions, depending on 
which sample values are within the linear range of the standard curve. Thus, from the 
experiment mentioned above, the mean hBAFF concentration was calculated from the dup-
licate OD values determined for each dilution, omitting OD values which were not within 
the linear range of the standard curve. Like this, for each sample three or four dilution 
specific mean concentrations were obtained. From these so-called dilution specific mean 
concentrations, the mean value and SD value was calculated. This SD value indicates how 
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wide the dilution specific mean values obtained for a single sample differ from each other. 
As can be seen in figure 6, the SD values are in most cases relatively small, meaning less 
than 10% and the maximum value for the deviation never exceeds 20%. Thus, the observed 
deviation values are within the range of 5-20%, which is given in the literature as the typical 
range for routine variations (2). This value has to be kept in mind when data from different 
dilutions have to be compared. 
 
Figure 6. Influence of the 
dilution factor on hBAFF 
concentration in serum and 
plasma of hBAFF transgenic 
mice. Serum and plasma were 
taken at the same day. From 
all samples two independently 
made dilution series ranging 
from 1:10 to 1:80 were ana-
lyzed. For each dilution a 
mean concentration value was 
calculated, and from these 
values a mean value and the 
SD value was determined. SD 
values are an indication for 
the variation of the dilution 
specific concentrations. 
 
 
The analysis of blood samples sometimes requires the prevention of blood clotting. Several 
different anticoagulants are commonly used, including lithium-heparin, sodium-citrate and 
EDTA. It is known that these additives can influence test results. In order to find out 
whether or not any of these anti-coagulants influence the measurement of hBAFF concen-
tration with the newly developed ELISA, blood from a patient suffering from Hashimoto’s 
thyroiditis was taken at the same time into several blood collection tubes provided with 
different anti-coagulants. Blood from this patient has been analyzed before and a high 
hBAFF concentration was determined. For the determination of the hBAFF concentration, 
all blood samples were diluted 1:10, 1:100 and 1:1000 and analyzed in duplicates. Only the 
OD values obtained for the 1:1000 dilution were within the linear range of the standard 
curve and have thus been taken for analysis. As shown in figure 7, the values determined for 
serum, lithium-heparin plasma and citrate plasma gave almost the same value. EDTA plas-
ma gave a roughly 25% higher value compared to serum and the other plasma preparations. 
Thus, for the determination of hBAFF concentration in blood from patients, preparations 
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done as serum or as plasma using heparin or citrate are to prefer. Data obtained from these 
preparations can be compared between each other, which is not possible if EDTA plasma 
was used for the analysis. 
 
 
Figure 7. Influence of different 
anticoagulants on hBAFF 
concentration meassured in 
human serum or plasma. Serum 
and plasma were taken at the same 
time from a patient suffering from 
Hashimoto’s thyroiditis. Blood was 
collected in different tubes to 
obtain serum, EDTA plasma, 
lithium-heparin plasma and citrate 
plasma. Samples were analyzed in 
duplicates at a dilution of 1:1000. 
Shown are mean values and the 
corresponding SD values. 
 
 
Taken together, the results obtained in the aforementioned experiments showed that the 
newly developed hBAFF ELISA is suitable for detection of hBAFF in serum and plasma of 
human patients. 
 
 
 
4.3 Monoclonal antibodies against murine BAFF-R 
4.3.1 Hybridoma production and selection by FACS 
BAFF-R exists only as a membrane bound protein, thus it was decided to use a rat myeloma 
cell line expressing membrane bound mouse BAFF-R as antigen. Cloning of mBAFF-R, 
transduction of cell lines and hybridoma production is described in chapter 2. For selection, 
hybridoma supernatants were screened with FACS using a mixture of untransduced (GFP-) 
40E1 and mBAFF-R transduced (GFP+) 40E1 cells, in order to find antibodies against 
mBAFF-R in one step with excluding antibodies giving unspecific staining. As shown in 
figure 8, several antibodies specific for mBAFF-R could be found. Specific antibodies, e. g. 
clones 1G10 and 5A12, gave a positive signal only on GFP+ but not on GFP- 40E1 cells. 
Unspecific binding, obvious from a positive signal on both GFP+ and GFP- cells (fig. 8, 
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clone 1A2 ), was also observed in many cases. Besides the non-specific binding antibodies, 
also the ones giving low signals (fig. 8, clone 1B7) or no signal at all (fig. 8, clone 1A1) 
were excluded. Hybridomas producing specific anti-mBAFF-R antibodies were subcloned 
and the corresponding antibody was purified by affinity chromatography. 
 
 
 
 
 
 
 
 
 
 
Figure 8. Selection of 
FACS plots from screening 
supernatants of hybridoma 
cultures possibly producing 
an anti-mBAFF-R anti-
body. Hybridoma superna-
tants were used to stain a 
mixture of normal (GFP-) 
and mBAFF-R expressing 
(GFP+) 40E1 cells. Binding 
of an antibody was revealed 
using anti-ratIgGbio and 
StrepPE. As positive control, 
a staining with HA-hBAFF, 
anti-HAbio and StrepPE was 
performed. 
 
 
 
 
4.3.2 Specification of anti-mBAFF-R antibody characteristics 
In order to find independent hybridoma clones producing antibodies with distinct features, 
several characteristics of the new anti-mBAFF-R antibodies were determined. 
 
 
4.3.2.1 Determination of IgG subclass 
Rat antibodies of the IgG class can be further subdivided into the subclasses IgG1, IgG2a, 
IgG2b and IgG2c. For the determination of the IgG subclasses, an ELISA using rat IgG 
subclass specific antibodies and supernatant from previously subcloned hybridomas was 
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performed. All of the antibodies tested were either of rat IgG2a or rat IgG2b subclass (data 
not shown and tab. 2). 
 
 
4.3.2.2 Determination of ability to block ligand binding 
BAFF-R is a tiny molecule, thus the possibility that binding of an antibody to this receptor 
inhibits the simultaneous binding of the corresponding ligand is relatively high. To analyze 
the blocking capacity of the anti-mBAFF-R antibodies, a mixture of un-transduced and 
mBAFF-R expressing Sp2/0 cells were incubated with different amounts of purified 
antibodies and then stained with HA-hBAFF. Bound HA-hBAFF was detected by staining 
with an monoclonal anti-HAbio antibody, followed by Strep-PE. In figure 2-6, the FACS 
plots for a selection of antibodies is shown. The variation of antibody amount in the range 
between10 µg and 0.5 µg had no influence on the outcome of the stainings (fig. 9B and data 
not shown). Compared with the control stainings, some of the antibodies, e.g. clones 5H10 
and 9B9, completely blocked the binding of ligand. In these cases no signal coming from 
bound HA-hBAFF could be detected (fig. 9, A and B, left panels). One antibody, namely 
clone 5A12, did not at all interfere with ligand binding at all, which was obvious from a 
high positive signal comparable to that of the positive control staining (fig. 9A). Other 
antibodies like clones 1G10 and 9B6 showed a low level of blocking ability, apparent from 
the reduced levels of HA-hBAFF staining (fig. 9A). All results are summarized in table 2. 
 
 
4.3.2.3 Investigations on anti-mBAFF-R antibody interference 
The fact that not all antibodies could block the binding of ligand to the receptor indicates 
that among the anti-mBAFF-R antibodies obtained there are independent clones recognizing 
different epitopes on the mBAFF-R receptor. This makes it possible that one antibody can 
bind to mBAFF-R receptor even if another antibody is already bound. To test this, mBAFF-
R expressing (GFP+) 40E1 cells were pre-incubated with unlabeled anti-mBAFF-R antibody 
5A12 or 7A5 and then with different biotin labeled anti-mBAFF-R antibodies. As depicted 
in figure 10, cells pre-incubated with anti-mBAFF-R antibody clone 5A12 could still bind 
all other clones of anti-mBAFF-R antibodies tested, except biotin-labeled 5A12 antibody. In 
contrast, cells pre-incubated with clone 7A5 could bind only clone 5A12bio, all other clones 
tested showed either a severely reduced signal or could not be bound at all. Therefore we 
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Figure 9. Blocking of hBAFF binding to mBAFF-R by anti-mBAFF-R antibodies. A) and B) A 
mixture of un-transduced (GFP-) and transduced (GFP+) Sp2/0 cells was pre-incubated with 
different amounts of purified anti-mBAFF-R antibodies and then stained with HA-hBAFF, anti-HAbio 
and Strep-PE. As controls, cells were stained with anti-HAbio and Strep-PE (negative control) or 
with HA-hBAFF, anti-HAbio and Strep-PE (positive control). A) Cells were pre-incubated with 10 
µg, 5 µg or 0.5 µg of anti-mBAFF-R antibody. Results for 0.5 µg are shown. B) Cells were pre-
incubated with 10 µg or 1 µg of anti-mBAFF-R antibody. 
 
 
concluded that clone 5A12 recognizes an epitope on mBAFF-R which is completely 
different from the epitopes recognized by the other antibody clones tested. The epitope
recognized by clone 7A5 on the other hand is either very similar to the epitopes recognized 
by the other clones tested, or in close vicinity thereto. The complete absence of any positive 
signal in the case of antibodies 5H10 and 7B7 makes it very possible that these two 
antibodies recognize the same epitope as clone 7A5, or in other words, antibodies 5H10, 
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7A5 and 7B7 may not represent independent clones. A reduction of signal strength in 
comparison to the positive control, as was observed for the other antibodies tested, is very 
likely attributed to the close vicinity of the different epitopes recognized. This would mean 
that clones 1G10, 7A5, 9B6 and 14H7 recognize different but closely located epitopes. 
 
 
Figure 10. Crossreactivity of several anti-mBAFF-R antibody clones. A mixture of un-transduced 
(GFP-) and transduced (GFP+) 40E1 cells was pre-incubated with A) antibody 5A12 or B) antibody 
7A5. Cells were then stained with the indicated biotinylated anti-mBAFF-R antibody clones and 
Strep-PE. 
 
 
Taken together, the combination of the obtained results (tab. 2) indicate that several inde-
pendent anti-mBAFF-R antibodies have been obtained. Antibody clones 1G10 and 7A5 are 
both of IgG subclass 2a and represent a ligand non-blocking and blocking clone, respec-
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tively. Clones 5A12, 5H10 and 9B9 are all of IgG2b subclass. While clone 5A12 does not 
block ligand binding, clones 5H10 and 9B9 efficiently block the binding of ligand. 
 
 
Table 2: Overview of anti-mBAFF-R antibodies and their features. Subclones chosen for 
production are indicated in bold. 
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clone
IgG 
subclass
blocking 
of hBAFF 
binding
binding 
blocked by 
pre-bound 
5A12
binding 
blocked by 
pre-bound 
7A5
subclones
1G10 2a +/- - +/- D4, D11, E4, E6, E8
5A12 2b - + - A11, B2, C1, D6, H8
5H10 2b + - + G8
6F9 2a - n.d. n.d. none
7A5 2a + - + A1, B3, E7
7B7 2b + - + none
8F11 2b + - + none
9B6 2a +/- - +/- B12, G1, G2, H12
9B9 2b + n.d. n.d. A11, D7, E7, H8, H9
14H7 2a - - +/- none
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5.1 Introduction 
The pool of peripheral B cells is continuously replenished by newly-formed immature B 
cells generated in the bone marrow. In the adult mouse, about 2x107 B cells are produced 
per day (1, 2). Following several steps of antigen-independent differentiation and depending 
upon successful rearrangement of the corresponding genes and expression of the B cell 
receptor (BCR) protein on their surface, only about 20% of the newly-generated bone 
marrow B cells migrate to the spleen as immature B cells (3-7). These cells are charac-
terized by a short half-life of about 2-4 days and upon further differentiation steps develop 
into mature, naïve B cells. It has been shown that upon engagement of their BCR, immature 
B cells undergo apoptosis whereas mature B cells, under the same conditions, are induced to 
proliferate (3-7). As for the early stages in the bone marrow, in the periphery the BCR 
signal is not the only requirement for the progression of B cells along their developmental 
pathway. The surrounding stromal microenvironment, the presence of appropriate growth 
factors, as well as their ability to respond to them, are all crucial players in the final 
maturation steps of developing B cells. 
Surface expression of CD93 is a hallmark for immature B cells and on splenic B cells is a 
phenotypic characteristic for so called transitional B cells (3, 5). The latter can be further 
subdivided according to the expression of CD21, CD23, IgM and IgD. Thus, transitional 
type 1 (T1) cells are CD21- CD23- IgMhigh and IgDlow, T2 are CD21+ CD23+  IgMhigh and 
IgDhigh, and T3 are CD21+ CD23+  IgMlow and IgDhigh cells (3, 5, 6). Recently, it has been 
suggested that T3 cells, rather than representing an intermediate in the formation of mature 
B cells, might identify an independent pool of anergic B cells (8). Therefore, only T1 and 
T2 cells would represent the immediate precursors of Follicular and marginal zone B cells, 
the two major mature splenic B cell subsets.  
BAFF (B cell activating factor), a member of the TNF family (also termed TALL-1, 
THANK, BlyS and zTNF4) and BAFF receptor (BAFF-R) play a fundamental role during 
the transition from immature T1 to T2 B cells and therefore for the generation of mature B 
cells in the spleen. This was clearly demonstrated by an almost complete lack of follicular 
and marginal zone B cells and by a block at the T1 cell stage in BAFF as well as in BAFF-R 
deficient mice (9-13). In these mice, the B-1 compartment was not affected, indicating that 
the development of this subset was independent of BAFF-BAFF-R signaling. On the other 
hand, transgenic mice over-expressing BAFF display an overall increase in all B cell 
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subsets, suggesting that all mature B cells express BAFF-R on their surface or are able to 
respond to BAFF (10, 14-16). 
The binding of BAFF to the BAFF-R leads to the activation of the NF-κB pathway and 
ultimately to the transcription of the anti-apoptotic factor Bcl-2 (17-19). The finding that 
Bcl-2 overexpression can, to a large extent, rescue the mature B cell compartment in BAFF 
signaling deficient mice, indicates that Bcl-2 expression induced by BAFF is crucial for the 
survival of B cells during the transition from immature to mature stages (18). 
Since BAFF-R is expressed on all mature peripheral B cells and its signaling promotes in 
vitro survival of immature as well as mature B-2 cells, we hypothesised that BAFF-BAFF-R 
signaling was also playing a central role in the in vivo maintenance of the peripheral mature 
B cell pool. However, the potential survival role of BAFF in the mature B cell pool is 
masked in both BAFF- and BAFF-R deficient animals due to the associated developmental 
block at the T1 stage. Therefore, to address this question, we generated a collection of anti- 
BAFF-R mAbs, some of which blocked and others failed to block BAFF binding.  
Administration of these blocking antibodies to wild-type mice resulted in an almost 
complete depletion of follicular B cells and a reduction of about 50% in the MZB cell 
compartment. Non-blocking antibodies had no, or only minor effects on the mature B cell 
pool. Moreover, by using FcRγ-deficient or Bcl-2-transgenic mice, we could show that this 
depletion was Fc-Receptor (FcR) and complement independent. Taken together, beyond its 
essential role in allowing the developmental progression from immature T1 cells into T2-T3 
and mature B cells, we formally demonstrate the essential role of the BAFF-BAFF-R 
signaling in the long-term survival and homeostasis of mature B-2 and marginal zone B 
cells.  
 
 
5.2 Results 
5.2.1 Characterization of anti-BAFF-R monoclonal antibodies  
A mixture of un-transfected and mouse BAFF-R-expressing Y3 rat myeloma cells was used 
to screen supernatants of individual hybridomas generated as described in Materials and 
Methods. As shown in figure 1A, BAFF-R expressing Y3 (GFP+) cells but not control un-
transfected cells (GFP-) stained with two of the generated anti-BAFF-R antibodies, 9B9 and 
5A12. After subcloning and re-testing, the supernatants of positively-identified clones were 
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used to stain the BAFF-R-expressing Abelson transformed pre-B cell line 40-E1. In total, 
eleven hybridomas producing anti-BAFF-R mAbs were obtained and of these, five were of 
rat IgG2a and 6 of IgG2b isotype. To evaluate their blocking capacity, again a mixture of 
Y3 (GFP-) and BAFF-R expressing Y3 cells (GFP+) was pre-incubated with these mAbs 
and subsequently with a saturating concentration of HA-tagged BAFF. These experiments 
were performed using human BAFF, but similar results were obtained using mouse BAFF. 
FACS analysis with an anti-HA mAb then allowed us to determine which of the generated 
anti-BAFF-R mAbs blocked BAFF binding. As depicted in figure 1B, pre-incubation of 
BAFF-R-expressing Y3 cells with mAbs 5A12 and 9B6 did not affect BAFF binding, 
whereas mAbs 9B9 and 5H10 could block BAFF binding. Of the eleven anti-BAFF-R 
mAbs generated, five were able to block BAFF binding.  
 
 
Figure 1. Binding of anti-BAFF-R antibodies to BAFF-R expressing Y3 rat myeloma cells. Panel 
A. FACS analysis of a 1:1 mixture of BAFF-R-IRES-GFP transfected and untransfected Y3 myeloma 
cells. Upper plot: irrelevant isotype control antibody. Lower plots: the anti-BAFF-R antibodies 9B9 
and 5A12 stained the BAFF-R expressing BAFF-R-IRES-GFP transfected Y3 myeloma cells but not 
the untransfected GFP negative cells. Panel B. The same mixture of BAFF-R-IRES-GFP transfected 
and untransfected Y3 myeloma cells was pre-incubated with or without the four different anti BAFF-
R antibodies as indicated: 5A12, 9B6, 9B9 and 5H10 followed by HA-tagged BAFF, which was 
revealed by a PE labeled anti-HA antibody (upper plot right). 9B9 and 5H10 (lower plots), but not 
5A12 and 9B6 (middle plots) were preventing the binding of HA-tagged BAFF to BAFF-R, revealing 
blocking capacity. Panel C. FACS analysis on the different B and T cell subsets for BAFF-R surface 
expression, as indicated for each plot. Dotted histograms represent isotype control stainings. 
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All BAFF-blocking and non-blocking mAbs were used to reveal the expression of BAFF-R 
on ex vivo isolated spleen, lymph node, bone marrow, peripheral blood and peritoneal cells. 
All mature B cells, irrespective of their localization within the lymphatic compartments, 
namely B-2, MZB, B-1a and B-1b B cells as well as the three immature transitional splenic 
B cell subsets (T1, T2 and T3) expressed similar levels of BAFF-R (figure 1C). Bone 
marrow precursor B cells and haematopoietic cells of other lineages did not express 
detectable surface BAFF-R (figure 1C and data not shown).  
 
 
5.2.2 In vivo depletion of circulating mature B cells with anti-BAFF-R 
mAbs that block BAFF binding. 
Since BAFF was shown to be a potent survival factor for mature and immature B cells in 
vitro, we reasoned that the in vivo use of blocking anti-BAFF-R mAbs would affect the B 
cell pool. Therefore wild-type C57BL/6 mice were treated with two BAFF-blocking and 
two BAFF non-blocking anti-BAFF-R mAbs; all four of the same isotype. At day 14 after 
treatment, the percentage of mature circulating peripheral blood B cells, characterized as 
CD19+ CD93- cells, was determined by flow cytometry. Mature B cells in the control group 
of PBS treated mice represent about 40% of the circulating leukocytes. Similar percentages 
were obtained with the non-blocking 5A12 mAb (figure 2, upper graph). For 9B6, also a 
non-blocking mAb, mature B cells ranged from 25-35%, whereas treatment with either 9B9 
or 5H10 mAb, both of which blocked BAFF binding, resulted in a dramatic decrease of up 
to 80-90% of circulating B cells (figure 2, upper graph). Therefore, whereas non-blocking 
mAbs had only a minimal or no effect, the use of mAbs that prevented BAFF binding 
drastically reduced circulating peripheral B cell numbers. Taken together, these results 
suggest that mature, circulating B cells require BAFF for their survival.  
In order to determine the kinetics of mature B cells depletion, C57BL/6 mice were injected 
with the BAFF-blocking mAb 9B9 and at days 4, 7 and 10 blood lymphocyte 
subpopulations were analyzed. Mice injected with either PBS or the in vivo-depleting anti-
CD4 mAb (GK1.5, rat IgG2b) were used as negative and positive controls, respectively. 
Results are summarized in figure 2, lower graph. Already by day 4 after treatment with 
GK1.5, almost all CD4+ T cells had disappeared and as a consequence, the other 
lymphocyte sub-populations had proportionately increased. Treatment with 9B9 resulted in 
a 40% depletion of mature B cells at day 4, which increased to 70% by day 7 and reached its 
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maximal level of 80% by day 10. In accordance with the in vivo expected half-life of IgG 
antibodies, B cell numbers started to recover by day 25-30 after antibody treatment (data not 
shown).  
 
 
Figure 2. Circulating mature B cells and 
kinetic analysis of peripheral blood B and 
T cell depletion. Upper graph: C57BL/6 
mice were injected i.v.  at day 0 with 0.5 
mg of a given anti-BAFF-R antibody, as 
indicated. At day 14 the percentage of 
CD93-CD19+ mature B cells was 
determined by FACS analysis on the 
peripheral blood mononucleated cells. 
Each symbol represents an individual 
mouse. Statistical analysis revealed a 
significant difference for control versus 
9B6, 9B9 and 5H10 (p<0.05). Lower 
graph: C57BL/6 mice were injected with 
either 0.5 mg of the anti-BAFF-R mAb 9B9 
(white bars), or 0.5 mg of the anti-CD4 
mAb GK1.5 (grey bars). Black bars 
represent PBS injected controls. The mAbs 
were injected at day 0 and the percentages 
of immature B cells (CD93+CD19+), 
mature B cells (CD93-CD19+), CD4 and 
CD8 T cells were determined by FACS at 
days 4, 7 and 10. Each column represents a 
time point: day 4 left column, day 7 middle 
and day 10 right column. Statistical 
analysis revealed a significant difference 
between PBS treated mice as compared to 
anti-BAFF-R mAb at each time point 
analyzed for mature B cells but not for 
immature B cells.  
 
 
 
5.2.3 The BAFF - BAFF-R interaction is essential for the maintenance 
of circulating mature B cells 
The finding that mAbs that prevented BAFF binding caused a pronounced depletion of 
circulating B cells whereas isotype-matched non-blocking ones had only a minor effect 
strongly suggested, that this ablation was neither due to antibody-dependent cellular cyto-
toxicity (ADCC) nor to complement-mediated depletion. In order to test this hypothesis, 
FcR common γ chain-deficient mice were injected with the BAFF-blocking mAb 9B9 or the 
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non-blocking mAb 5A12. At day 14 after injection, the percentage of circulating mature B 
cells (CD19+CD93-) was determined in the blood and compared to untreated mice. In 
untreated or 5A12-treated mice a similar percentage of circulating mature B cells was 
detected, namely 35% and 25-38%, respectively. In contrast, there were only 7-12% 
circulating B cells in FcRγ-deficient mice treated with the BAFF-blocking mAb 9B9 (figure 
3A). This result shows that the depletion of circulating mature B cells with BAFF-blocking 
mAb is FcR independent.  
 
 
Figure 3. Circulating mature B cells in FcRγ  deficient and Bcl2-transgenic mice following anti-
BAFF-R 9B9 injection. Panel A. FcRγ−/− mice were injected at day 0 and the percentage of CD93-
CD19+ mature B cells in the blood was determined at day 14 by FACS analysis. Non-injected 
FcRγ−/− mice were used as controls. The difference between FcRγ−/− treated versus untreated mice 
was statistically significant (p<0.05). Panel B. The percentage of mature B cells in the blood of 
C57BL/6 and Bcl2 transgenic mice at day 14 following the injection of 9B9 mAb. The difference 
between C57BL/6 and Bcl2 transgenic mice following 9B9 treatment was statistically significant 
(p<0.01).  
 
 
It has been shown that BAFF-induced B cell survival is achieved through an NF-κB 
mediated increase in anti-apoptotic molecules, including members of the Bcl-2 family. 
Based on this finding, we wondered whether B cell depletion with BAFF-R blocking mAbs 
would still be seen in transgenic mice over-expressing Bcl-2. Therefore, C57BL/6 and Bcl-2 
transgenic mice were injected with the 9B9 mAb and analyzed after 14 days. As shown in 
figure 3B, the mature B cell pool in the blood of C57BL/6 mice treated with 9B9 was 
reduced by 80-90%. In marked contrast, only a 5-10% reduction was observed in 4 out of 5 
Bcl-2 transgenic animals (figure 3B). Transgenic over-expression of the anti-apoptotic Bcl-
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2 gene was therefore able to overcome to a large extent the B cell depleting effect of 
blocking anti-BAFF-R mAbs. Collectively, these results rule out a role for either ADCC or 
complement-mediated lysis in the observed depletion of recirculating B cells and strongly 
suggest that interactions between BAFF and BAFF-R are crucial for the survival and 
maintenance of the mature B cell pool. 
 
 
5.2.4 BAFF is a survival factor for B-2 and marginal zone B cells in 
vivo 
Mature, peripheral B cells in the mouse can be subdivided into B-2, also called follicular B 
(Fol B), MZB and B-1 B cells. In order to determine the effect of a blocking anti-BAFF-R 
mAb on the different B cell subsets, we injected C57BL/6 mice with the mAb 9B9 and 
analyzed the bone marrow, spleen, lymph nodes and peritoneal cavity lymphocytes at days 
14 to 21. In the spleen, the immature transitional B cell subpopulations were only slightly 
affected with no reduction of T1 and a two fold reduction in T2/T3 subsets (figure 4A and 
B). Mirroring the depletion of circulating B cells, injections with the mAb 9B9 resulted in a 
4 -5 fold reduction of CD93-CD19+ mature splenic B cells. The highest reduction, 80-90%, 
was observed among follicular (CD21+CD23+) B cells, whereas MZB (CD21highCD23low) 
cells were only decreased by 50%. The number of CD21-CD23- mature splenic B cells, 
which to a large extent comprises B-1 B cells, was not affected at all. CD4 and CD8 T cells 
also remained unchanged (figure 4B).  
Mature B cells in the bone marrow or lymph nodes, both of which consist almost entirely of 
B-2 B cells, were also reduced by 80-90% upon 9B9 treatment (data not shown). Bone 
marrow B cell progenitors were not affected by the treatment (data not shown). 
Mature B cell subsets in the peritoneal cavity can be subdivided into B-2 (CD19+CD23+), B-
1a (CD19+CD23-CD11b+CD5+) and B-1b (CD19+CD23-CD11b+CD5-) B cells (figure 4C 
upper plots). All these subsets express similar levels of BAFF-R (figure 1C). However, 
upon 9B9 treatment, whereas 70% of the B-2 B cells were depleted, both B-1a and B-1b cell 
subpopulations remained unaffected (figure 4C).  
Taken together, these findings show that maintenance of the vast majority of B-2 and about 
half of the marginal zone B cells is highly dependent upon the interaction between BAFF 
and BAFF-R, whereas that of B-1 B cells is largely BAFF-R independent. The fact that 
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Figure 4. Depletion of the B and T cell subsets following anti BAFF-R 9B9 antibody injection. 
For description see next page. 
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some B-2 and about half MZB cells remained following antibody treatment might suggest 
either that some of these B cells do not require BAFF-BAFF-R interaction for their survival 
or that B-2 and MZB cells are constantly re-generated having a high turnover rate but are 
still dependent upon BAFF for their survival. In order to discriminate between these 
alternatives, we determined the turnover rate of splenic B cell subpopulations in control and 
9B9 treated mice by BrdU labeling. In accordance to their high turn-over rate, after 10 days 
of continuous BrdU labeling, the vast majority of T1 and T2/T3 in control and 9B9 treated 
mice were found to be BrdU positive (figure 5A), whereas only about 10% of control and 
18% of B-2 cells from 9B9 treated mice were BrdU positive (figure 5A). Taken together, the 
turnover rate of the remaining B-2 cells in 9B9 treated mice was similar to that of B-2 cells 
in control mice and is indicative of a BAFF-BAFF-R-independent mechanism for the 
maintenance of this small number of B-2 cells in treated mice. After 10 days of BrdU 
labeling, about 25% of the MZB cells from the control and 20% from the 9B9 treated mice, 
were positive (figure 5A).  
In order to test whether prolonged treatment would improve the B cell depletion, mice were 
injected over a 5 months time. FACS analysis revealed that such a prolonged treatment did 
not alter the outcome of the B cell depletion. Meaning that, B-1 B cell compartment was not 
affected (data not shown), MZB cells were reduced by half and 10-20% of the B-2 B cell 
compartment was still present (figure 5B). Thus, the vast majority of B-2 cells are highly 
dependent for their survival on BAFF-BAFF-R signaling, and only about half of the MZB 
cells seem to be BAFF-BAFF-R dependent.  
 
 
 
  
Figure 4. Depletion of the B and T cell subsets following anti BAFF-R 9B9 antibody injection. 
Panel A. Representative FACS plot of the immature (CD93+CD19+) and mature (CD93-CD19+) B 
cell compartments in the spleen of C57BL/6 mice; upper plots untreated control, lower plots day 14 
after 0.5mg of anti-BAFF-R 9B9 injection. On the left side total splenocytes are depicted. On the 
right side, gated on mature B cells (CD93-CD19+) follicular (CD21+CD23+) and MZB 
(CD21highCD23low) B cells are shown. Panel B. Absolute numbers of splenic T1 and T2/3 immature 
B cells, B-2 and  MZ B cells, CD4 and CD8 T cells in controls (black bars) and 9B9 injected 
C57BL/6 mice at day 14 after injection (white bars). 5 mice were analyzed for each group. A 
significant difference could be observed for T2/T3, B-2 and MZB cell numbers in control as 
compared to 9B9 injected mice. Panel C. Representative FACS plot analysis indicating the 
percentages of CD19+CD23+ B-2, CD19+CD11b+ B-1b and CD19+CD5+ B-1a B cells in the 
peritoneal cavity of control (upper dot plots) and C57BL/6 mice injected with 9B9 mAb at day 14 
after injection (lower dot plots). 
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Figure 5. Turnover of splenic B cells following injection with anti-BAFF-R 9B9. Panel A. 
Turnover of splenic B cell populations in control (black bars) and 9B9 injected C57BL/6 mice (white 
bars). C57BL/6 mice were injected with 1mg of BrdU and BrdU was added to the drinking water. 10 
days after, splenic T1, T2/3, B-2 and MZ B cells were stained, sorted and the percentage of BrdU 
positive cells was determined by FACS analysis. Mean values with standard deviation are shown. 4 
mice were analyzed for each group. Differences were statistically not significant. Panel B. 
Representative FACS plot analysis of the immature (CD93+CD19+) and mature (CD93-CD19+) B 
cell compartments in the spleen of C57BL/6 mice treated over a 5 months period with anti-BAFF-R 
9B9 mAb. Depicted on the right side, CD21 and CD23 staining gated on immature B cells (upper 
plot) and on mature B cells (lower plot). Indicated are the percentages of the cells represented in 
each quadrant.  
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5.2.5 Immune response in 9B9 treated mice 
In the spleen of normal mice, IgMlow IgDhigh follicular B (B-2) cells are clustered in B cell 
follicles and are surrounded by a rim of IgMhigh IgDlow marginal zone B cells (figure 6). 
Plasma cells, characterized by strong cytoplasmic IgM expression, are localized outside the 
follicles within the red pulp. In mice treated with the BAFF-R blocking mAb 9B9 splenic B 
cell follicles were considerably smaller (figure 6) as a consequence of the drastic reduction 
of the follicular B cells. T cell areas did not show a significant reduction in size, confirming 
the results obtained from the FACS analysis (figure 6). As in controls, plasma cells in anti-
BAFF-R treated mice were localized in the red pulp and were identical in numbers, as 
determined by ELISpot assay (data not shown). Collectively, these results show that 
treatment with a blocking anti-BAFF-R mAb perturbs the splenic follicular organization by 
severely depleting mature B cell numbers and thereby reducing follicular size. 
 
 
 
Figure 6. Immunohistochemistry of spleen sections. Spleen histology of C57BL/6 mice 14 days 
after injection of either the non-blocking 5A12 or blocking 9B9 anti-BAFF-R mAbs, as indicated. 
Cryosections were stained with anti-IgM (red) and CD90 (T cells) (green), left panels, and with 
anti-IgM (green) and anti-IgD (red), right panels, as indicated above. Magnification 240x 
 
 
CHAPTER 5  SURVIVAL OF MATURE B CELLS DEPENDS ON BAFF-R 
   
  107 
In order to test whether the B cell depletion and alteration of the splenic architecture, 
induced by the treatment, would influence humoral immune responses, mice were 
immunized with NIP-ficoll or NIP-ovalbumin 10 days after treatment with 9B9 mAb. 
Serum IgM and IgG anti-NIP titers were determined at day 12 after antigen administration. 
Depletion following anti-BAFF-R treatment was not affecting IgM titers upon challenge 
with T cell independent NIP-ficoll antigen (data not shown), whereas a 5 to 10 fold 
reduction in the titers was observed in 9B9 treated compared to control animals, following a 
T dependent NIP-ovalbumin (NIP-OVA) immunization (figure 7A). However, 9B9 injected 
mice were still able to mount a significantly higher immune response (3-5 fold), compared 
to mice depleted of CD4 T cells by GK1.5 mAb injections (figure 7A). Consistent with this 
finding, the presence of small germinal centers could be detected in 9B9 treated mice after 
immunization by histological analysis (data not shown). Thus, mice treated with an anti-
BAFF-R mAb which prevents BAFF binding showed an impaired but not a completely 
abrogated ability to mount a primary antigen specific IgG response. 
To evaluate the impact of B cell depletion on the formation of memory B cells mice were 
injected with the 9B9 blocking mAb or the 5A12 control non-blocking mAb 14 days before 
being immunized with NIP-OVA. The Ab treatment was continued over a two months 
period and at day 60 after priming mice were boosted, and the recall IgG anti-NIP response 
was determined at day 74. As shown in figure 7B (3 versus 6) the IgG anti-NIP titer of the 
memory response was 5-10 fold lower in the 9B9 treated group (figure 7B group 6) as 
compared to the 5A12 treated group (figure 7B group 3). Thus, treatment with an anti-
BAFF-R mAb that prevents BAFF binding impaired the formation of memory B cells. 
Nevertheless the induction of memory formation was not completely abrogated by 9B9 
treatment, since the antigen specific IgG response was still higher as compared to not 
immunized (figure 7B group 1), not immunized 9B9 treated (figure 7B group 4) mice as 
well as mice which received only the booster immunization, irrespective of the 9B9 
treatment (figure 7B group 2 and 7B group 5, respectively). 
To address the role of BAFF-BAFF-R signaling on the maintenance of memory B cells, 
NIP-OVA primed mice were injected with 9B9 mAb at day 60 and 74 following 
immunization. At day 80 after priming mice were boosted and the IgG anti-NIP titer was 
determined at day 94. As shown in figure 7B group 7, the mice mounted an IgG anti-NIP 
response that was not significantly different from control treated mice (figure 7B group 3). 
Collectively, these results suggest that formation of memory B cells requires BAFF - BAFF-
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R signaling, while the maintenance and survival of memory B cells is not affected by 9B9 
treatment and therefore BAFF independent.  
 
 
Figure 7. Humoral immune 
response. Panel A. 12 days after T 
dependent immunization serum levels 
of anti-NIP IgG were measured by 
ELISA in groups of 5 controls (1) and 
5 C57BL/6 mice injected either with 
anti-BAFF-R mAb 9B9 (2) or anti-
CD4 mAb GK1.5 (3), as indicated. 
Immunization with NIP-ovalbumin 
was performed 10 days after injection 
of the 9B9 or the GK1.5 mAbs. The 
titer is defined as the serum dilution 
that gives OD values twice the 
background and is depicted on a 
logarithmic scale. Each symbol 
represents a mouse. A significant 
difference could be observed in the 
response of 9B9 as well as GK1.5 
mAbs treated mice as compared to 
untreated. Panel B. Sera of mice 
subjected to different treatments was 
collected at different time points as 
indicated for each group. Mice 
received repeated injections of the 
mAb every third week, over the 
indicated period of time. Levels of 
anti-NIP IgG were measured. Each 
symbol represents a mouse. The titer 
is defined as the serum dilution that 
gives OD values twice the 
background and is depicted on a 
logarithmic scale. Groups 1 and 4: 
serum collected at day 1. Mice were 
treated with 5A12 mAb (non-
blocking) and 9B9 mAb (blocking), 
respectively, from day 1 to day 14. 
Mice were not immunized. Groups 2 and 5: serum was collected at day 74. Mice were treated with 
5A12 mAb (non-blocking) and 9B9 mAb (blocking), respectively, from day 1 to day 74. Mice were 
only boosted at day 60. Groups 3 and 6: Serum was collected at day 74. Mice were treated with 
5A12 mAb (non-blocking) and 9B9 mAb (blocking), respectively, from day 1 to day 74. Mice were 
primed with NIP-ovalbumin at day 14 and boosted at day 60. Group 7: Serum was collected at day 
94. Mice were treated with 9B9 mAb (blocking) from day 60 to day 74. Mice were primed with NIP-
ovalbumin at day 14 and boosted at day 80. Statistical analysis revealed a significant difference for 
group 3 versus group 6, but not for group 3 versus 7.  
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5.3 Discussion  
The role of BAFF in the development of mouse B cells was most clearly demonstrated by 
the generation of two different BAFF deficient strains and by the characterization of BAFF-
R deficient mice (9-13). These mutant mice displayed a severe block in B cell development 
at the differentiation from, so called, T1 to T2 B cells in the spleen, whereas the develop-
ment of B-1 B cells appeared to be unaffected. As a consequence of the profound decrease 
in T2 B cell numbers, their downstream mature B cell progeny, namely follicular and 
marginal zone B cells, were drastically depleted. Whether BAFF was necessary either for 
the survival of T2 cells or for promoting their differentiation and maturation, however, 
remained an open question. Furthermore, the role of BAFF in the survival of mature B cell 
in vivo could not be addressed using these mice, since their precursors depended on BAFF 
for their generation and development.  
By the generation and administration of anti-BAFF-R monoclonal antibodies capable of 
preventing BAFF binding, we show in this report, that the in vivo survival of almost all 
follicular and half of the marginal zone B cells is dependent upon BAFF-BAFF-R signaling. 
Injection of mice with a blocking anti-BAFF-R antibody induced a profound depletion of 
the mature B cell compartment, whereas a non-blocking antibody had only a minimal or no 
effect. The possible scenarios which could explain this phenomenon include: an antibody-
dependent cellular cytotoxicity (ADCC), a complement-mediated lysis, an impairment of 
the survival through prevention of BAFF binding or a limited generation of newly formed 
mature B cells as a consequence of the depletion of transitional B cells. The fact, that an 
isotype-matched non-blocking anti-BAFF-R monoclonal antibody is not affecting the 
peripheral mature B cell pool and that in addition the detectable presence of the non-
blocking anti-BAFF-R antibody on the surface of non-depleted B cells (data not shown) 
taken together would indicate an ADCC mechanism is unlikely. Moreover, that B cell 
depletion is still occurring in FcRγ-chain (20) deficient mice confirms that ADCC is most 
likely not involved. In comparison to the rapid ADCC dependent anti-CD4-mediated 
depletion of T cells by GK1.5, the relatively slow kinetic of B cell deletion observed after 
the administration of blocking anti-BAFF-R antibody suggested a major role for BAFF-R 
signaling on mature B cell survival. Moreover, treatment of Bcl-2 transgenic mice (21), 
where B cells were only slightly reduced, further corroborates the hypothesis of a BAFF 
mediated survival on the one hand and makes complement mediated cell lysis improbable 
on the other hand. 
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Yet an alternative explanation for the observed depletion of mature B cells upon treatment 
would be that the numbers of differentiating T2/T3 immature B cells into mature cells 
decrease with time. However, based on BrdU in vivo labeling studies performed by us and 
others, this seems to be an unlikely scenario (3, 7). These studies showed that in an adult 
mouse about 1% of the mature B-2 cells are replaced per day. Upon treatment we see 
already an 80-90% reduction of mature B cells at day 10-14, whereas only a 10-14% 
reduction could be explained by the differentiation block of T2/T3 into mature B-2 cells. 
Therefore collectively our findings demonstrate, that the vast majority of B-2 cells and 
about half of MZB cells require BAFF for their survival.  
Different experimental approaches, performed by other groups, were also suggestive of a 
survival role of BAFF-BAFF-R signaling in mature B cells. Treatment of mice with a 
TACI-Fc fusion protein was shown to lead to a reduction of B cells (22-24). However, in 
these studies the extent of B-2 and MZB cells depletion was not analyzed in detail (22, 23). 
Moreover, given that TACI can interact with both BAFF and APRIL (24), the potential role 
for APRIL in this depletion process could not be excluded. Several groups showed that 
treatment of mice with a BAFF-R-Fc fusion protein also resulted in a depletion of B cells 
(22, 25). Since BAFF is the only known ligand for BAFF-R, these studies strongly suggest 
that peripheral B cells require BAFF for their survival. In one of these studies a more 
detailed analysis of the extent of depletion of the various mature B cell subpopulations is 
reported (25). This analysis revealed that after such a treatment the B-2 and MZB 
compartments were largely reduced, whereas the B-1 cell numbers were practically not 
affected. In other words, treatment of mice with a BAFF-R-Fc fusion protein results in a 
very similar B cell depletion as we observed here upon treatment with the blocking anti-
BAFF-R mAbs. Thus, our results confirm and extent previously reported findings on the 
role of BAFF - BAFF-R signaling in the survival and maintenance of the mature B cell 
compartments. 
B-1 B cells express relatively high amounts of BAFF-R on their surface. However, as 
shown in BAFF as well as BAFF-R deficient mice their generation and maintenance is not 
affected (9-13). Also the here described short-term and long-term (5 months) treatment with 
anti-BAFF-R mAbs that block BAFF binding did not affect the B-1 B cell compartment. 
Moreover, we could rule out an inability of the injected mAbs to enter the peritoneal cavity 
since FACS analysis with an anti-rat IgG revealed the presence of the anti-BAFF-R mAb on 
the surface of B-1 B cells (data not shown). Thus the role of the BAFF-R in B-1 B cell 
biology still needs to be elucidated. However, the finding that the B-1 B cell compartment is 
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largely expanded in BAFF transgenic mice (10, 14-16) might suggest that BAFF can act as 
a B-1 B cell growth factor. 
Following anti-BAFF-R treatment, we observed that the B-2 B cell compartment was the 
most affected B cell subset, indicating that the majority of B-2 cells rely on BAFF signaling 
for their survival. Marginal zone B cells were reduced only by half upon treatment, which 
compared to their almost complete absence observed in BAFF and BAFF-R deficient mice, 
is indicative for a crucial role of BAFF signaling during marginal zone B cell development 
or survival of their progeny, but dispensable for their survival subsequent to maturation. In 
BAFF-R deficient mice, over-expression of Bcl-2 could not overcome the marginal zone B 
cell defect (18), arguing for an instructive role of BAFF for their development, which still 
needs to be elucidated.  
By BrdU labeling experiments and FACS analysis we show that the survival of a small 
subset of B-2 B cells seemed to be BAFF-independent and not reflecting newly formed 
mature B cells. A similar result was shown in BAFF as well as BAFF-R deficient mice, 
where the mature follicular B cell compartment was drastically reduced but still present in 
small numbers (26). The follicular B cells that survived this BAFF-R blockage could not be 
distinguished according to phenotypic criteria (data not shown). Because B-1 cells were not 
affected by anti-BAFF-R treatment and considering their predominant origin during 
fetal/neonatal development, we wondered whether the surviving B-2 cells were also of fetal 
origin. A hallmark of B cell development during fetal life is the lack of expression of 
deoxynucleotidyl transferase which prevents non-templated nucleotide additions in the V-D 
and D-J junction of the BCR heavy chain. No difference could be observed comparing 
junctional regions of untreated to 9B9 treated B-2 B cells, ruling out this hypothesis (data 
not shown).  
Prolonged (5 months) treatment with the 9B9 mAb did not improve the depletion of these 
mature B cell subsets. FACS analysis with an anti-rat IgG mAb revealed the presence of 
9B9 on the surface of B-2 and MZB cells surviving the treatment (data not shown). 
Moreover, the surface available BAFF-R seemed to be saturated by the injected 9B9, as 
other anti-BAFF-R mAbs were undetectable by FACS analysis (data not shown). Therefore, 
the survival of these mature B cell subsets seems to be BAFF - BAFF-R signaling in-
dependent. 
It has been shown that surface BCR expression is mandatory for mature B cell survival, 
since conditional ablation of BCR expression subsequent to the establishment of steady-
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state B cell numbers resulted in rapid death of most peripheral B cells (27). The mechanism 
by which BCR expression influences B cell longevity remains to be clarified. 
The survival of mature B cells is dependent on signaling processes that use the NF-κB 
signal transduction pathway (28, 29). Two pathways leading to NF-κB activation in B cells 
have been described, namely the classical and the alternative pathways (30). Several 
mutations affecting one or both NF-κB signaling cascades were shown to affect the B cell 
compartment (12, 31-37). Since the two NF-κB pathways employ both shared and distinct 
components, the role of each activation pathway in B cells remains to be elucidated (18). 
Several in vitro studies have demonstrated a survival role of BAFF on transitional as well as 
mature B cells (16, 38). The mechanism by which this increased survival is achieved seems 
to be dependent on the NF-κB mediated upregulation of anti-apoptotic Bcl-2 family proteins 
and inhibition of the nuclear translocation of the pro-apoptotic protein kinase Cδ (39, 40). 
Collectively, BCR as well as BAFF-R signaling seem to be essential for the maintenance of 
mature B cells and this is probably achieved by up-regulating anti-apoptotic pathways, 
where Bcl-2 might be a key player. In fact, transgenic expression of Bcl-2 was able to 
rescue the survival of B cells upon BCR deletion (27), and we show that it is able to 
overcome, to a large extent, the ablating effect of anti-BAFF-R blocking antibodies. Mature 
B cell survival seems to be regulated by the achievement of a certain activation state 
induced by a combination of basal BCR and BAFF - BAFF-R signaling, with a different 
contribution of the two pathways, which might also be dependent on the B cell subset. 
Nevertheless, it still remains to be clarified how BCR and BAFF-R signals act on one 
another and are integrated within the cell to maintain cell survival. The different impact of 
BCR and BAFF - BAFF-R signaling on the activation state and as a consequence on the 
survival of mature B cells could explain why some B cells survive anti-BAFF-R treatment 
as a BAFF-independent subset. In agreement with this hypothesis is the finding that many 
marginal zone B and B-1 B cells survived treatment with anti-BAFF-R mAb.   
It is believed that formation of the different mature B cell compartments is influenced by 
specific BCR-ligand interactions (41-43). Thus, B cells in transgenic mice expressing 
recombinant BCRs for self-antigens tend to differentiate into B-1 and marginal zone B cells 
(44). Both, B-1 and MZB cells are enriched for self reactive clones, whereas follicular B 
cells generally require higher levels of BCR signaling for their formation. Therefore, if for 
the survival of mature B cells a certain threshold of activation is required and if this 
activation is a combination of basal BCR signaling and competition for as well as the 
availability of BAFF, prevention of BAFF binding would rather favor the survival of those 
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B cells with relatively higher affinity for self-antigens, such as B-1 and MZB cells. 
Nevertheless, we cannot rule out an alternative explanation for the BAFF independent 
survival of MZB cells, namely that their location next to metallophilic macrophages could 
provide them with a specific environmental niche favoring their survival. Moreover, 
considering that their development is dependent on Notch signaling (45, 46), different 
Notch ligands might also be involved in their maintenance.  
As a consequence for the observed B cell depletion in anti-BAFF-R treated mice, we show 
that splenic follicles are greatly reduced in size. Moreover, the primary immune response to 
T dependent antigen was impaired, with IgG titers reduced by a factor of 5 to 10 following 
treatment with an anti-BAFF-R blocking antibody, whereas total immunoglobulin levels 
were not affected. This result is in line with what was shown for BAFF-R deficient mice, 
where the IgG1 response to T-dependent antigen was significantly reduced (12). Moreover, 
we showed that in absence of BAFF-R signaling the induction memory B cells is strongly 
impaired. However, the maintenance of memory B cells seems to be BAFF - BAFF-R 
signaling independent, since 9B9 mAb treatment of mice primed before with a T cell 
dependent antigen did not impair the recall response. This finding confirms the very recent 
data published by Benson et al. (22), showing that treatment of antigen primed mice with 
TACI-Ig or BAFF-R-Ig does not impair their ability to mount an efficient recall response. 
These findings enlighten a new role of BAFF - BAFF-R signaling as a crucial factor for the 
formation of memory or the survival of developing memory B cells, while confirming its 
dispensable role in the maintenance of memory B cells. Therefore, the question whether 
therapies based on BAFF as well as BAFF-R neutralization in B cell mediated autoimmune 
diseases could be successful remains uncertain. On the other hand, since elevated BAFF 
serum levels and deregulated BAFF-R signaling were shown to contribute to the pathogenic 
B survival in oncological as immunological disorders (47-52), a potential use of anti-BAFF-
R mAb might represent an optimal targeted therapy, which would not compromise the 
ability of these patients to respond to already encountered antigens.  
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6.1 Introduction 
The random assembly of V, D and J immunoglobulin (Ig) gene segments in developing 
lymphocytes results in the formation of an immense number of different B cell receptors 
(BCR) able to recognize a diverse repertoire of antigens. However, this random assembly of 
BCR can lead to the formation of Ig receptors that are either autoreactive or functionally 
impaired. In general, such cells are eliminated from the system by negative selection. 
Receptor editing is an important salvage mechanism to eliminate cells bearing potentially 
autoreactive or signaling-incompetent receptors, while at the same time preventing un-
necessary deletion of cells. B cells expressing an inappropriate BCR can undergo secondary 
Ig gene rearrangements to form a BCR with a new specificity (1, 2). Thus, receptor editing 
plays a major role in both positive and negative selection (3). The main selection checkpoint 
seems to be at the immature B cell stage, even though a first checkpoint occurs already at 
the pre-BI cell stage. Appropriate signaling by the pre-BCR, which consist of µH and 
surrogate light (SL) chains, is important for the survival of pre-BI cells and their develop-
mental progression to cycling large pre-BII cells, whereas insufficient pre-BCR signaling 
results in their developmental arrest.  
Ig light chain (LC) locus rearrangement takes place at the pre-BII cell stage and the first 
cells expressing a complete BCR are newly formed immature B cells. Analyses of 
production and turnover rates revealed severe cell losses among immature B cells, as from 
the about 20 million immature B cells produced in the BM per day, only 20% exited the 
marrow (4, 5). These findings indicate that strong selection takes place at the immature B 
cell stage. Negative selection may not account for all of the losses observed at this point of 
development, since positive selection in form of continuous BCR signaling was shown to be 
important for survival of both immature and mature B cells (6, 7). The mechanism(s) 
underlying positive selection of B cells are less well characterized compared to those for 
negative selection. One of the main factors for positive selection seems to be ligand-
independent (tonic) signaling via the BCR. Although several co-receptors and internal 
signaling molecules involved in positive selection have been identified (8), to date it is not 
clear whether B cell survival is directly accomplished by tonic signals, or whether these 
tonic signals lead to the expression and maintenance of survival-promoting intracellular 
proteins and/or cell surface receptors. One candidate for such a receptor is BAFF-R (B cell 
activating factor belonging to the TNF family receptor). For transitional and mature B cell 
subtypes, it has been shown that BAFF-R expression levels are regulated by BCR signaling 
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(9). BAFF signaling via BAFF-R is known to be important for the survival of immature B 
cells as well as their further development into mature B cells in the spleen. Both BAFF and 
BAFF-R deficient mice show a block in B cell differentiation at the transitional type 1 (T1) 
stage in the spleen, resulting in decreased numbers of down-stream transitional type 2 (T2), 
mature follicular (Fol) and marginal zone (MZ) B cells (10-12).  
Here we report that during B cell development BAFF-R expression first occurs on a 
subpopulation of CD19+ CD93+ IgM+ CD23- BM B cells and that BAFF-R expression in 
this subpopulation is regulated by signals of a BCR that must not be self-reactive, thus 
making BAFF-R a useful marker for immature B cells that might be positively selected. 
 
 
 
6.2 Results and Discussion 
6.2.1 BAFF-R is expressed only on IgMhigh immature B cells in the BM 
To characterize our newly generated monoclonal antibodies against mouse BAFF-R (13) we 
used five-color flow cytometric analyses with antibodies against CD19, CD21, CD23, CD93 
and mBAFF-R (clones 7A5 and 9B9, respectively). As shown in figure 1A, anti-mBAFF-R 
clone 9B9 detects BAFF-R on splenic T1 (CD19+ CD93+ CD21- CD23-), T2/3 (CD19+ 
CD93+ CD21+ CD23+), follicular (CD19+ CD93- CD21+ CD23+) and marginal zone B cells 
(CD19+ CD93- CD21+ CD23-). On all splenic B cell subsets, BAFF-R was expressed 
homogenously and to the same extent. BAFF-R expression could also be detected on both 
B-1a (CD19+ CD5+) and B-1b (CD19+ CD11b+) B cells from the peritoneal cavity. In 
contrast, no expression of BAFF-R could be detected on CD4+ or CD8+ splenic T cells. 
Similar results were obtained using another anti-mBAFF-R antibody (clone 7A5, data not 
shown).  
Contrary to the splenic and peritoneal B cells, BAFF-R expression on BM B cells was 
heterogeneous. We found that there was no FACS-detectable expression of BAFF-R on 
B220+ IgM- B cells (Fig. 1B, gate A), but that BAFF-R was highly expressed on B220high 
IgM+ recirculating B cells (Fig. 1B, gate C). Interestingly, by gating on B220int IgM+ newly 
formed B cells we observed that this was a mixed population with regard to BAFF-R 
expression (Fig. 1B, gate B). A BAFF-R positive fraction could be clearly distinguished 
from a BAFF-R negative fraction, with about 40% of the newly formed B cells being 
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positive for BAFF-R in a 6-8 week old C57BL/6 mouse. BM B cells defined as B220int 
IgM+ are the progeny of pre-BII cells and express for the first time a complete BCR. Thus, 
B cells in this compartment are in a developmental stage where BCR editing may occur. 
This prompted us to look for a correlation between BAFF-R expression and putative BCR 
editing. 
 
 
Figure 1. BAFF-R expression on B and T cell subsets. A) Splenic B cell subsets (upper panel) were 
delineated using markers CD19, CD93, CD21 and CD23 and BAFF-R expression on transitional T1 
and T2/3 B cells as well as mature MZ and Fol B cells was analyzed. Furthermore, BAFF-R 
expression was measured on B-1a (CD19+ CD5+) and B-1b (CD19+ CD11b+) B cells from the 
peritoneal cavity as well as on splenic CD4+ and CD8+ T cells. Dotted line histograms represent the 
negative controls. B) Bone marrow B cell subsets were delineated using markers B220 and IgM, and 
BAFF-R expression on IgM- B220+ cells (A), IgM+ B220low newly formed B cells (B) and IgM+ 
B220high recirculating B cells (C) was analyzed. Dotted line histograms represent the negative 
controls. 
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6.2.2 BAFF-R expression levels correlate with surface IgM levels 
BCR editing is known to be associated with low levels of surface IgM expression on B cells 
in the BM (14). If our assumption was correct, that there was a correlation between BAFF-R 
expression and BCR editing, there should also be a correlation between BAFF-R and IgM 
expression. More recently published data revealed that B cell maturation to mature, long-
lived B cells occurs not only in the spleen but might be also occurring in the BM (15, 16). 
To rule out that our B220int IgM+ newly formed B cell subpopulation contained more 
mature BM specific B cell developmental intermediates, we used the surface markers CD19, 
CD93, IgM and CD23 to delineate differentiation stages (Fig. 2A). We found that CD19+ 
CD93+ IgM+ CD23+ BM B cells were all positive for BAFF-R, with an expression level 
similar to splenic B cells (Fig. 2B, right), whereas CD19+ CD93+ IgM+ CD23- BM B cells 
are heterogeneous concerning BAFF-R expression (Fig. 2B, left). Since it could only be 
assumed that within the CD19+ CD93+ IgM+ CD23- B cells there is a BAFF-R- and a BAFF-
R+ fraction, we sorted and reanalyzed the putative two populations. We found, that two 
clearly definable fractions exist, a BAFF-R- and a BAFF-R+ one (Fig. 2C, left). Upon 
analysis of the surface IgM expression we found that the level was lower on the BAFF-R- 
fraction of CD19+ CD93+ IgM+ CD23- B cells compared to the BAFF-R+ fraction (Fig. 2C, 
right). Since cells showing low levels of IgM expression in BM have been indicated to 
undergo receptor editing (14), our findings might suggest that BAFF-R expression 
discriminates between receptor editing and non-editing immature B cells. 
 
 
6.2.3 Analysis of BCR knock-in mice 
Further evidence supporting our hypothesis comes from the analysis of BCR knock-in B1-
8Hi; 3-83κi mice which carry pre-rearranged HC and LC genes in their appropriate genomic 
context and express only an innocuous BCR consisting of the B1-8 HC and the 3-83 κ-LC. 
As B cell receptor editing is the main mechanism through which B cells expressing 
autoreactive BCRs are eliminated, these mice do not have B cells that undergo receptor 
editing. Staining of BM B cells of B1-8Hi; 3-83κi mice for B220 and IgM revealed that 
there are almost no B220+ IgM- progenitor B cells (17). This observation has been explained 
by the direct and rapid maturation of progenitors into immature B cells due to the absence of 
negative selection and receptor editing. Our finding, that BAFF-R is expressed only on 
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Figure 2. Newly formed B cells from the 
bone marrow can be subdivided into a 
BAFF-R- and a BAFF-R+ fraction. A) 
BM B cell subsets were delineated using 
markers CD19, CD93, CD23 and IgM. 
B) BAFF-R expression on newly formed 
CD19+ CD93+ IgM+ CD23- B cells (left) 
and on mature CD19+ CD93+ IgM+ 
CD23+ B cells (right). Thin line histo-
grams represent the negative controls. C) 
Newly formed CD19+ CD93+ IgM+ 
CD23- B cells (B, left picture) where 
sorted according to BAFF-R expression 
and reanalyzed. The left overlay 
represents the reanalysis of the sorted 
BAFF-R- fraction (thin line histogram) 
and BAFF-R+ fraction (thick line 
histogram). The right hand overlay 
shows the IgM expression on IgM+ 
CD23- BAFF-R- (thin line histogram) 
and BAFF-R+ (thick line histogram) 
cells.  
 
 
 
newly formed B cells that need not to be eliminated by negative selection, leads to the 
assumption that all of the newly formed immature B cells in the BM of these knock-in mice 
should homogenously express BAFF-R. FACS staining of the BM of the B1-8Hi; 3-83κi 
mice for IgM, B220 and mBAFF-R revealed that, in fact, the newly formed IgMhigh B220int 
B cells express BAFF-R homogenously (Fig. 3, fraction B), which is in contrast to the 
finding in BM of WT mice (Fig. 1B, fraction B). As expected and in accordance with the 
results obtained for WT mice (Fig. 1B, fractions A and C), IgM- B220+ B cells in these 
knock-in mice are negative for BAFF-R expression (Fig. 3, fraction A), and all IgM+ 
B220high recirculating B cells express BAFF-R (Fig. 3, fraction C). This result supports our 
assumption, that BAFF-R is expressed first on immature BM B cells that have passed the 
negative selection process. 
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Figure 3. BAFF-R is expressed homogenously on newly formed BM B which do not undergo 
receptor editing. Bone marrow B cell subsets from A) WT and B) B1-8 transgenic knock-in mice 
were delineated using markers B220 and IgM, and BAFF-R expression on IgM- B220+ cells (A), 
IgM+ B220low newly formed B cells (B) and IgM+ B220high recirculating B cells (C) was analyzed. 
 
 
6.2.4 BAFF-R expression correlates negatively with RAG-2 expression 
and BCR editing 
B cells that undergo receptor editing need to express RAG-1 and RAG-2, as these proteins 
are absolutely necessary for V(D)J recombination. Considering that BAFF-R expression 
might be related to BCR editing, there might also be a correlation with RAG expression. 
Therefore, we analyzed BCR LC editing and RAG-2 expression in B cell populations 
subjected to different in vitro conditions. Thus, we sorted κ-LC+ CD19+ CD93+ CD23- 
BAFF-R- (referred to as CD23- BAFF-R-), κ-LC+ CD19+ CD93+ CD23- BAFF-R+ (referred 
to as CD23- BAFF-R+) and κ-LC+ CD19+ CD93+ CD23+ BAFF-R+ (referred to as CD23+ 
BAFF-R+) B cells from the BM and incubated them either in the presence or absence of an 
anti-κ-LC antibody. After 36 h we analyzed the cells by FACS, using an anti-λ-LC antibody 
to follow LC editing from κ to λ. RAG-2 expression was determined by semi-quantitative
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Figure 4. RAG-2 is expressed only in BAFF-R- newly formed B cells from the BM, but can be 
induced in BAFF-R+ newly formed B cells from the BM by culturing with anti-κ-LC antibody. A) 
and B) B cells from the BM were sorted as CD19+ CD93+ κ-LC+ CD23- BAFF-R- (left panel), 
CD19+ CD93+ κ-LC+ CD23- BAFF-R+ (middle) and CD19+ CD93+ κ-LC+ CD23+ BAFF-R+ (right 
panel) and incubated for 36 h in medium alone (A) or in the presence of 25 µg/ml anti-κ-LC 
antibody (B). LC editing from κ- to λ-LC was analyzed using IgM and λ1+2-LC specific antibodies. 
C) RAG-2 expression was measured by semi-quantitative PCR for BM B cell subpopulations sorted 
and cultured as mentioned in A and B. 
 
 
RT-PCR. When cultured in the absence of anti-κ-LC antibody, CD23- BAFF-R- B cells 
(Fig. 4A, left) underwent extensive LC editing, as was apparent by 7.2% of previously κ-
LC+ cells that had become λ-LC+. About 15 % of the cells had down-regulated their BCR 
and were now IgM negative. These cells were probably not able to further edit their LCs 
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and presumably were in the process of apoptosis. Interestingly, both of the other B cell 
subtypes analyzed, which were both BAFF-R+, did not show any sign of receptor editing 
and kept expressing κ-LC BCRs (Fig. 4A, middle and right). RT-PCR analysis revealed, 
that only the BAFF-R- subpopulation expressed RAG-2, whereas both of the BAFF-R+ 
subpopulations were negative for RAG-2 expression (Fig. 4C, upper panel). 
This result supports the previous finding and confirms, that only CD23- BAFF-R- BM B 
cells can undergo V(D)J recombination and LC editing, whereas CD23- BAFF-R+ as well as 
CD23+ BAFF-R+ BM B cells did not undergo LC editing, probably because they expressed 
already a harmless (non-autoreactive) and functional BCR. 
When we performed the same experiment in the presence of an anti-κ-LC antibody in order 
to induce receptor editing (Fig. 4B), then CD23- BAFF-R- BM B cells showed increased LC 
editing, which was apparent from the about 17% λ-LC+ B cells (Fig. 4B, left). As before, the 
two BAFF-R+ subpopulations analyzed behaved almost the same, showing around 6% λ-
LC+ cells in the case of CD23- BAFF-R+ cells and 2% λ-LC+ cells for CD23+ BAFF-R+ 
cells (Fig. 4B, middle and right). Cells that were not able to edit the BCR from κ- to λ-LC 
showed reduced surface IgM expression levels (Fig. 4B). In the presence of the anti-κ-LC 
antibody, RAG-2 expression could be detected for all three subpopulations, but BAFF-R+ 
cells showed lower levels than BAFF-R- cells (Fig. 4C, lower panel). 
These results clearly indicate that CD23- BAFF-R- immature B cells do not yet express an 
appropriate BCR, as evidenced by the still existing RAG-2 expression and the high 
percentage of cells undergoing LC editing. Moreover, our findings indicate that BAFF-R 
expression does not inhibit LC editing, since BCR ligation of both CD23- BAFF-R+ and 
CD23+ BAFF-R+ B cells was able to re-induce RAG expression and LC editing. In this 
context it is worthwhile noting that LC editing in CD23- BAFF-R+ and CD23+ BAFF-R+ B 
cells by the anti-κ-LC antibody could not be prevented by the addition of BAFF (data not 
shown). These findings suggest, that the B cell autoimmunity observed in transgenic mice 
which over-express BAFF (18, 19) is not due to BAFF interfering with negative selection 
and/or receptor editing of autoreactive immature bone marrow B cells, but rather might be a 
result of BAFF rescuing anergic/self-reactive B cells in the periphery (20). 
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6.2.5 Changes of surface BAFF-R expression levels upon BCR ligation 
depends on the B cell maturation stage  
To test whether BAFF-R expression levels change upon BCR ligation, IgM+ CD93+ BAFF-
R- CD23- and IgM+ CD93+ BAFF-R+ CD23- as well as IgM+ CD93+ BAFF-R+ CD23+ B 
cells from the BM, and transitional T1 and T2/3 and mature follicular B cells from the 
spleen were purified by cell sorting. Cells were then incubated either in the presence or 
absence of anti-IgM antibody. FACS analysis after 36 h revealed, that all BM B cell subsets 
analyzed expressed BAFF-R at the same level when cultured in the absence of anti-Ig 
antibody (Fig. 5A, thick solid histogram). IgM+ CD93+ CD23- BAFF-R- B cells become
 
 
Figure 5. Surface BAFF-R levels on B cell subsets change during culturing with anti-IgM. A) BM 
B cells were sorted as CD19+ CD93+ κ-LC+ CD23- BAFF-R- (left panel), CD19+ CD93+ κ-LC+ 
CD23- BAFF-R+ (middle) and CD19+ CD93+ κ-LC+ CD23+ BAFF-R+ (right panel) and expression 
levels of BAFF-R were analyzed after culturing the cells in the absence (thick line histograms) or 
presence (dotted line histograms) of anti-IgM antibody for 36 h. Thin line histograms represent the 
negative controls. B) Splenic B cells were sorted as CD19+ CD93+ CD23- κ-LC+ (T1), CD19+ 
CD93+ CD23+ κ-LC+ (T2/3) or CD19+ CD93- CD23+ κ-LC+ (Fol B) and BAFF-R expression was 
analyzed after culturing the cells in the absence (thick line histograms) or presence (dotted line 
histograms) of anti-IgM antibody for 36 h. Thin line histograms represent the negative controls. 
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BAFF-R+, since they continued their developmental program. When incubated in the 
presence of the anti-IgM antibody, we observed that BAFF-R was down modulated in all 
BM B cell subtypes analyzed (Fig. 5A, dotted histogram). Incubation of CD23- BAFF-R- 
cells in the presence of antibody (Fig. 4B, left) leads to down-modulation of IgM expression 
in more than 80% of the cells. This population also shows low to negative expression of 
BAFF-R. The splenic transitional T1 and T2/3 subpopulations behaved the same as the BM 
subpopulations, as they kept BAFF-R expression in the absence of anti-IgM antibody and 
down-regulated BAFF-R in the presence of the antibody (Fig. 5B, left and middle). 
Interestingly, Fol B cells also kept BAFF-R expression when cultured in the absence of the 
anti-IgM antibody, but in contrast to BM and splenic transitional type B cells, they up-
regulated BAFF-R expression in the presence of BCR ligation (Fig. 5B, right). Thus, our 
results suggest that BAFF-R expression is regulated by BCR signaling and that the outcome 
of BCR signaling on BAFF-R expression is B cell developmental stage dependent i.e. 
down-modulation on immature B cells and up-regulation on mature B cells. 
Findings in support of this assumption come from the observations made in mice lacking 
both Rac-1 and Rac-2. Such mice show defective BCR signaling, resulting in diminished 
numbers of splenic B cells, but normal numbers of BM B cells. Furthermore, this impaired 
BCR signaling also leads to reduced levels of BAFF-R, pointing to a direct regulation of 
BAFF-R expression by BCR signaling via the Rac-1 and Rac-2 pathway (21).  
Our finding that in B cells susceptible to negative selection, engagement of the BCR leads 
to down-regulation of BAFF-R expression might suggest that their survival time upon BCR 
ligation is reduced and therefore these cells might be more easily eliminated. This could be 
part of the mechanisms by which autoreactive B cells are deleted. On the other hand, 
however, absence of down-modulation of the BAFF-R upon BCR engagement by immature 
B cells might lead to autoimmunity. 
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7 ANALYSIS OF SERUM BAFF LEVELS IN HUMANS 
WITH AUTOIMMUNE AND OTHER DISEASES WITH B 
CELL IMPLICATION 
7.1 Introduction 
Despite the numerous tolerance checkpoints that exist in the immune system in order to 
prevent the formation and activation of self-reactive B and T lymphocytes, inappropriate 
immune responses against normal components of the body occur in about 5% of the human 
population (1). These autoimmune diseases can either be directed against a single organ, as 
in autoimmune thyroid diseases (AITD), type 1 diabetes mellitus and myasthenia gravis, or 
be systemic illnesses, such as rheumatoid arthritis (RA), multiple sclerosis (MS), systemic 
lupus erythematosus (SLE) or Sjögren’s syndrome (SS). 
The etiopathogenic mechanisms initiating autoimmune diseases still remain undefined, due 
to their complex nature which is reflected in the various factors that have been found to be 
associated with these diseases. The influence of genetic factors was obvious from the obser-
vation of familial tendencies and the study of monozygotic twins. The results obtained from 
the studies in monozygotic twins also indicated that inherited factors alone are not sufficient 
for the development of an autoimmune disease. Several environmental factors like infec-
tions, vaccination, drugs, toxins and nutrition are discussed in this respect (2). Another 
possibility might be somatic mutations that occur during normal B- or T-cell development. 
The combination of this mutation together with an inherited defect or the accumulation of 
several somatic mutations could make it possible for the affected cell to evade tolerance 
checkpoints. Thus, a stepwise mechanism may underlay the pathogenesis of autoimmune 
diseases, resembling cancer development (1). 
The genes which were associated with a higher susceptibility for autoimmune diseases 
encode for proteins that are involved in all steps of normal B- and T-cell maturation and 
activation. Of particular importance are HLA, AIRE, CTLA-4 and TLR. Polymorphisms 
and mutations in these genes lead to dysregulation of the normal developmental and 
activation process of B or T lymphocytes. In the case of HLA, specific alleles code for HLA 
molecules that allow the presentation of specific autoantigens. This has been investigated in 
detail for the HLA-DQ gene and the presence or absence of an Asp residue at position 57 in 
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type 1 diabetes mellitus (T1DM) (3, 4). Individuals with defects in the transcription factor 
AIRE show an impaired negative selection of T-cells in the thymus due to the failure to 
produce peripheral antigens in the medullary thymic epithelial cells. This breakdown of 
central tolerance results in an increased frequency of auto-reactive naive T-cells in the 
periphery. The autoimmune disorder APECED seems to be strongly associated with AIRE 
mutations (5). CTLA-4 is a negative regulator of T-cell activation, which competes against 
CD28 for binding to CD80 or CD86, respectively, and thus inhibits further activation of the 
T-cell. Polymorphisms in the gene encoding for CTLA-4 have been associated with a 
number of autoimmune diseases such as T1DM, myasthenia gravis, SS, SLE and AITD (6-
12). Toll-like receptors belong to the pattern recognition receptors and usually are activated 
by pathogen-associated molecular patterns such as LPS, flaggelin or dsRNA. Recent 
evidence suggests that TLR7, TLR8 and TLR9 are associated with the induction of auto-
immunity (13). TLRs have also been found to bind to endogenous antigens, such as 
fibrinogen, components of the extracellular matrix, heat shock proteins and host derived 
DNA and mRNA (14). The involvement of TLRs in the development of autoimmunity thus 
connects the innate immune system with autoimmune diseases. Infections seem to be of 
importance in the pathogenesis of at least some autoimmune diseases. Several mechanism 
by which an infection of the host can lead to autoimmunity have been proposed, including 
molecular mimicry, epitope spreading, bystander activation and cryptic antigen presen-
tation. A strong evidence for a link between infection and induction of autoimmunity has to 
date only been found for Campylobacter jejuni infection and subsequent development of 
Guillain Barré Syndrome (15). 
The role of B cells in pathogenesis of autoimmune diseases has long been neglected, but in 
recent years their considerable contribution became more and more evident. The production 
of autoantibodies and the resulting formation and deposition of immune complexes have 
long been considered to be the only part of central importance by which B cells participate 
in the pathogenesis of autoimmune diseases. Besides their antibody-producing capacity, B 
cells also have the capability to efficiently present antigens and secrete cytokines. Several 
studies in mice have shown that the presence of B-cells is required for the development of 
certain autoimmune diseases such as lupus, fibrosis or type 1 diabetes mellitus, but not their 
antibody-secreting capability (16-18). Nevertheless, both the autoantibody production and 
antigen-presenting capabilities of B-cells seem to be required for the induction of arthritis in 
mice (19). A contribution of B cells in human autoimmune disease development or main-
CHAPTER 7  SERUM BAFF LEVELS IN HUMAN DISEASES  
   
  135 
tenance became apparent when a B-cell depletion therapy showed significant efficacy in 
patients with rheumatoid arthritis (20). 
A correlation between BAFF and autoimmune diseases was supposed when the analysis of 
BAFF transgenic mice revealed a phenotype which closely resembles human SLE. Like in 
humans afflicted with SLE, these mice show high levels of serum immunoglobulins 
including anti-DNA antibodies and rheumatoid factor, circulating immune complexes, Ig 
depositions in the kidney and proteinuria (21, 22). Moreover, with age BAFF transgenic 
mice also develop symptoms similar to human SS, with B cell infiltrates in salivary glands 
and reduced saliva production (23). 
Besides the autoimmune diseases, BAFF might be involved in the genesis or maintenance of 
other diseases with B cell contribution. In this respect, the most obvious disorders are B cell 
malignancies. B cells from patients with B cell chronic lymphocytic leukemia (B-CLL) 
were found to express BAFF-R and TACI, and in contrast to normal B cells these cells also 
express BAFF and APRIL, thus establishing an autocrine survival pathway (24). Chronic 
infections are another type of disorders where BAFF might be involved, as patients with 
chronic infections often develop additional diseases, including autoimmune disorders. 
Serum BAFF levels in patients afflicted with different autoimmune and cancerous diseases 
were already analyzed by several groups, but the reported data are inconsistent. To further 
elucidate whether elevated BAFF levels are associated with certain diseases in humans, a 
sensitive ELISA for hBAFF was developed and sera from patients suffering from an 
autoimmune disorder, lymphoma or chronic infection were analyzed. 
 
 
 
7.2 Results 
7.2.1 Analysis of hBAFF concentration in healthy blood donors 
In order to determine the normal hBAFF concentration present in the blood of healthy 
persons, serum from 48 voluntary healthy blood donors was analyzed, using the newly 
developed hBAFF ELISA (see chapter 4). Therefore, two-fold serial dilutions ranging from 
1:10 to 1:80 were analyzed in duplicates. As shown in figure 1, most of the donors showed a 
serum hBAFF concentration of 20 ng/ml or below, and only two persons presented with 
high levels of more than 50 ng/ml. 
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Figure 1. hBAFF concentration in 
serum of healthy blood donors. 48 
samples from healthy individuals 
were analyzed in duplicates. 
Standard deviation values were to 
small to be depicted. 
 
 
A more detailed analysis of the distribution of hBAFF concentration levels is shown in 
figure 2. In 59% of all voluntary blood donors tested, the serum hBAFF concentration was 5 
ng/ml or lower, 13% showed a value between 5 and 10 ng/ml, 9% had a value between 10 
and 15 ng/ml, and 4% had a value between 15 and 20 ng/ml. Higher hBAFF values were 
found in seven persons. Two persons or 4% had values in the range of 20-30 ng/ml, one 
person or 2% had a value between 30 and 40 ng/ml, and two persons or 4% were within the 
range of 40-50 ng/ml or above 50 ng/ml, respectively. From this result it was concluded, 
that healthy individuals have in general a serum hBAFF concentration of 5 ng/ml or below. 
 
 
 
 
 
 
 
Figure 2. Percentage 
distribution of hBAFF 
concentration in serum of 
healthy blood donors. 
Values of serum hBAFF 
concentration were 
grouped as indicated and 
the percentage of persons 
within one group was 
calculated based on the 
values shown in figure 1. 
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7.2.2 Serum hBAFF concentration in patients suffering from SLE 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with extremely 
heterogeneous clinical manifestations and disease courses (revied in (25)). SLE affects most 
frequently the skin, joints, lungs, heart, kidneys and central nervous system but can involve 
almost any organ. The disease is commonly associated with periods of illness (flares) and 
remission. To assess disease phase, several different disease activity indices have been 
developed. These include the SLE disease activity index (SLEDAI), the British Isles lupus 
assessment group (BILAG), the systemic lupus activity measure (SLAM) and the European 
consensus lupus activity measurement (ECLAM). Clinical criteria for diagnosis include skin 
rashes, photosensitivity, non-erosive arthritis, oral ulcers, serositis, glomerulonephritis, 
hematological and neuronal disorders and the presence of antibodies to certain autoantigens, 
such as dsDNA, cardiolipin and ribonucleoproteins termed Smith (Sm). Production of 
numerous autoantibodies is the characteristic feature of SLE. In the sera of patients with 
SLE over 100 different autoantibody specificities have been detected, including antibodies 
against nuclear components, serum proteins and cellular antigens of mainly hematopoietic 
cells (26). The deposition of immune complexes or self-associating complexes formed by 
some of these autoantibodies is considered to cause chronic inflammation in the affected 
tissues, leading to the observed tissue damages. A relation between the production of a 
particular autoantibody and the occurrence of a certain tissue damage has to date only been 
shown for anti-dsDNA antibodies in glomerulonephritis and anti-cardiolipin antibodies in 
thrombosis (27). 
The etiology of SLE is still poorly understood. Genetic factors have been shown to be 
involved, as was suggested by the observation of increased frequencies of SLE among first-
degree relatives and in monozygotic twins (25). It turned out that not a single gene defect 
accounts for SLE pathogenesis but rather a number of genes and alleles on multiple loci. 
Genes controlling SLE can be of either susceptible or modifying type. Each SLE patient has 
therefore a specific set of susceptibility and disease modifying genes, which most likely 
explains the observed heterogeneity of SLE. Besides the genetic factors, also the 
involvement of environmental factors in SLE pathogenesis is discussed. Intense exposure to 
UV light (sun), emotional stress or infections can cause a flare of SLE symptoms. 
Analysis of humans affected with SLE showed several signs for B cell hyperactivity, 
including abnormalities in B cell activation, signaling and migration, constitutively 
enhanced expression of costimulatory molecules like CD154 (CD40 ligand), enhanced 
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production of cytokines that stimulate B cells such as IL-6 and IL-10, and abnormalities in 
positive and negative selection of B cells. All the findings listed above are in accordance 
with a B-cell mediated disease and thus an involvement of BAFF in formation or 
maintenance of SLE is conceivable (27). 
Sera from 46 patients suffering from SLE were analyzed. From eleven of these patients, two 
or three serum samples that were taken at diverse time points were available, so that in total 
66 different serum samples were available for measurement. As can be seen in figure 3, 
around 65% of all samples analyzed showed a hBAFF concentration of 5 ng/ml or below, a 
value that was found in the majority of healthy persons. 85% of all samples are within the 
range of 0-10 ng/ml. Thus, about 15% of all samples showed an increased hBAFF 
concentration. These 10 samples belong to 8 different patients, because the three highest 
values found for male patients belong to different samples from the same patient (see patient 
I in fig. 4). Among the 46 patients, 41 were of female and five of male gender, reflecting the 
fact that SLE more frequently affects women than men. No difference can be seen when 
hBAFF serum concentrations of female and male samples are compared, taking into 
consideration that from one male patient with an increased hBAFF serum level three 
samples were measured (fig. 3). 
 
 
 
 
Figure 3. hBAFF concen-
tration in serum of SLE 
patients. Serum samples from 
46 different female and male 
patients were analyzed in 
duplicates. As from some 
patients several samples 
taken at different time points 
were at hand, the total sample 
number was 66. Standard 
deviation values were to small 
to be depicted. 
 
 
As mentioned above, from eleven patients two or three serum samples were available, 
which were taken at different time points. One to two years lie between the single blood 
takes, so that hBAFF serum concentration could be followed over a period of two to three 
CHAPTER 7  SERUM BAFF LEVELS IN HUMAN DISEASES  
   
  139 
years in the course of disease. hBAFF concentration values remained almost constant over 
the years or decreased (fig. 4). Only for one patient who presented with a considerably 
elevated hBAFF level from the beginning, an increase in hBAFF concentration of 1.5 fold 
within two years could be observed (fig. 4, patient I). Interestingly, ECLAM values, which 
are a measure for disease activity, changed in these patients over the years, without being 
reflected in hBAFF concentration values (see below and fig. 5). 
 
Figure 4. hBAFF con-
centration in serum of 
SLE patients followed 
over some years. From 
eleven patients, sam-
ples taken in the course 
of the disease over a 
period of two to three 
years were analyzed. 
Within the data set for 
each patient, the value 
obtained for the 
earliest time point is 
shown at the left side 
and the value obtained 
for the latest time point 
is at the right side. 
Female () and male () patients are depicted separately. Samples were analyzed in duplicates. 
Standard deviation values were to small to be depicted. 
 
 
ECLAM is a standardized measure to assess SLE disease activity, as already mentioned 
earlier. For the ECLAM value, 20 clinical manifestations and eleven laboratory tests are 
scored. Possible ECLAM values are within the range of 1-10, with a higher score reflecting 
more active disease. Looking at the correlation between ECLAM values and hBAFF 
concentration, including all patient samples, showed that no relation exists (fig. 5). The two 
patients with the highest ECLAM values of 9 and 10, respectively, had hBAFF 
concentration values below 10 ng/ml. The patient with the highest hBAFF concentration 
had an ECLAM value of 7, but three other patients with the same ECLAM value showed 
hBAFF concentrations below 10 ng/ml. Moreover, male patient I (see fig. 4) showed an 
increase in hBAFF concentration levels from 30 ng/ml to 46 ng/ml over a period of two 
years, while at the same time the corresponding ECLAM values decreased from 4 to 2. 
Besides, no difference could be observed regarding female or male samples. 
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Figure 5. Correlation between hBAFF concentration and ECLAM values. Female () and male 
patients () are depicted separately. Samples were analyzed in duplicates. Standard deviation 
values were to small to be depicted. 
 
 
A hallmark of SLE is the formation of numerous different antibodies, particularly against 
nuclear components. The patient samples examined here have been analyzed for anti-
dsDNA antibodies using the Farr assay. In this assay, anti-dsDNA antibodies are quantified 
through precipitation of antibody-antigen complexes with ammonium sulfate, using radio-
actively labeled dsDNA as antigen. A standard anti-dsDNA antibody is used in order to 
indicate results as international units per ml. As depicted in figure 6, no direct correlation 
between anti-dsDNA antibody titer and serum hBAFF concentration can bee seen. The 
majority of patients showed hBAFF concentration values of 10 ng/ml or below in combina-
tion with an anti-dsDNA antibody concentration of 100 U/ml or below. Surprisingly, six of 
the seven patients with values above 300 U/ml for anti-dsDNA antibody concentration 
showed hBAFF concentration values of less than 10 ng/ml, which is within the normal 
range, and the remaining patient showed a value of less than 20 ng/ml. Furthermore, all 
patients with increased hBAFF concentration values showed relatively low values for anti-
dsDNA antibody concentration. 
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Figure 6. Correlation between hBAFF concentration and anti-dsDNA antibody titer. Samples 
were analyzed for their hBAFF concentration using an ELISA and for their anti-dsDNA antibody 
titer using the Farr assay. Female () and male patients () are depicted separately. Standard 
deviation values were to small to be depicted. 
 
 
As the anti-dsDNA antibody concentration values obtained with the Farr assay are a 
measurement for antibody binding and thus are influenced by both antibody concentration 
and avidity, it is difficult to draw conclusions from the observations made. For medical 
evaluation, not a single anti-dsDNA concentration value is considered, but the chronological 
progression of these values. Thus, the correlation of hBAFF and anti-dsDNA antibody 
concentration during disease progression was analyzed, using only the data from patients of 
which several serum samples were available. Interestingly, even large changes in anti-
dsDNA antibody concentration during the progression of disease did not correlate with 
hBAFF concentration values (fig. 7, patients B and H). Also, changes in hBAFF 
concentration are not connected with anti-dsDNA antibody concentration, meaning that 
neither more antibody nor antibodies with a higher avidity for dsDNA were produced. 
Looking for gender-specific differences revealed that all patients showing high values for 
anti-dsDNA antibody concentration were of female gender, whereas all male patients 
showed relatively low anti-dsDNA antibody concentration values. As the overall number of 
male patients analyzed was quite limited, further investigations are necessary in order to 
confirm this finding and to analyze its relevance. 
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Figure 7. Correlation between hBAFF and anti-dsDNA antibody concentration during 
progression of disease. Upper graph: From eleven different patients each two or three serum 
samples, taken at different time points, were at hand. Different patients are indicated by different 
colors, using different characters for female () and male () gender. Within the data set of each 
patient, samples are ordered chronologically from left to right. Lower graph: Seperate depiction of 
selected patients. 
 
 
Finally, we looked for a correlation between hBAFF concentration levels and patient age. 
The analyzed patients were between 19 and 81 years old (fig. 8). Highest hBAFF 
concentration values were observed in patients around the age of 30, but most of the patients 
within this age showed hBAFF concentration levels of 10 ng/ml or below. No difference 
between female and male samples was observed. Thus, a relation between age of the patient 
and serum hBAFF concentration does not exist. 
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Figure 8. Correlation between hBAFF concentration and patient age. Serum samples of 58 
different patients suffering from SLE were analyzed. Female () and male patients () are depicted 
separately. Standard deviation values were to small to be depicted. 
 
 
Taken together, the data obtained in this analysis do not support the idea of a general 
involvement of hBAFF in human SLE, as only a subpopulation of patients have increased 
hBAFF levels. Furthermore, no correlation between hBAFF levels and disease activity, 
reflected by the ECLAM values, or anti-dsDNA antibody concentration could be observed. 
 
 
7.2.3 Serum hBAFF concentration in patients suffering from AITD 
Up to 5% of the overall population are affected with autoimmune thyroid diseases (AITD), 
making it one of the most common autoimmune disorders (for a review see (28)). The 
thyroid is an exocrine gland, producing the thyroid hormones, thyroxine (T4) and 
triiodothyronine (T3), which control diverse metabolic pathways. For production of the 
thyroid hormones, iodine is oxidized by thyroid peroxidase (TPO) and then coupled to 
tyrosine residues found at the end of the glycoprotein thyroglobulin. T3 and T4 are formed 
in an oxidative reaction catalyzed by TPO and thyroglobulin is also the storage form of T3 
and T4. The release of these hormones is regulated by thyroid stimulating hormone (TSH). 
Proteolysis of thyroglobulin releases T3 and T4, whereby some of the T4 is deiodinized to 
T3. Triiodothyronine is the active form of the thyroid hormones and is either released 
directly from the thyroid gland or formed by extrathyroidal deiodination of T4, mainly in 
liver and kidney. 
SERUM BAFF LEVELS IN HUMAN DISEASES  CHAPTER 7 
   
 
144 
Within the AITDs, Hashimoto’s thyroiditis (HT) and Graves’ disease (GD) are the most 
common disorders. As found for other autoimmune diseases, both genetic and 
environmental factors play a role in the etiology of HT and GD. Environmental factors 
include iodine excess and deficiency, selenium deficiency, use of certain drugs such as 
lithium or oral contraceptives, infections, allergies, smoking and stress (29). In what way 
these environmental factors contribute to the development of AITD is not yet fully 
understood. Among the genetic factors, both common and unique susceptibility genes exist 
for HT and GD. Common genetic factors include HLA and CTLA-4. In contrast, a 
chromosomal region containing the CD40 gene was linked only to GD, but not to HT. Both 
GD and HT are characterized by lymphocytic infiltration and production of autoantibodies 
against thyroid-specific proteins. In HT, which is the most frequent form of AITD, the 
thyroid gland shows massive infiltration by lymphocytes and thyrocyte destruction through 
T cells. Clinically, HT is characterized by manifestations of hypothyroidism, which are 
fatigue, hair loss, dry skin, muscle cramps, weight gain, depression, constipation and 
bradycardia. 
Patients suffering from Graves’ disease produce autoantibodies against the TSH receptor, 
which is found on thyrocytes. Binding of these autoantibodies to the receptor mimics the 
normal function of TSH, resulting in production and release of T3 and T4. As the 
stimulation of the TSH receptor by autoantibodies is permanent and not regulated in a feed-
back-loop, patients have symptoms of hyperthyroidism. These symptoms mainly reflect an 
increased metabolism, including hyperactivity, tremor, insomnia, sweating, palpitations, 
arrhythmia, weight loss and diarrhea. 
Another disorder of the thyroid gland is the toxic multinodular goiter, in which the thyroid 
gland is enlarged and contains multiple nodules that are producing excess thyroid hormone, 
leading to hyperthyroidism. Symptoms are mainly as described above for Graves’ disease, 
but there is an increased risk of developing thyroid cancer with time. 
Sera of 63 patients suffering from AITDs were analyzed for their hBAFF concentration. 
Within these 63 patients, 57 patients were of female gender and only six of male gender. 13 
patients were diagnosed with Graves’ disease, with eleven female and two male patients. 
Hashimoto’s thyroiditis was found in 34 patients, of which 31 were of female and three of 
male gender. 16 patients presented with a toxic multinodular goiter, including 15 female and 
one male patient. Twelve of the 13 patients with GD showed hBAFF concentration values 
below 5 ng/ml, and one patient had a value of about 8.5 ng/ml. Thus, all values are within 
the normal range (fig. 9). From the 34 patients with HT, 62% or 21 patients had hBAFF 
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concentration values below 5 ng/ml and two other patients were within the range of 5-10 
ng/ml. Four patients presented with slightly elevated hBAFF levels which were within the 
10-20 ng/ml range, and seven patients showed markedly increased levels above 20 ng/ml. 
Thus, the majority of patients with HT have hBAFF serum levels that are within the normal 
range, while 20% of patients had severely increased values. 
 
 
Figure 9. hBAFF concentration levels in patients with different forms of AITD. Serum samples of 
13 patients with Graves’ disease, 34 patients with Hashimoto’s thyreoditis and 16 patients with toxic 
multinodular goiter were analyzed for their hBAFF levels. All samples were analyzed in duplicates. 
Standard deviation values were too small to be depicted. 
 
 
Of the 16 patients with a toxic multinodular goiter, eleven patients had hBAFF levels below 
5 ng/ml and two patients were within the range of 5-10 ng/ml, thus 81% of patients had 
hBAFF values within the normal range. Extremely elevated hBAFF levels  with values 
between 40 and 120 ng/ml were found in three patients or 19%. Several of the patients 
diagnosed with HT were suffering from other autoimmune diseases including celiac disease 
or type 1 diabetes, but no correlation between serum hBAFF concentration and the presence 
of further autoimmune diseases could be found (data not shown). In all AITDs analyzed, 
neither age nor gender correlated with hBAFF values (data not shown). Moreover, no 
correlation could be found between hBAFF concentration and levels of IgG, IgA and IgM 
(data not shown). In addition, from some of the patients, serum levels of several cytokines, 
including TNF-α, IFN-γ, IL-2, IL-4, IL-10 and IL-12 had been determined. Patients affected 
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with GD or HT showed no correlation between hBAFF and any of these cytokines (data not 
shown). Interestingly, patients suffering from toxic multinodular goiter showed an inverse 
correlation between hBAFF and TNF-α, IL-2 or IFN-γ values, respectively. As depicted in 
figure 10, the three patients with increased hBAFF levels showed low values for TNF-α, IL-
2 and IFN-γ, and all patients with increased levels of TNF-α, IL-2 and IFN-γ had relatively 
low hBAFF values of 10 ng/ml or below. No correlation between hBAFF concentration and 
levels of IL-4, IL-10 and IL-12 could be found in patients suffering from toxic multinodular 
goiter (data not shown). TNF-α, IL-2 and IFN-γ are cytokines that usually are elevated in 
TH1 immune responses, while serum levels of IL-4, IL-10 and IL-12 are found to be 
increased in TH2 immune responses. Thus, hBAFF levels were found to be low in patients 
with a strong TH1 immune response. Nevertheless, as among the patients with toxic 
multinodular goiter only three patients with increased hBAFF levels were present, the 
statistical significance of this observation is questionable and further research is necessary. 
 
 
Figure 10. Correlation between concentration levels of hBAFF and certain cytokines in patients 
with a toxic multinodular goiter. Serum levels of hBAFF, TNF-α (), IL-2 () and IFN-γ () from 
eleven patients with a toxic multinodular goiter were measured and cytokine levels were plotted 
against hBAFF values. 
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7.2.4 Serum hBAFF concentrations in patients suffering from 
Sjögren’s Syndrome 
Sjögren’s syndrome (SS) is a common, chronic autoimmune disorder affecting exocrine 
glands (for a review see (30, 31)). Characteristically, patients have diminished lacrimal and 
salivary gland functions, resulting in dryness of the eyes (keratoconjunctivitis) and mouth 
(xerostomia). This can severely affect the daily life of patients, interfering with functions 
such as eating and speaking. Furthermore, decreased mucus gland secretion of the upper and 
lower respiratory tract may produce dryness of the nose, throat and trachea, sometimes 
leading to a chronic dry cough. Besides this, other organs including the kidneys, lungs, 
blood vessels, liver, pancreas and brain may be involved. All these symptoms may be 
attributed to the presence of organ-specific autoantibodies against cellular antigens of 
salivary ducts, the thyroid gland, the gastric mucosa, the pancreas, the prostate, erythrocytes 
and nerve cells. As for many systemic diseases, the clinical picture of Sjögren’s syndrome is 
quite heterogeneous. Some patients experience only the mild symptoms of dry eyes and 
mouth, whereas others have more severe symptoms, like recurrent mouth infections, joint 
pain, fatigue or renal problems. In primary Sjögren’s syndrome, the exocrinopathy occurs 
alone, whereas in secondary Sjögren’s syndrome there is an association with a systemic 
autoimmune rheumatic disease like rheumatoid arthritis (RA), systemic lupus erythematosus 
(SLE) or systemic sclerosis. The heterogeneity of the clinical manifestations hampers 
diagnosis of Sjögren’s syndrome and often leads to misdiagnosis. Until now, there is no 
specific treatment for Sjögren’s syndrome available and treatment of patients is only 
symptomatic. 
In Sjögren’s syndrome, a chronic stimulation of the immune system is observed. In lympho-
cytic infiltrates, found in salivary and lacrimal glands and other exocrine glands of the respi-
ratory and gastrointestinal tracts, T cells, B cells and plasma cells are present. Among these, 
activated CD4+ T helper cells are predominant, producing IL-2, IL-4, IL-6, IL-1β and TNF-
α. B-cell hyperreactivity is obvious from polyclonal B cell activation, hypergammaglobuli-
nemia and formation of ectopic germinal centers in the exocrine glands, thus it is assumed 
that also Sjögren’s syndrome is a B-cell mediated autoimmune disease. 
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Sera from 17 patients suffering from Sjögren’s syndrome were analyzed. As shown in figure 
11, eleven patients (65%) had extremely low hBAFF values, with a serum concentration of 
less than 2 ng/ml, and three patients showed values between 10 and 15 ng/ml. Thus, 82% or 
14 patients had a hBAFF serum concentration within or slightly above the normal range 
found for healthy people. The other three patients showed in part extremely elevated hBAFF 
values between 30 and 290 ng/ml. No additional clinical data were available from any of 
these patients, thus it can not be ruled out that the increased hBAFF values observed might 
be correlated with another autoimmune disease, as Sjögren’s syndrome often appears in 
combination with other autoimmune diseases like RA or SLE (secondary SS), as mentioned 
above. 
 
 
Figure 11. hBAFF concentration in serum of patients suffering from Sjögren’s syndrome. 
Samples were analyzed in duplicates. In the left picture, all samples tested are shown. The right 
picture shows only the patients for which a value of less than 35 ng/ml was measured, meaning that 
patients number 1 and 15 were omitted. Standard deviation values were too small to be depicted. 
 
 
7.2.5 Serum hBAFF concentrations in patients having lymphomas 
Lymphomas are, as leukemias, malignant tumors of hematopoietic cells. In leukemias, the 
neoplastic cells proliferate as single cells and can be found in the blood, whereas 
lymphomas grow as solid tumors and are located in lymphoid tissues, such as the bone 
marrow, lymph nodes, thymus or MALT. As observed for cancer development in general, 
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the mechanisms leading to a neoplastic transformation of B- and T-cells is a multistep 
process, which is to date only partially understood. 
Lymphomas are classified according to the WHO classification as Hodgkin’s lymphoma 
(HL) and non-Hodgkin’s lymphoma (NHL) (32). The hallmark of Hodgkin’s lymphoma is 
the presence of multinucleated large cells, called Reed-Sternberg cells (RSCs), and Hodgkin 
cells, which are atypical mononuclear RSCs. Hodgkin’s lymphoma are further subdivided, 
based on differences in morphology and phenotype of the lymphoma cells and the 
composition of cellular infiltrates, into classical HL and nodular lymphocyte-predominant 
HL. The later accounts only for about 5% of all cases. Classical HL itself is further 
subdivided into four specific forms. All lymphomas not characterized as HLs fall into the 
group of NHLs. Non-Hodgkin’s lymphomas account for around 90% of all malignant 
lymphomas. According to the WHO classification, more than 35 subtypes of both B- and T-
cell origin can be distinguished, with B-cell type lymphomas being more prevalent. Thus, 
the part of lymphomas classified as NHLs represents an extremely diverse group. Several 
inherited disorders of the immune system and infectious agents like HIV and EBV are 
associated with lymphoma development. Recent evidence suggests a role for hepatitis C 
virus (HCV) in lymphoma development, whereas the role of simian virus 40 is still 
uncertain. Also, some bacteria are brought in context with lymphoma development, 
including Helicobacter pylori and maybe also Borrelia burgdorferi. In addition, in 
autoimmune and chronic inflammatory disorders an excess risk of lymphoma development 
has been reported. This includes RA, SLE, SS, celiac disease and chronic thyroiditis (33). 
The mechanisms leading to lymphoma development in these disorders is to date not 
completely clear. Chronic inflammation and antigen activation is discussed in this context, 
besides other factors like treatment of patients with immunosuppressants and TNF-blocking 
reagents. 
The sera of nine patients diagnosed as Morbus Hodgkin (MH) and 14 patients suffering 
from NHL were analyzed. From the patients, only gender and age were known. As can be 
seen in figure 12, six of the nine patients suffering from MH showed hBAFF values below 
10 ng/ml. One patient had a slightly increased value in the range of 10-15 ng/ml and two 
patients showed markedly increased values between 15 and 25 ng/ml. From one patient 
(termed patient number 9) another blood sample which was taken several weeks later was 
available (termed patient numer 10). This second sample showed an extremely high hBAFF 
value of 285 ng/ml. Interestingly, at the time point of the first blood take this patient showed 
a relatively low value for the hBAFF concentration of 1.2 ng/ml (see fig. 12, patient number 
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9), thus, the patient had an increase in serum hBAFF concentration of more than 200 times 
at the second time point of blood take. This increase might be due to medical treatment of 
the lymphoma, but this could not be addressed further as additional patient data was not 
available. Furthermore, no difference in hBAFF levels between female and male patients 
could be observed. 
 
 
Figure 12. hBAFF concentration in serum of patients suffering from Morbus Hodgkin (MH). 
Samples from female () and male patients () suffering from MH were analyzed in duplicates. In 
the left picture, all samples tested are shown. The right picture shows only patients for which a value 
of less than 30 ng/ml was measured, meaning that sample number 10 was omitted. Note that samples 
9 and 10 are from the same patient, with sample 10 taken at a later time point than sample 9. 
Standard deviation values were too small to be depicted. 
 
 
Of the 14 patients with NHL, only three patients (21%) showed serum hBAFF values below 
5 ng/ml (fig. 13). Seven patients had hBAFF values in the range of 5-10 ng/ml. One patient 
had a value in the range of 10-15 ng/ml and the remaining three patients showed increased 
values between 15 and 30 ng/ml. Between female and male patients, no significant 
differences in hBAFF values could be found. The low percentage of patients with a serum 
hBAFF concentration below 5 ng/ml is interesting, as this was found to be the normal range 
for the majority of healthy persons. As the number of NHL patients was quite small, further 
investigations are necessary to confirm this observation. 
Altogether, 22 patients suffering from Hodgkin or non-Hodgkin lymphomas have been 
analyzed for serum hBAFF concentrations. Most of the patients with NHL had increased 
hBAFF levels, while elevated hBAFF levels in patients with MH could be observed only in 
about half of the patients. 
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Figure 13. hBAFF concentration in serum of patients suffering from NHL. Samples of female () 
and male () patients suffering from NHL were analyzed in duplicates. Standard deviation values 
were too small to be depicted. 
 
 
7.2.6 Serum hBAFF concentration in patients suffering from chronic 
hepatitis C 
Hepatitis C is caused by one of the six identified hepatitis viruses, named A-G. Among 
these viruses, hepatitis C virus (HCV) is considered to be the most serious one. Acute 
infections with hepatitis C are often unnoticed, as they commonly produce no signs or only 
mild flu-like symptoms. In 60-80% of cases, acute hepatitis C infections become chronic 
without the development of any symptoms in the beginning. After 10 to 30 years, 20-30% 
of the patients develop liver cirrhosis, leading to liver failure. In addition, 1-4% of these 
patients develop hepatocellular carcinoma. Furthermore, an increased risk exists of develop-
ing extra-hepatic diseases like cryoglobulinemia, NHL, arthralgia, SS or Raynaud’s syn-
drome. All of these disorders are connected to either a disturbed B cell homeostasis or to 
autoimmunity, or both. As hepatitis C virus is known to be not only a hepatotropic but also 
a lymphotropic virus, it might be that hBAFF regulation is disturbed in patients with chronic 
hepatitis C (for reviews see (34, 35)). 
Serum samples from 41 patients suffering from hepatitis C were analyzed. 24 or 58% of 
these patients showed serum hBAFF levels below 5 ng/ml and five patients had a value in 
the range of 5-10 ng/ml (fig. 14, right). Seven patients had increased serum levels of hBAFF 
in the range of 10-20 ng/ml (fig. 14, right), two patients showed markedly elevated hBAFF 
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levels between 25 and 40 ng/ml, and three patients showed extremely increased hBAFF 
levels above 50 ng/ml (fig. 14, left). From all patients, several data and blood test results 
were available, including liver enzymes (AST, ALT, GGT and alkaline phosphatase), creati-
nine, bilirubin, CRP, albumin, globulin as well as leucocyte and thrombocyte numbers. No 
correlation between increased hBAFF concentrations and age or gender, respectively, could 
be found (data not shown). Furthermore, neither the values for the liver enzymes nor any 
other of the aforementioned blood parameters correlated with an elevated hBAFF 
concentration. Especially, CRP values were relatively low in the three patients with the 
highest hBAFF values, indicating that these patients had no acute infections at the time 
blood was taken (data not shown). Taken together, the majority of patients with chronic 
hepatitis C infection did not show increased hBAFF levels, albeit about 40% of the patients 
had considerably elevated hBAFF levels. Thus, elevated hBAFF levels were found only in a 
subgroup of hepatitis C patients.  
 
 
Figure 14. hBAFF concentration in serum of patients suffering from chronic hepatitis C. Samples 
of 41 patients were analyzed in duplicates. The right image shows a detail of the left image, 
including only patients showing hBAFF concentrations up to 40 ng/ml. Standard deviation values 
were to small to be depicted. 
 
 
7.3 Discussion 
In this study we found that within the analyzed autoimmune diseases, only a subgroup of 
patients show increased levels of serum hBAFF, while the majority of patients have hBAFF 
levels within the normal range. In SLE, 17% of all patients have elevated hBAFF 
concentration levels, and there is no correlation between hBAFF levels and disease activity 
or anti-dsDNA antibody titer. Of the 17 patients suffering from SS, 65% have amazingly 
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low levels of serum hBAFF, while the remaining 35% show increased levels, which 
partially are extremely elevated. Several groups report a general increase in serum hBAFF 
levels in SLE and SS patients and a correlation between hBAFF values and autoantibody 
titers (36-40), which is in contrast to the findings presented here. Nonetheless, one of the 
first studies analyzing hBAFF levels in patients with SLE or SS found elevated levels in 
23% of the SLE patients and in 36% of the SS patients (23). Furthermore, in this study no 
correlation between hBAFF levels and titer of total IgG or RF was found. Moreover, a 
closer look on the results presented by one group revealed that the majority of patients with 
SLE analyzed had serum hBAFF levels comparable to the healthy control group, and only a 
subgroup of the analyzed patients with SLE showed increased hBAFF levels (40). 
Furthermore, in an analysis of SLE patients over a period of one year, no effect of serum 
hBAFF levels on disease activity was found (36). Thus, for SLE and SS, the findings of 
several different groups are consistent with the results presented in this thesis. 
Within the AITDs we found that all 13 patients with Graves’ disease have normal or only 
marginally elevated serum hBAFF levels, while about one third of the 34 patients with 
Hashimoto’s thyroiditis and approximately one fifth of the 16 patients with multinodular 
goiter show markedly increased hBAFF levels. In all AITDs, no correlation could be found 
between hBAFF levels and autoantibody titers. Until now there is no analysis on hBAFF 
levels in human AITDs reported, thus the results obtained in our group can not be discussed 
further. 
In contrast to the findings for autoimmune diseases, we found that the majority of patients 
suffering from one of the two types of lymphomas analyzed, have increased levels of serum 
hBAFF. In MH, 55% of the nine patients show elevated levels and of the 14 patients with 
NHL, nearly 80% have elevated levels. Several groups have analyzed hBAFF levels in 
patients with different types of lymphomas. Elevated levels of serum hBAFF were found in 
patients with NHL, B-CLL and Waldenström’s macroglobulinemia (24, 41, 42). In this 
thesis, elevated levels in the majority of patients with NHL could be confirmed and in 
addition were also found in more than half of the patients with MH. 
Furthermore, we found that serum hBAFF levels are elevated in about 40% of the patients 
with a chronic hepatitis C infection. Other groups also reported elevated hBAFF levels in a 
subgroup of patients with chronic hepatitis C infection and it seems as hBAFF levels are 
only weakly associated with the presence of cryoglobulins, RF and arthritis or vasculitis 
(43, 44), thus confirming our results. 
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Even though most of the results presented in this thesis have been confirmed by the findings 
of other groups, there are still some inconsistencies. First of all, the serum hBAFF value for 
healthy individuals varies quite a lot in all the reports published so far. Some groups found 
as a normal hBAFF level a value of around 5 ng/ml (37, 39, 40), which is consistent with 
our result, whereas other groups found both higher mean values of about 10 ng/ml (23) and 
lower mean values around 1 to 2.5 ng/ml (38, 43, 44). These differences can most likely be 
ascribed to the different antibodies used in the ELISA assays and the different sensitivity of 
the assays. Furthermore, in most of the reports, the distribution of serum hBAFF values for 
healthy donors is quite homogeneous, while in our study we observed a more heterogeneous 
picture. While around 60% of the healthy controls had hBAFF values of 5 ng/ml or below, 
around 10% of donors were found both in the range of 5-10 ng/ml and 10-15 ng/ml. In 
addition, around 10% of the patients had extremely elevated hBAFF levels between 40 and 
160 ng/ml. There are a few reports published were also some control patients had markedly 
increased hBAFF levels (23, 39). It might be that the blood donors, who were supposed to 
be healthy on the basis of a short medical examination preceding the blood donation, suffer 
from a yet undiscovered or a harmless chronic disease like an allergy. To date, serum 
hBAFF levels during a normal immune response or in patients with allergic disorders have 
not been analyzed. As further medical data from the healthy blood donors analyzed by our 
group was not available, the reason for the elevated hBAFF concentration levels observed in 
allegedly healthy individuals remains to be determined. 
Another interesting observation made by us and other groups is the heterogeneity of the 
hBAFF levels in patient samples. In almost all disease types analyzed, there were patients 
with extremely low or high levels. Incorrect levels of hBAFF might be meassured in patient 
serum containing BAFF - APRIL heterotrimers. Depending on the epitopes recognized by 
the antibodies used in the ELISA assay, these heterotrimers do not influence the assay if 
they are not recognized by the capture antibody, or lead to lower levels, if recognized by the 
capture antibody alone, and to higher levels, if recognized by both the capture and detection 
antibody. The presence and serum level of BAFF - APRIL heterotrimers could have been 
meassured using an ELISA with a combination of an anti-APRIL and an anti-BAFF 
antibody. As no anti-APRIL antibody was at hand, this issue could not be addressed. The 
high hBAFF values might reflect interference in the hBAFF ELISA. It is known that the 
presence of rheumatoid factor (RF) can lead to high values in ELISA assays due to 
unspecific binding to the antibodies used. In order to determine whether the observed high 
hBAFF levels result from the presence of RF and its interference in the ELISA assay, the 
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serum samples could have been depleted from antibodies by the use of commercially 
available resins, for instance, or the ELISA could have been performed using an isotype 
matched antibody of an irrelevant specificity for coating. Due to shortness in the amount of 
patient serum available, this issue could not be pursued. Another possibility is the change of 
hBAFF levels due to medical treatment of the actual disease. Hepatitis C, for instance, is 
usually treated with IFN-α, which has been shown to increase the amount of hBAFF 
secreted from monocytes in vitro (45) and treatment of patients suffering from autoimmune 
hepatitis or chronic graft-versus-host disease with corticosteroids lead to a reduction in 
serum hBAFF levels (46, 47). Unfortunately, from none of the patients could we analyze 
samples collected both before and after starting of medication. Thus, this aspect remains to 
be elucidated in future experiments. Furthermore, the number of patient samples was quite 
limited in some disease types, thus the obtained results might not reflect the actual situation. 
Moreover, within most of the analyzed disease types, the clinical picture differs in part 
substantially from patient to patient. SLE and SS are systemic diseases affecting a variety of 
different organs, and the serum hBAFF level might be dependent on the clinical picture. In 
this respect it would have been interesting to analyze the data of the SS patients with respect 
to the presence of other diseases. As already mentioned, SS can appear alone (primary SS) 
or in combination with other autoimmune diseases like RA or SLE (secondary SS). This 
subject could not be addressed due to the lack of further patient data. Also, it might be that 
in inflammations which are limited to a specific organ, hBAFF levels are only locally 
elevated and this increase is not reflected in the serum levels. Indeed, local production of 
hBAFF was observed for instance in patients with RA, where hBAFF is produced by 
synoviocytes, leading to high hBAFF levels in the synovial fluid (48). 
Another aspect that has until to date not been investigated thoroughly is the possible 
involvement of APRIL and BAFF - APRIL heterotrimers in formation or maintenance of 
different diseases. Also APRIL levels have been shown to be elevated in patients with 
different types of lymphomas, systemic sclerosis or SS (49-53), indicating that in some 
diseases both BAFF and APRIL levels might be of importance. Furthermore, nothing is 
known about the function of the BAFF - APRIL heterotrimer and its potential implication in 
diseases. Also, the function of membrane bound BAFF, which might be different from that 
of soluble BAFF, has not yet been explored, as well as the function of the splice variant 
deltaBAFF and the fusion protein TWE-PRIL. 
Several different BAFF antagonists have been developed for the treatment of various human 
disorders (54), including monoclonal antibodies against hBAFF (belimumab) and BAFF-R, 
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and fusion proteins of the extracellular domain of BAFF-R and TACI, respectively, with the 
Fc part of human IgG1, termed BR3-Fc and TACI-Ig. All reagents have been tested in 
cynomolgus monkeys, where a reduction in serum Ig and numbers of circulating B cell was 
observed, but plasma cells were not affected. All reagents showed a similar effect on B 
cells, but serum IgM and IgA levels were more profoundly decreased when TACI-Ig was 
used, which binds both BAFF and APRIL. At the moment, all reagents are in clinical trials, 
and the outcome of these studies will shed more light on the question, how BAFF and 
APRIL are involved in autoimmune and other diseases with disturbed B cell homeostasis. 
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8 GENERAL DISCUSSION 
The regulation of lymphocyte numbers and activation is a critical point, necessary to both 
keep the immune system functioning and to prevent diseases. The maintenance of B cell 
homeostasis is quite challenging, as mature B cells are distributed throughout the body. B 
cell homeostasis is regulated at numerous different stages of B lymphocyte development 
and it has become clear in the last years that this is mainly achieved by cell extrinsic signals. 
Through the combination of these signals, a cell fate decision is produced, resulting in 
survival, proliferation or apoptosis of a specific B cell. When the normal mechanisms of 
homeostatic regulation get out of control, the outcome of this is increased cell death or 
inappropriate cell activation and proliferation, leading to diseases such as 
immunodeficiency, autoimmunity and cancer. 
The control of B lymphocyte homeostasis by mainly extrinsic signals is an elegant way of 
regulating such a complex system. The approach of making the decision for a certain cell-
fate not dependent on an individual cell but on other cells allows the control over cell 
numbers and cell activation by regulating microenvironmental conditions and costimulatory 
signals. Furthermore, B lymphocytes at different stages of development are dependent on 
different extracellular stimuli, thus allowing a subset-specific control. 
A wide variety of receptors are known to be responsible for controlling B cell homeostasis 
at different developmental stages. One of the earliest receptors expressed on multi-lineage 
precursor cells is FLT3. Signaling via FLT3 is necessary for the maintenance of these 
precursors, and the level of FLT3L seems to control the numbers of precursor cells, as mice 
deficient for FLT3L have reduced numbers of CLPs, and treatment of mice with FLT3 leads 
to an increase in progenitor cells, including EPLMs (this thesis). The downregulation of 
FLT3 has been shown to be important for the comittment of precursor cells to the B cell 
lineage, and maintained or increased signaling via FLT3 results in the preference of the 
myeloid developmental pathway. Thus, FLT3L does not only control the pool of 
hematopoietic progenitor cells but also drives the induction of a specific cell fate. 
Another important factor in murine B cell development is IL-7. Mice lacking either IL-7 or 
its receptor have reduced numbers of mature B cells and B cell precursors. Signaling via the 
IL-7R influences not only survival of the B cell precursors, but also acts in a synergistic 
way with PAX5 and the pre-BCR to control and maintain B cell lineage comittment. 
Immature B cells that express a complete BCR downregulate the IL-7R, but start expression 
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of BAFF-R (this thesis). Thus, IL-7 is an important regulator of the immature B cell pool in 
the BM, and regulation of B cell homeostasis is switched to BAFF at the time the cells leave 
the BM. 
Survival of peripheral B cell subsets is dependent on signaling via the BAFF - BAFF-R 
axis. This includes splenic transitional and mature Fol and MZ B cells, but not B1 B cells. 
Furthermore, the survival of long-lived plasma cells is dependent on the presence of either 
BAFF or APRIL, while survival of memory B cells seems to be independent of both ligands 
(1). The number of immature B cells that survive the selection process in the spleen is 
dependent on the amount of BAFF, and an increase in BAFF allows autoreactive B cells to 
survive. Another receptor important for the survival of peripheral B cells is the BCR. Cells 
that are unable to produce a signaling competent BCR die by neglect and mature B cells fail 
to survive upon elimination of the BCR by conditional gene targeting (2). To date, it is still 
unclear how the basal BCR signals that are necessary for B cell survival are generated. In 
this respect, constant low-level interactions with self or environmental antigens that 
stimulate BCR signaling, or ligand independent, tonic signaling are discussed. 
Taken together, homeostasis of B cells is achieved by the spatio-temporal control of 
extrinsic survival and differentiation signals. Although many of these signaling factors have 
been uncovered, some open questions remain. Most interesting are the differences between 
the human and the mouse system in the requirement for IL-7 and BAFF. In contrast to mice, 
humans deficient for IL-7Rα or the γc chain (X-SCID) have normal numbers of B cells. In 
vitro, human HSCs are able to develop into B cells without IL-7. To date, the human factor 
mediating survival of lymphocyte progenitor cells has not been identified. In the BAFF-
APRIL system, the differences to the mouse system have just begun to be discovered. In 
humans, the ligands show a different affinity for their receptors, and humans deficient for 
TACI, which was found to be a negative regulator in the murine system, suffer from 
immunodeficencies. The analysis of patients with mutations in BAFF-R, BCMA or one of 
the ligands will allow to identify the functions of these molecules in the human system. 
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Abbreviations 
aa amino acid 
APRIL a proliferation inducing ligand 
bp base pair 
BCMA B cell maturation antigen 
BAFF B cell activating factor of the TNF family 
BAFF-R BAFF receptor 
BCR B cell receptor 
BM bone marrow 
BrdU 5-bromo-2’-deoxyuridine 
BSA bovine serum albumine 
CAML calcium modulator and cyclophilin ligand 
CD cluster of differentiation 
CSR class switch recombination 
DMSO dimethylsulfoxid 
DTT dithiothreitol 
EDTA ethylenediamine-tetraacetate 
FCS fetal calf serum 
FITC fluorescein-isothiocyanate 
Fol B follicular B 
FLT3 FMS-like tyrosine kinase 
FLT3L FLT3 ligand 
GC germinal center 
Ig immunoglobulin 
H chain heavy chain 
kb kilo bases 
L chain light chain 
MALT mucosal associated lymphoid tissue 
min minutes 
MHC major histocompatibility complex 
MZ marginal zone 
NIK NF-κB inducing kinase 
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NIP 4-Hydroxy-3-nitro-5-iodo-phenylacetyl 
OD optical density 
O/N over night 
PCR polymerase chain reaction 
PI propidium iodide 
preBCR pre-B cell receptor 
RAG recombination activating gene 
rpm rounds per minute 
RT room temperature 
RT-PCR reverse transcriptase-PCR 
SDS sodium dodecylsulfate 
SL chain surrogate light chain 
SLE systemic lupus erythematosus 
T1 (T2, T3) transitional type 1 
TACI transmembrane activator and CAML interactor 
TD T cell dependent 
TdT terminal deoxynucleotidyl transferase 
TI T cell independent 
TRAF TNF receptor associated factor 
UV ultra violett 
WT wild type 
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